U.S. patent application number 14/853063 was filed with the patent office on 2016-03-10 for compositions and methods for joint health.
This patent application is currently assigned to UNIGEN, INC.. The applicant listed for this patent is Unigen, Inc., Unigen, Inc.. Invention is credited to Lidia Alfaro Brownell, Min Chu, Mei-Feng Hong, Eu-Jin Hyun, Qi Jia, Ping Jiao, Young-Chul Lee, Mesfin Yimam.
Application Number | 20160067296 14/853063 |
Document ID | / |
Family ID | 52105165 |
Filed Date | 2016-03-10 |
United States Patent
Application |
20160067296 |
Kind Code |
A1 |
Brownell; Lidia Alfaro ; et
al. |
March 10, 2016 |
Compositions and Methods for Joint Health
Abstract
The present disclosure provides mixtures of prenylated
flavonoids, stilbenes, or both with flavans or curcuminoids or both
capable of modulating joint inflammation, joint pain, joint
stiffness, cartilage degradation, or improving mobility, range of
motion, flexibility, joint physical function, or any combination
thereof. Such a mixture of prenylated flavonoids, stilbenes, or
both with flavans or curcuminoids or both can optionally be used in
combination with other joint management agents, such as
non-steroidal anti-inflammatory agents/analgesics, COX/LOX
inhibiting agents, glucosamine compounds, neuropathic pain relief
agents, or the like.
Inventors: |
Brownell; Lidia Alfaro;
(Tacoma, WA) ; Chu; Min; (Newcastle, WA) ;
Hong; Mei-Feng; (Lacey, WA) ; Hyun; Eu-Jin;
(Cheonan-si, KR) ; Jia; Qi; (Olympia, WA) ;
Jiao; Ping; (Newcastle, WA) ; Lee; Young-Chul;
(Daejeon, KR) ; Yimam; Mesfin; (Tacoma,
WA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Unigen, Inc.
Unigen, Inc. |
Seattle
Cheonan-si |
WA |
US
KR |
|
|
Assignee: |
UNIGEN, INC.
Seattle
WA
|
Family ID: |
52105165 |
Appl. No.: |
14/853063 |
Filed: |
September 14, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14305839 |
Jun 16, 2014 |
|
|
|
14853063 |
|
|
|
|
61836113 |
Jun 17, 2013 |
|
|
|
61895234 |
Oct 24, 2013 |
|
|
|
Current U.S.
Class: |
514/35 ; 514/455;
514/456; 514/733 |
Current CPC
Class: |
A61K 31/353 20130101;
A61K 36/605 20130101; A61K 31/7028 20130101; A61K 36/605 20130101;
A61K 31/352 20130101; A61K 36/48 20130101; A61K 31/7034 20130101;
A61K 36/534 20130101; A61K 36/48 20130101; A61K 2300/00 20130101;
A61K 2300/00 20130101; A61K 31/05 20130101; A61K 2300/00 20130101;
A61P 19/00 20180101; A61K 36/534 20130101; A61P 19/02 20180101;
A61K 31/7008 20130101 |
International
Class: |
A61K 36/605 20060101
A61K036/605; A61K 31/7034 20060101 A61K031/7034; A61K 31/352
20060101 A61K031/352; A61K 31/05 20060101 A61K031/05; A61K 36/48
20060101 A61K036/48; A61K 31/353 20060101 A61K031/353 |
Claims
1-65. (canceled)
66. A composition for joint health comprising a mixture of a Morus
extract and an Acacia extract.
67. The composition of claim 66, wherein the Morus extract is
enriched for one or more prenylated flavonoids, one or more
stilbenes or a combination thereof.
68. The composition of claim 66, wherein the Acacia extract is
enriched for flavans.
69. The composition of claim 66, wherein the Morus extract is
enriched for one or more prenylated flavonoids, one or more
stilbenes or a combination thereof and wherein the Acacia extract
is enriched for flavans.
70. The composition of claim 66, wherein the Morus extract and the
Acacia extract are blended in a 2:1 weight ratio.
71. The composition of claim 66, wherein the Morus extract is from
Morus alba, and the Acacia extract is from Acacia catechu.
72. The composition of claim 68, wherein the Acacia extract
comprises about 0.01% to 99.9% of flavans.
73. The composition of claim 67, wherein the Morus extract
comprises about 0.1% to 49.9% of prenylated flavonoids.
74. The composition of claim 67, wherein the Morus extract
comprises about 0.1% to about 49.9% of stilbenes.
75. The composition of claim 67, wherein the one or more prenylated
flavonoids comprises Albanin G, Kuwanon G, Morusin, or any
combination thereof.
76. The composition of claim 67, wherein the one or more stilbenes
comprises oxyresveratrol, mulberroside A, or a combination
thereof.
77. The composition of claim 66, wherein the active ingredients in
the Acacia extract are catechin, epicatechin, or a combination
thereof.
78. The composition of claim 66, wherein the composition
additionally comprises a glucosamine-type compound.
79. The composition of claim 78, wherein the glucosamine-type
compound comprises glucosamine sulfate, glucosamine hydrochloride,
N-acetylglucosamine, chondroitin sulfate, methylsulfonylmethane,
hyaluronic acid or a combination thereof.
80. The composition of claim 78, wherein the glucosamine-type
compound consists essentially of glucosamine sulfate, glucosamine
hydrochloride, N-acetylglucosamine, chondroitin sulfate,
methylsulfonylmethane, hyaluronic acid or a combination
thereof.
81. The composition of claim 66, wherein the composition further
comprises a pharmaceutically or nutraceutically acceptable carrier,
diluent, or excipient, wherein the pharmaceutical or nutraceutical
formulation comprises from about 0.5 weight percent to about 90
weight percent of active ingredients of the extract mixture.
82. The composition of claim 81, wherein the composition is
formulated as a tablet, hard capsule, soft gel capsule, powder, or
granule.
83. The composition of claim 69, wherein the Morus extract and the
Acacia extract are blended in a 2:1 weight ratio.
84. The composition of claim 69, wherein the composition further
comprises a pharmaceutically or nutraceutically acceptable carrier,
diluent, or excipient, wherein the pharmaceutical or nutraceutical
formulation comprises from about 0.5 weight percent to about 90
weight percent of active ingredients of the extract mixture.
85. The composition of claim 69, wherein the composition is
formulated as a tablet, hard capsule, soft gel capsule, powder, or
granule.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C.
.sctn.119(e) of U.S. Provisional Patent Application No. 61/836,113,
filed Jun. 17, 2013 and U.S. Provisional Patent Application No.
61/895,234, filed Oct. 24, 2013. These applications are
incorporated herein by reference in their entireties.
BACKGROUND
[0002] The most abundant heteropolysaccharides in the body are
glycosaminoglycans (GAGs). They are composed of repetitive
disaccharide units of a hexosamine and hexuronic acid attached
through a linker oligosaccharide region to the core protein of
proteoglycans. A high number of GAGs are linked to the core protein
of cartilage aggrecan. GAGs are highly negatively charged molecules
with extended an extended conformation that imparts viscosity to a
solution. These negatively charged carbohydrates are responsible
for the high swelling capacity of cartilage. GAGs are located
primarily on the surface of cells or in the extracellular matrix
(ECM). GAGs are important molecular constituents of both cell
surface proteoglycans, as well as large and small proteoglycans of
the extracellular matrix of cartilage. Along with high viscosity of
GAGs comes low compressibility, which makes these molecules ideal
for a lubricating fluid in the joints. At the same time, their
rigidity provides structural integrity to cells and provides
passageways between cells.
[0003] Glycosaminoglycan is a major component of joint cartilage,
joint fluid, and other soft connective tissue. The
glycosaminoglycans (GAGs) of articular cartilage have been
identified as chondroitin 6-sulfate, chondroitin 4-sulfate,
dermatan sulfate, heparin, heparin sulfate and keratin sulfate.
GAGs are released from the degrading cartilage matrix in large
amounts during inflammation of the joints. Changes in the levels or
molecular nature of GAGs have been associated with some connective
tissue diseases. For example, patients with arthritis and
scleroderma have elevated concentrations of GAGs in blood and
synovial fluid, and destruction of involved joints in arthritis
patients correlates positively with high GAG levels in synovial
fluid. Histochemical and biochemical studies of cartilage from
arthritic joints have shown a significant decrease in the GAG
content and that the decrease in approximately proportional to the
severity of the disease.
[0004] Morus alba L (Moraceae), the mulberry or white berry plant,
is native to northern China, and has been cultivated and
naturalized elsewhere, from India to the Middle East to Southern
Europe, and recently to the North American area. The root-bark is
used in traditional medicine known as Sang bai pi or Cortex Mori
(Pharmacopoeia of the People's Republic of China, 2005). This herb
is also known as Pong-na-moo in Korean and Sohakuhi in Japan. In
contemporary pharmacological research, Morus alba root-bark has
been reported to have antibacterial, anti-viral, antioxidant,
hypoglycemic, hypolipidemic, neuroprotective, antiulcer, analgesic
and anti-inflammatory activities. A variety of bioactive compounds
from Morus alba root-bark have in vivo and in vitro
anti-inflammatory activity.
[0005] Acacia is a genus of leguminous trees and shrubs. The genus
Acacia includes more than 1000 species belonging to the family of
Leguminosae and the subfamily of Mimosoideae. Acacias are
distributed worldwide in tropical and subtropical areas of Central
and South America, Africa, parts of Asia, as well as Australia,
which has the largest number of endemic species. Acacias occur
primarily in dry and arid regions, where the forests are often in
the nature of open thorny shrubs. Acacias are very important
economically, providing a source of tannins, gums, timber, fuel and
fodder. Tannins, which are isolated primarily from bark, are used
extensively for tanning hides and skins Some Acacia barks are also
used for flavoring local spirits. Some indigenous species like A.
sinuata also yield saponins, which are used in detergents, foaming
agents and emulsifiers. The flowers of some Acacia species are
fragrant and used to make perfume. The heartwood of many Acacias is
used for making agricultural implements and also provides a source
of firewood. Acacia gums find extensive use in medicine and
confectionary and as sizing and finishing materials in the textile
industry.
[0006] Uncaria gambir (Rubiaceae) is a climbing shrub with round
branches, which is believed to strengthen teeth when chewed with
piper bettle leaves. All parts of the plant have astringent
properties. Leaves of the U. gambir plant contain free catechins as
well as polymerized catechins--tannins--which are more abundant in
younger leaves as compared to older leaves. U. gambir is listed in
the Food Additive Database in EAFUS (Everything Added to Food in
the United States), in the Korea Food Additives Code by KFDA, and
in the Japan Food Additives Code by MHLW as a natural flavoring
agent. U. gambir is also listed in the Korea Pharmaceutical Codex
(KP), Japan Pharmaceutical Codex (JP) and China Pharmaceutical
Codex (CP). In South Korea, there are many over-the-counter (OTC)
drugs that contain U. gambir extract, especially for dyspepsia,
halitosis, vomiting and anorexia. In Japan, U. gambir is used for
diarrhea, vomiting and gastritis. In the United States, U. gambir
is used as a dietary supplement to support liver function and fat
metabolism.
[0007] Curcuma longa L, with common name as turmeric, is a
perennial plant of the ginger family, Zingiberaceae. The name of
turmeric might come from Latin, terra merita (merited earth) or
turmeryte, which is related to saffron. It is originally from
tropical south Asia and cultivated extensively in India and
Southeast Asia. Turmeric is prepared from the ground rhizome and
has been used in India for thousands of years. Besides its culinary
usage, modern research has revealed that turmeric has
antibacterial, antioxidant, chemopreventive, chemotherapeutic,
antiproliferative, antiparasitic, anti-antimalarial,
antinociceptive, and anti-inflammatory properties.
BRIEF SUMMARY
[0008] In brief, the present disclosure is directed to compounds
and compositions useful for joint health management, including
stereoisomers, pharmaceutically or nutraceutically acceptable
salts, tautomers, glycosides and prodrugs of the disclosed
compounds, and to related methods of improving joint health.
[0009] In certain embodiments, this disclosure provides a
composition comprising a mixture of a Morus extract, optionally
enriched for one or more prenylated flavonoids (e.g., Diels-Alder
adducts of a chalcone and a prenylphenyl moiety), or one or more
stilbenes, or a combination thereof, and an Acacia extract,
optionally enriched for flavans. In further embodiments, this
disclosure provides a composition comprising a mixture of a Morus
extract, optionally enriched for prenylated flavonoids (e.g.,
Diels-Alder adducts of a chalcone and a prenylphenyl moiety), or
one or more stilbenes, or a combination thereof, and an Uncaria
gambir extract, optionally enriched for flavans. In further
embodiments, this disclosure provides a composition comprising a
mixture of a Morus extract enriched for one or more prenylated
flavonoids (e.g., Diels-Alder adducts of a chalcone and a
prenylphenyl moiety), or one or more stilbenes, or a combination
thereof, and a Curcuma extract. In other embodiments, this
disclosure provides a composition comprising a mixture of a Morus
extract enriched for one or more prenylated flavonoids (e.g.,
Diels-Alder adducts of a chalcone and a prenylphenyl moiety), or
one or more stilbenes, and a Peppermint extract. In other
embodiments, any of the compositions further, optionally, contain
one or more glucosamine compounds, such as N-acetyl
glucosamine.
[0010] For example, a mixture of Curcuma and Morus alba root-bark
extracts in a 1:1 ratio demonstrated beneficial synergistic effects
with enhanced anti-inflammatory and anti-nociceptive efficacy
compared with either Curcuma or Morus alba root-bark extracts
alone.
[0011] In another aspect, the present disclosure provides methods
for managing joint health. In certain embodiments, the compositions
of this disclosure can be used in methods for treating, preventing,
or managing joint cartilage, minimizing cartilage degradation,
promoting healthy joints by protecting cartilage integrity,
diminishing the action of enzymes that affect joint health,
improving joint movement and/or function, alleviating joint pain,
alleviating joint stiffness, improving joint range of motion and/or
flexibility, promote mobility, and/or any combination thereof.
[0012] These and other aspects of the invention will be apparent
upon reference to the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 shows the inhibition of BKB1 receptor binding by
Curcuma longa 88 HTP fractions.
DETAILED DESCRIPTION
[0014] In certain aspects, the present disclosure provides
prenylated flavonoids and resveratrol compounds mixed with flavans
or curcuminoids for use in improving joint health. In certain
embodiments, prenylated flavonoids and resveratrol compounds are
extracted Morus alba, such as from the Morus alba root. In yet
another embodiment, a Morus extract combined with flavans is
optionally further combined with other joint health management
agents, such as non-steroidal anti-inflammatory agents/analgesics,
COX/LOX inhibiting agents such as acetaminophen, ibuprofen,
celecoxib, Boswellia extract, glucosamine compounds such as
glucosamine sulfate, glucosamine hydrochloride,
N-acetylglucosamine, chondroitin sulfate and methylsulfonylmethane,
hyaluronic acid, .omega.-3 fatty acids (such as eicosapentaenoic
acid, EPA and docosahexaenoic acid, DHA), hydrolyzed collagen
(e.g., from bovine type I collagen, chicken sternal type II
collagen), collagen derived peptides or a mixture of collagen amino
acids, xanthophyll carotenoids (e.g., astaxanthin, which is
distributed in marine bacteria, algae, crustaceans, fish),
multivitamins and minerals such as vitamin D and calcium
fructoborate, neuropathic pain relief agents, herbal and/or plant
extracts promoting joint health, or dietary supplements that
promote joint health.
[0015] Other embodiments relate to methods of use of the
compositions of this disclosure, such as maintaining joint
cartilage, minimizing cartilage degradation, promoting healthy
joints by protecting cartilage integrity, diminishing the action of
enzymes that affect joint health, improving joint movement and/or
function, alleviating joint pain, alleviating joint discomfort,
alleviating joint pain and discomfort, alleviating joint stiffness,
improving joint range of motion and/or flexibility, promote
mobility, or the like.
[0016] In the following description, certain specific details are
set forth in order to provide a thorough understanding of various
embodiments of this disclosure. However, one skilled in the art
will understand that the invention may be practiced without these
details.
[0017] In the present description, any concentration range,
percentage range, ratio range, or integer range is to be understood
to include the value of any integer within the recited range and,
when appropriate, fractions thereof (such as one tenth and one
hundredth of an integer), unless otherwise indicated. Also, any
number range recited herein relating to any physical feature, such
as polymer subunits, size or thickness, are to be understood to
include any integer within the recited range, unless otherwise
indicated. As used herein, the terms "about" and "consisting
essentially of" mean.+-.20% of the indicated range, value, or
structure, unless otherwise indicated. It should be understood that
the terms "a" and "an" as used herein refer to "one or more" of the
enumerated components. The use of the alternative (e.g., "or")
should be understood to mean either one, both, or any combination
thereof of the alternatives. Unless the context requires otherwise,
throughout the present specification and claims, the word
"comprise" and variations thereof, such as, "comprises" and
"comprising," as well as synonymous terms like "include" and "have"
and variants thereof, are to be construed in an open, inclusive
sense; that is, as "including, but not limited to."
[0018] Reference throughout this specification to "one embodiment"
or "an embodiment" means that a particular feature, structure or
characteristic described in connection with the embodiment is
included in at least one embodiment of the present invention. Thus,
the appearances of the phrases "in one embodiment" or "in an
embodiment" in various places throughout this specification are not
necessarily all referring to the same embodiment. Furthermore, the
particular features, structures, or characteristics may be combined
in any suitable manner in one or more embodiments.
[0019] "Amino" refers to the --NH.sub.2 radical.
[0020] "Cyano" refers to the --CN radical.
[0021] "Hydroxy" or "hydroxyl" refers to the --OH radical.
[0022] "Imino" refers to the .dbd.NH substituent.
[0023] "Nitro" refers to the --NO.sub.2 radical.
[0024] "Oxo" refers to the .dbd.O substituent.
[0025] "Thioxo" refers to the .dbd.S substituent.
[0026] "Alkyl" refers to a straight or branched hydrocarbon chain
radical consisting solely of carbon and hydrogen atoms, which is
saturated or unsaturated (i.e., contains one or more double or
triple bonds), having from one to twelve carbon atoms
(C.sub.1-C.sub.12 alkyl), or one to eight carbon atoms
(C.sub.1-C.sub.8 alkyl) or one to six carbon atoms (C.sub.1-C.sub.6
alkyl), and which is attached to the rest of the molecule by a
single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl
(iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl),
3-methylhexyl, 2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl,
pent-1-enyl, penta-1,4-dienyl, ethynyl, propynyl, butynyl,
pentynyl, hexynyl, and the like. Unless stated otherwise
specifically in the specification, an alkyl group may be optionally
substituted.
[0027] "Alkylene" or "alkylene chain" refers to a straight or
branched divalent hydrocarbon chain linking the rest of the
molecule to a radical group, consisting solely of carbon and
hydrogen, which is saturated or unsaturated (i.e., contains one or
more double or triple bonds), and having from one to twelve carbon
atoms, e.g., methylene, ethylene, propylene, n-butylene,
ethenylene, propenylene, n-butenylene, propynylene, n-butynylene,
and the like. The alkylene chain is attached to the rest of the
molecule through a single or double bond and to the radical group
through a single or double bond. The points of attachment of the
alkylene chain to the rest of the molecule and to the radical group
can be through one carbon or any two carbons within the chain.
Unless stated otherwise specifically in the specification, an
alkylene chain may be optionally substituted.
[0028] "Alkoxy" refers to a radical of the formula --OR.sub.a where
R.sub.a is an alkyl radical as defined above containing one to
twelve carbon atoms. Unless stated otherwise specifically in the
specification, an alkoxy group may be optionally substituted.
[0029] "Alkylamino" refers to a radical of the formula --NHR.sub.a
or --NR.sub.aR.sub.a where each R.sub.a is, independently, an alkyl
radical as defined above containing one to twelve carbon atoms.
Unless stated otherwise specifically in the specification, an
alkylamino group may be optionally substituted.
[0030] "Thioalkyl" refers to a radical of the formula --SR.sub.a
where R.sub.a is an alkyl radical as defined above containing one
to twelve carbon atoms. Unless stated otherwise specifically in the
specification, a thioalkyl group may be optionally substituted.
[0031] "Aryl" refers to a hydrocarbon ring system radical
comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic
ring. For purposes of this disclosure, the aryl radical may be a
monocyclic, bicyclic, tricyclic or tetracyclic ring system, which
may include fused or bridged ring systems. Aryl radicals include
aryl radicals derived from aceanthrylene, acenaphthylene,
acephenanthrylene, anthracene, azulene, benzene, chrysene,
fluoranthene, fluorene, as-indacene, s-indacene, indane, indene,
naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and
triphenylene. Unless stated otherwise specifically in the
specification, the term "aryl" or the prefix "ar-" (such as in
"aralkyl") is meant to include aryl radicals that are optionally
substituted.
[0032] "Aralkyl" refers to a radical of the formula
--R.sub.b--R.sub.c where R.sub.b is an alkylene chain as defined
above and R.sub.c is one or more aryl radicals as defined above,
for example, benzyl, diphenylmethyl and the like. Unless stated
otherwise specifically in the specification, an aralkyl group may
be optionally substituted.
[0033] "Cycloalkyl" or "carbocyclic ring" refers to a stable
non-aromatic monocyclic or polycyclic hydrocarbon radical
consisting solely of carbon and hydrogen atoms, which may include
fused or bridged ring systems, having from three to fifteen carbon
atoms, or having from three to ten carbon atoms, and which is
saturated or unsaturated and attached to the rest of the molecule
by a single bond. Monocyclic radicals include, for example,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and
cyclooctyl. Polycyclic radicals include, for example, adamantyl,
norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the
like. Unless otherwise stated specifically in the specification, a
cycloalkyl group may be optionally substituted.
[0034] "Cycloalkylalkyl" refers to a radical of the formula
--R.sub.bR.sub.d where R.sub.b is an alkylene chain as defined
above and R.sub.d is a cycloalkyl radical as defined above. Unless
stated otherwise specifically in the specification, a
cycloalkylalkyl group may be optionally substituted.
[0035] "Fused" refers to any ring structure described herein which
is fused to an existing ring structure in the compounds of this
disclosure. When the fused ring is a heterocyclyl ring or a
heteroaryl ring, any carbon atom on the existing ring structure
which becomes part of the fused heterocyclyl ring or the fused
heteroaryl ring may be replaced with a nitrogen atom.
[0036] "Halo" or "halogen" refers to bromo, chloro, fluoro or
iodo.
[0037] "Haloalkyl" refers to an alkyl radical, as defined above,
that is substituted by one or more halo radicals, as defined above,
e.g., trifluoromethyl, difluoromethyl, trichloromethyl,
2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl,
1,2-dibromoethyl, and the like. Unless stated otherwise
specifically in the specification, a haloalkyl group may be
optionally substituted.
[0038] "Heterocyclyl" or "heterocyclic ring" refers to a stable 3-
to 18-membered non-aromatic ring radical which consists of two to
twelve carbon atoms and from one to six heteroatoms selected from
the group consisting of nitrogen, oxygen and sulfur. Unless stated
otherwise specifically in the specification, the heterocyclyl
radical may be a monocyclic, bicyclic, tricyclic or tetracyclic
ring system, which may include fused or bridged ring systems; and
the nitrogen, carbon or sulfur atoms in the heterocyclyl radical
may be optionally oxidized; the nitrogen atom may be optionally
quaternized; and the heterocyclyl radical may be partially or fully
saturated. Examples of such heterocyclyl radicals include
dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl,
imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl,
morpholinyl, octahydroindolyl, octahydroisoindolyl,
2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl,
oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl,
pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl,
tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl,
thiamorpholinyl, 1-oxo-thiomorpholinyl, and
1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in
the specification, a heterocyclyl group may be optionally
substituted.
[0039] "N-heterocyclyl" refers to a heterocyclyl radical as defined
above containing at least one nitrogen and where the point of
attachment of the heterocyclyl radical to the rest of the molecule
is through a nitrogen atom in the heterocyclyl radical. Unless
stated otherwise specifically in the specification, a
N-heterocyclyl group may be optionally substituted.
[0040] "Heterocyclylalkyl" refers to a radical of the formula
--R.sub.bR.sub.e where R.sub.b is an alkylene chain as defined
above and R.sub.e is a heterocyclyl radical as defined above, and
if the heterocyclyl is a nitrogen-containing heterocyclyl, the
heterocyclyl may be attached to the alkyl radical at the nitrogen
atom. Unless stated otherwise specifically in the specification, a
heterocyclylalkyl group may be optionally substituted.
[0041] "Heteroaryl" refers to a 5- to 14-membered ring system
radical comprising hydrogen atoms, one to thirteen carbon atoms,
one to six heteroatoms selected from the group consisting of
nitrogen, oxygen and sulfur, and at least one aromatic ring. For
purposes of this disclosure, the heteroaryl radical may be a
monocyclic, bicyclic, tricyclic or tetracyclic ring system, which
may include fused or bridged ring systems; and the nitrogen, carbon
or sulfur atoms in the heteroaryl radical may be optionally
oxidized; the nitrogen atom may be optionally quaternized. Examples
include azepinyl, acridinyl, benzimidazolyl, benzothiazolyl,
benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl,
benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl,
1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl,
benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl,
benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl),
benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl,
cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl,
isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl,
isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl,
isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl,
oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl,
1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl,
phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl,
pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl,
isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl,
triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl).
Unless stated otherwise specifically in the specification, a
heteroaryl group may be optionally substituted.
[0042] "N-heteroaryl" refers to a heteroaryl radical as defined
above containing at least one nitrogen and where the point of
attachment of the heteroaryl radical to the rest of the molecule is
through a nitrogen atom in the heteroaryl radical. Unless stated
otherwise specifically in the specification, an N-heteroaryl group
may be optionally substituted.
[0043] "Heteroarylalkyl" refers to a radical of the formula
--R.sub.bR.sub.f where R.sub.b is an alkylene chain as defined
above and R.sub.f is a heteroaryl radical as defined above. Unless
stated otherwise specifically in the specification, a
heteroarylalkyl group may be optionally substituted.
[0044] The term "substituted" used herein means any of the above
groups (i.e., alkyl, alkylene, alkoxy, alkylamino, thioalkyl, aryl,
aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl,
N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl or
heteroarylalkyl), wherein at least one hydrogen atom is replaced by
a bond to a non-hydrogen atoms such as a halogen atom such as F,
Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups,
alkoxy groups, and ester groups; a sulfur atom in groups such as
thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups,
and sulfoxide groups; a nitrogen atom in groups such as amines,
amides, alkylamines, dialkylamines, arylamines, alkylarylamines,
diarylamines, N-oxides, imides, and enamines; a silicon atom in
groups such as trialkylsilyl groups, dialkylarylsilyl groups,
alkyldiarylsilyl groups, and triarylsilyl groups; and other
heteroatoms in various other groups. "Substituted" also means any
of the above groups in which one or more hydrogen atoms are
replaced by a higher-order bond (e.g., a double- or triple-bond) to
a heteroatom, such as oxygen in oxo, carbonyl, carboxyl, and ester
groups; and nitrogen in groups such as imines, oximes, hydrazones,
and nitriles. For example, "substituted" includes any of the above
groups in which one or more hydrogen atoms are replaced with
--NR.sub.gR.sub.h, --NR.sub.gC(.dbd.O)R.sub.h,
--NR.sub.gC(.dbd.O)NR.sub.gR.sub.h, --NR.sub.gC(.dbd.O)OR.sub.h,
--NR.sub.gSO.sub.2R.sub.h, --OC(.dbd.O)NR.sub.gR.sub.h, --OR.sub.g,
--SR.sub.g, --SOR.sub.g, --SO.sub.2R.sub.g, --OSO.sub.2R.sub.g,
--SO.sub.2OR.sub.g, .dbd.NSO.sub.2R.sub.g, and
--SO.sub.2NR.sub.gR.sub.h. "Substituted" also means any of the
above groups in which one or more hydrogen atoms are replaced with
--C(.dbd.O)R.sub.g, --C(.dbd.O)OR.sub.g,
--C(.dbd.O)NR.sub.gR.sub.h, --CH.sub.2SO.sub.2R.sub.g,
--CH.sub.2SO.sub.2NR.sub.gR.sub.h. In the foregoing, R.sub.g and
R.sub.h are the same or different and independently hydrogen,
alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl,
heterocyclylalkyl, heteroaryl, N-heteroaryl or heteroarylalkyl.
"Substituted" further means any of the above groups in which one or
more hydrogen atoms are replaced by a bond to an amino, cyano,
hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy,
alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl,
heteroaryl, N-heteroaryl or heteroarylalkyl group. In addition,
each of the foregoing substituents may also be optionally
substituted with one or more of the above substituents.
[0045] "Glycoside" refers to a molecule in which a sugar group is
bonded through its anomeric carbon to another group via a
glycosidic bond. Exemplary sugars include glucose, rhamnose,
manose, galactose, arabinose, glucuronide and others. Glycosides
can be linked by an O-(an O-glycoside), N-(a glycosylamine), S-(a
thioglycoside), or C-(a C-glycoside) glycosidic bond. Compounds of
this disclosure can form glycosides at any suitable attachment
point.
[0046] A "prenyl group" is a moiety comprising a five-carbon
backbone of the following structure:
##STR00001##
In some embodiments, prenyl groups comprise one or more
carbon-carbon double bonds and/or are substituted with one or more
substituents. "Prenyl" refers to the
##STR00002##
radical. Isoprenyl refers to the
##STR00003##
radical (cis or trans). Prenyl groups are substituted or
unsubstituted, such as
##STR00004##
[0047] "Prenylphenyl" refers to a phenyl moiety connected to a
prenyl moiety as defined above. Prenylphenyls include substituted
phenyls such as flavonoids and other substituted phenyls and
heteroaryls, provided there is at least one prenyl group in the
molecule. In the case of substituted phenyls and heteroaryl, the
prenyl moiety need not be directly attached to the phenyl ring, but
can be attached at any point in the molecule.
[0048] "Chalcone" refers to a compound comprising the following
core structure:
##STR00005##
Chalcones can be variously substituted at any of the above carbon
atoms.
[0049] "Prodrug" is meant to indicate a compound that may be
converted under physiological conditions or by solvolysis to a
biologically active compound of this disclosure. Thus, the term
"prodrug" refers to a metabolic precursor of a compound of this
disclosure that is pharmaceutically and nutraceutically acceptable.
A prodrug may be inactive when administered to a subject in need
thereof, but is converted in vivo to an active compound of this
disclosure. Prodrugs are typically rapidly transformed in vivo to
yield the parent compound of this disclosure, for example, by
hydrolysis in blood or intestine or metabolized in the liver. The
prodrug compound often offers advantages of solubility, tissue
compatibility or delayed release in a mammalian organism (see
Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier,
Amsterdam)). A discussion of prodrugs is provided in Higuchi, T.,
et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible
Carriers in Drug Design, Ed. Edward B. Roche, American
Pharmaceutical and Nutraceutical Association and Pergamon Press,
1987.
[0050] The term "prodrug" is also meant to include any covalently
bonded carriers, which release the active compound of this
disclosure in vivo when such prodrug is administered to a mammalian
subject. Prodrugs of a compound of this disclosure may be prepared
by modifying functional groups present in the compound of this
disclosure in such a way that the modifications are cleaved, either
in routine manipulation or in vivo, to the parent compound of this
disclosure. Prodrugs include compounds of this disclosure wherein a
hydroxy, amino or mercapto group is bonded to any group that, when
the prodrug of the compound of this disclosure is administered to a
mammalian subject, cleaves to form a free hydroxy, free amino or
free mercapto group, respectively. Examples of prodrugs include
acetate, formate and benzoate derivatives of alcohol or amide
derivatives of amine functional groups in the compounds of this
disclosure and the like.
[0051] The instant disclosure is also meant to encompass all
pharmaceutically or nutraceutically acceptable compounds of any one
of structures (I)-(VI) being isotopically-labelled by having one or
more atoms replaced by an atom having a different atomic mass or
mass number. Examples of isotopes that can be incorporated into the
disclosed compounds include isotopes of hydrogen, carbon, nitrogen,
oxygen, phosphorous, fluorine, chlorine, and iodine, such as
.sup.2H, .sup.3H, .sup.11C, .sup.13C, .sup.14C, .sup.13N, .sup.15N,
.sup.15O, .sup.17O, .sup.18O, .sup.31P, .sup.32P, .sup.35S,
.sup.18F, .sup.36Cl, .sup.123I, and .sup.125I, respectively. These
radiolabelled compounds could be useful to help determine or
measure the effectiveness of the compounds, by characterizing, for
example, the site or mode of action, or binding affinity to
pharmacologically important site of action. Certain
isotopically-labelled compounds of any one of structures (I)-(VI),
for example, those incorporating a radioactive isotope, are useful
in drug or substrate tissue distribution studies. The radioactive
isotopes tritium, i.e., .sup.3H, and carbon-14, i.e., .sup.14C, are
particularly useful for this purpose in view of their ease of
incorporation and ready means of detection.
[0052] Substitution with heavier isotopes such as deuterium, i.e.,
.sup.2H, may afford certain therapeutic advantages resulting from
greater metabolic stability, for example, increased in vivo
half-life or reduced dosage requirements, and hence may be
preferred in some circumstances.
[0053] Substitution with positron emitting isotopes, such as
.sup.11C, .sup.18F, .sup.15O and .sup.13N, can be useful in
Positron Emission Topography (PET) studies for examining substrate
receptor occupancy. Isotopically-labeled compounds of any one of
structures (I)-(VI) can generally be prepared by conventional
techniques known to those skilled in the art or by processes
analogous to those described in the preparations and examples as
set out herein using an appropriate isotopically-labeled reagent in
place of the non-labeled reagent previously employed.
[0054] The instant disclosure is also meant to encompass the in
vivo metabolic products of the disclosed compounds. Such products
may result from, for example, the oxidation, reduction, hydrolysis,
amidation, esterification, and the like of the administered
compound, primarily due to enzymatic processes. Accordingly, this
disclosure includes compounds produced by a process comprising
administering a compound of this disclosure to a mammal for a
period of time sufficient to yield a metabolic product thereof.
Such products are typically identified by administering a
radiolabelled compound of this disclosure in a detectable dose to
an animal, such as rat, mouse, guinea pig, dog, cat, pig, sheep,
horse, monkey, or human, allowing sufficient time for metabolism to
occur, and isolating its conversion products from the urine, blood
or other biological samples.
[0055] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0056] "Mammal" includes humans and both domestic animals, such as
laboratory animals or household pets (e.g., rat, mouse, guinea pig,
cats, dogs, swine, cattle, sheep, goats, horses, rabbits,
primates), and non-domestic animals, such as wildlife or the
like.
[0057] "Optional" or "optionally" means that the subsequently
described element, component, event or circumstances may or may not
occur, and includes instances where the element, component, event
or circumstance occur and instances in which they do not. For
example, "optionally substituted aryl" means that the aryl radical
may or may not be substituted--in other words, the description
includes both substituted aryl radicals and aryl radicals having no
substitution.
[0058] "Pharmaceutically or nutraceutically acceptable carrier,
diluent or excipient" includes any adjuvant, carrier, excipient,
glidant, sweetening agent, diluent, preservative, dye/colorant,
flavor enhancer, surfactant, wetting agent, dispersing agent,
suspending agent, stabilizer, isotonic agent, solvent, or
emulsifier which has been approved by the United States Food and
Drug Administration as being acceptable for use in humans or
domestic animals.
[0059] "Pharmaceutically or nutraceutically acceptable salt"
includes both acid and base addition salts.
[0060] "Pharmaceutically or nutraceutically acceptable acid
addition salt" refers to those salts which retain the biological
effectiveness and properties of the free bases, which are not
biologically or otherwise undesirable, and which are formed with
inorganic acids such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid and the like, and
organic acids such as acetic acid, 2,2-dichloroacetic acid, adipic
acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic
acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid,
camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid,
carbonic acid, cinnamic acid, citric acid, cyclamic acid,
dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic
acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid,
galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid,
glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid,
glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric
acid, lactic acid, lactobionic acid, lauric acid, maleic acid,
malic acid, malonic acid, mandelic acid, methanesulfonic acid,
mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic
acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid,
orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic
acid, pyroglutamic acid, pyruvic acid, salicylic acid,
4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid,
tartaric acid, thiocyanic acid, p-toluenesulfonic acid,
trifluoroacetic acid, undecylenic acid, or the like.
[0061] "Pharmaceutically or nutraceutically acceptable base
addition salt" refers to those salts which retain the biological
effectiveness and properties of the free acids, which are not
biologically or otherwise undesirable. These salts are prepared
from addition of an inorganic base or an organic base to the free
acid. Salts derived from inorganic bases include the sodium,
potassium, lithium, ammonium, calcium, magnesium, iron, zinc,
copper, manganese, aluminum salts and the like. In certain
embodiments, the inorganic salts are ammonium, sodium, potassium,
calcium, or magnesium salts. Salts derived from organic bases
include salts of primary, secondary, and tertiary amines,
substituted amines including naturally occurring substituted
amines, cyclic amines and basic ion exchange resins, such as
ammonia, isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, diethanolamine, ethanolamine,
deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol,
dicyclohexylamine, lysine, arginine, histidine, procaine,
hydrabamine, choline, betaine, benethamine, benzathine,
ethylenediamine, glucosamine, methylglucamine, theobromine,
triethanolamine, tromethamine, purines, piperazine, piperidine,
N-ethylpiperidine, polyamine resins and the like. Particularly
useful organic bases include isopropylamine, diethylamine,
ethanolamine, trimethylamine, dicyclohexylamine, choline, or
caffeine.
[0062] Often crystallizations produce a solvate of the compound of
this disclosure. As used herein, the term "solvate" refers to an
aggregate that comprises one or more molecules of a compound of
this disclosure with one or more molecules of solvent. The solvent
may be water, in which case the solvate may be a hydrate.
Alternatively, the solvent may be an organic solvent. Thus, the
compounds of the present disclosure may exist as a hydrate,
including a monohydrate, dihydrate, hemihydrate, sesquihydrate,
trihydrate, tetrahydrate and the like, as well as the corresponding
solvated forms. The compound of this disclosure may be true
solvates, while in other cases, the compound of this disclosure may
merely retain adventitious water or be a mixture of water plus some
adventitious solvent.
[0063] A "pharmaceutical composition" or "nutraceutical
composition" refers to a formulation of a compound of this
disclosure and a medium generally accepted in the art for the
delivery of the biologically active compound to mammals, e.g.,
humans. For example, a pharmaceutical composition of the present
disclosure may be formulated or used as a stand alone composition,
or as a component in a prescription drug, an over-the-counter (OTC)
medicine, a botanical drug, an herbal medicine, a homeopathic
agent, or any other form of health care product reviewed and
approved by a government agency. Exemplary nutraceutical
compositions of the present disclosure may be formulated or used as
a stand alone composition, or as a nutritional or bioactive
component in food, a novel food, a functional food, a beverage, a
bar, a food flavor, a food additive, a medical food, a dietary
supplement, or an herbal product. A medium generally accepted in
the art includes all pharmaceutically or nutraceutically acceptable
carriers, diluents or excipients therefor.
[0064] As used herein, "enriched for" refers to a plant extract or
other preparation having at least a two-fold up to about a
1000-fold increase in the amount or activity of one or more active
compounds as compared to the amount or activity of the one or more
active compounds found in the weight of the plant material or other
source before extraction or other preparation. In certain
embodiments, the weight of the plant material or other source
before extraction or other preparation may be dry weight, wet
weight, or a combination thereof.
[0065] As used herein, "major active ingredient" or "major active
component" refers to one or more active compounds found in a plant
extract or other preparation, or enriched for in a plant extract or
other preparation, which is capable of at least one biological
activity. In certain embodiments, a major active ingredient of an
enriched extract will be the one or more active compounds that were
enriched in that extract. Generally, one or more major active
components will impart, directly or indirectly, most (i.e., greater
than 50%) of one or more measurable biological activities or
effects as compared to other extract components. In certain
embodiments, a major active ingredient may be a minor component by
weight percentage of an extract (e.g., less than 50%, 25%, 20%,
15%, 10%, 5%, or 1% of the components contained in an extract) but
still provide most of the desired biological activity. Any
composition of this disclosure containing a major active ingredient
may also contain minor active ingredients that may or may not
contribute to the pharmaceutical or nutraceutical activity of the
enriched composition, but not to the level of major active
components, and minor active components alone may not be effective
in the absence of a major active ingredient.
[0066] "Effective amount" or "therapeutically effective amount"
refers to that amount of a compound or composition of this
disclosure that, when administered to a mammal, such as a human, is
sufficient to effect treatment, including any one or more of: (1)
treating or preventing loss of cartilage in a mammal; (2) promoting
joint health; (3) suppressing loss of cartilage in a mammal; (4)
increasing joint flexibility in a mammal; (5) treating or
preventing joint pain in a mammal; (6) modifying inflammation of a
joint in a mammal; and (7) increasing joint range of motion. The
amount of a compound or composition of this disclosure that
constitutes a "therapeutically effective amount" will vary
depending on the compound, the condition being treated and its
severity, the manner of administration, the duration of treatment,
or the body weight and age of a subject to be treated, but can be
determined by one of ordinary skill in the art having regard to his
own knowledge and to this disclosure.
[0067] "Supplements" as used herein refers to a product that
improves, promotes, supports, increases, regulates, manages,
controls, maintains, optimizes, modifies, reduces, inhibits, or
prevents a particular condition, structure or function associated
with a natural state or biological process (i.e., are not used to
diagnose, treat, mitigate, cure, or prevent disease). In certain
embodiments, a supplement is a dietary supplement. For example,
with regard to joint health-related conditions, dietary supplements
may be used to maintain joint cartilage, minimize cartilage
degradation, promote healthy joints by protecting cartilage
integrity, diminish the action of enzymes that affect joint health,
improve joint movement and/or function, support joint function,
alleviate joint pain, alleviate joint discomfort, alleviate joint
stiffness, improve joint range of motion, improve joint
flexibility, improve joint range of motion and flexibility, promote
mobility, or the like. In certain embodiments, dietary supplements
are a special category of diet, food or both, and are not a
drug.
[0068] "Treating" or "treatment" or "ameliorating" refers to either
a therapeutic treatment or prophylactic/preventative treatment of a
disease or condition of interest in a mammal, such as a human,
having or suspected of having a disease or condition of interest,
and includes: (i) preventing the disease or condition from
occurring in a mammal, in particular, when such mammal is
predisposed to the condition but has not yet been diagnosed as
having it; (ii) inhibiting the disease or condition, i.e.,
arresting its development; (iii) relieving the disease or
condition, i.e., causing regression of the disease or condition; or
(iv) relieving the symptoms resulting from the disease or
condition, (e.g., relieving pain, reducing inflammation, reducing
loss of cartilege) without addressing the underlying disease or
condition. As used herein, the terms "disease" and "condition" may
be used interchangeably or may be different in that the particular
malady or condition may not have a known causative agent (so that
etiology has not yet been worked out) and it is therefore not yet
recognized as a disease but only as an undesirable condition or
syndrome, wherein a more or less specific set of symptoms have been
identified by clinicians. In certain embodiments, the compositions
and methods of the instant disclosure are used to treat, for
example, osteoarthritis, rheumatoid arthritis, or both.
[0069] As used herein, "statistical significance" refers to a p
value of 0.050 or less as calculated using the Students t-test and
indicates that it is unlikely that a particular event or result
being measured has arisen by chance.
[0070] The chemical naming protocol and structure diagrams used
herein are a modified form of the I.U.P.A.C. nomenclature system,
using the ACD/Name Version 9.07 software program or ChemDraw Ultra
Version 11.0 software naming program (CambridgeSoft), wherein the
compounds of this disclosure are named herein as derivatives of the
central core structure, e.g., the imidazopyridine structure. For
complex chemical names employed herein, a substituent group is
named before the group to which it attaches. For example,
cyclopropylethyl comprises an ethyl backbone with cyclopropyl
substituent. Except as described below, all bonds are identified in
the chemical structure diagrams herein, except for some carbon
atoms, which are assumed to be bonded to sufficient hydrogen atoms
to complete the valency.
[0071] As noted herein, in certain embodiments, the present
disclosure provides a composition comprising prenylated flavonoids.
Flavonoids include flavans, flavones, flavonols, flavanones,
flavanonols, isoflavonoids, neoflavonoids, chalcones,
arylbenzofuran, or the like.
[0072] In certain embodiments, a flavonoid compound of the present
disclosure has structure (III), as follows:
##STR00006##
wherein R.sub.1-R.sub.12 are each independently H, hydroxyl, a
prenyl group, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkylcarbonyl, aralkylcarbonyl, or a bond to a compound of
structure (III) or (IV); or one of R.sub.1-R.sub.12 joins with
another one of R.sub.1-R.sub.12 to form a ring, and the remaining
R.sub.1-R.sub.12 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkylcarbonyl, aralkylcarbonyl or a bond to a compound of
structure (III) or (IV), provided that all valencies are satisfied
(e.g., when the optional double bond is present in ring C, then
R.sub.12 is absent and at least one of R.sub.10 or R.sub.11 is
absent). In certain embodiments, at least one of R.sub.1-R.sub.12
is a prenyl group, such as
##STR00007##
In further embodiments, the optional double bond is present in ring
C, R.sub.11 and R.sub.12 are absent, and R.sub.10 is a prenyl
group. In still further embodiments, at least one of
R.sub.1-R.sub.9 is a prenyl group and R.sub.10-R.sub.12 are
independently H or hydroxyl. In certain specific embodiments, the
prenylated flavonoids include Albanin G, Kuwanon G, Morusin, or any
combination thereof.
[0073] In certain embodiments, a flavonoid compound of the present
disclosure has structure (IV) as follows:
##STR00008##
wherein R.sub.1-R.sub.12 are each independently H, hydroxyl, a
prenyl group, flavonoid, chalcone, glycoside, halogen, sulfhydryl,
amino, aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12
alkthio, C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl,
heteroaryl, aralkyl, alkylcarbonyl, aralkylcarbonyl, or a bond to a
compound of structure (III) or (IV); or one of R.sub.1-R.sub.12
joins with another one of R.sub.1-R.sub.12 to form a ring, and the
remaining R.sub.1-R.sub.12 are each independently H, hydroxyl, a
prenyl group, flavonoid, chalcone, glycoside, halogen, sulfhydryl,
amino, aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12
alkthio, C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl,
heteroaryl, aralkyl, alkylcarbonyl, aralkylcarbonyl or a bond to a
compound of structure (III) or (IV), provided that all valencies
are satisfied (e.g., when the optional double bond is present in
ring C, then R.sub.12 is absent and at least one of R.sub.10 or
R.sub.11 is absent). In certain embodiments, at least one of
R.sub.1-R.sub.12 is a prenyl group, such as
##STR00009##
In further embodiments, the optional double bond is present in ring
C, R.sub.11 and R.sub.12 are absent, and R.sub.10 is a prenyl
group. In still further embodiments, at least one of
R.sub.1-R.sub.9 is a prenyl group and R.sub.10-R.sub.12 are
independently H or hydroxyl. In certain specific embodiments, the
prenylated flavonoids include Albanin G, Kuwanon G, Morusin,
morusinol, Sanggenon, isoxanthoumol, glabridin, cathayanon A, or
any combination thereof.
[0074] In some embodiments, a chalconoid compound of the present
disclosure has structure (V) as follows:
##STR00010##
wherein R.sub.1-R.sub.10 are each independently H, hydroxyl, a
prenyl group, flavonoid, chalcone, glycoside, halogen, sulfhydryl,
amino, aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12
alkthio, C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl,
heteroaryl, aralkyl, alkylcarbonyl, or aralkylcarbonyl. In certain
embodiments, at least one of R.sub.1-R.sub.10 is a prenyl group,
such as
##STR00011##
In further embodiments, the optional double bond is present in ring
C, R.sub.11 and R.sub.12 are absent, and R.sub.10 is a prenyl
group. In still further embodiments, at least one of
R.sub.1-R.sub.9 is a prenyl group and R.sub.10-R.sub.12 are
independently H or hydroxyl. In certain specific embodiments, a
chalconoid compound includes xanthohumol.
[0075] In certain embodiments, a stilbene compound of the present
disclosure is an (E)-stilbene (trans isomer) structure of formula I
or (Z)-stilbene (cis isomer) structure of formula II, as
follows:
##STR00012##
wherein R.sub.1-R.sub.10 are each independently H, hydroxyl,
glycoside, a prenyl group, flavonoid, chalcone, halogen,
sulfhydryl, amino, aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkenyl,
C.sub.1-12 alkoxy, C.sub.1-12 alkthio, C.sub.1-12 alkyamino,
cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkyl
carbonyl, or aralkylcarbonyl. In certain embodiments, at least one
of R.sub.1-R.sub.12 is a prenyl group, such as
##STR00013##
In further embodiments, R.sub.1, R.sub.5, R.sub.6 and R.sub.10 are
H. In still further embodiments, R.sub.2 is a glucoside, or R.sub.2
and R.sub.8 are glycosides, and one or more of R.sub.4, R.sub.9,
and R.sub.10 are hydroxyl. In yet further embodiments, R.sub.1,
R.sub.5, and R.sub.6 are H, and one or more of R.sub.2-R.sub.4 and
R.sub.7-R.sub.10 are independently hydroxyl, C.sub.1-3 alkoxy, or
any combination thereof. In certain specific embodiments, a
stilbene includes oxyresveratrol, resveratrol, piceatannol,
pinosylvin, 3,4'-dihydroxystilbene, combretastatin A-1,
pterostilbene, rhapontigenin, and a stilbene glycoside includes
mulberroside A, rhaponticin, piceid, astringin, or any combination
of these stilbenes or stilbene glycosides.
[0076] It is understood that any embodiment of the compounds of
structure (I) to (VI), as set forth above, and any specific
substituent set forth herein for the compounds of structure (I) to
(VI), may be independently combined with other embodiments or
substituents of any one of the compounds of structure (I) to (VI)
to form embodiments of this disclosure not specifically set forth
above. In addition, in the event that a list of substituents is
listed for any particular R group in a particular embodiment or
claim, it is understood that each individual substituent may be
deleted from the particular embodiment or claim and that the
remaining list of substituents will be considered to be within the
scope of this disclosure.
[0077] For the purposes of administration, compounds and
compositions of the present disclosure may be administered as a raw
chemical or may be formulated as pharmaceutical or nutraceutical
compositions. In certain embodiments, pharmaceutical or
nutraceutical compositions of the present disclosure comprise any
one or more of the compounds having structure (I) to (VI) and a
pharmaceutically or nutraceutically acceptable carrier, diluent or
excipient. The compounds of structures (I) to (VI) are individually
or in combination present in the composition in an amount that is
effective to treat a particular disease or condition of interest.
Promoting, managing, or improving joint health or treating disease
with compounds as set forth in any one of structures (I) to (VI)
can be determined by one skilled in the art, for example, as
described in the Examples herein.
[0078] In certain embodiments, compounds and compositions (e.g.,
pharmaceutical, nutraceutical) of the present disclosure may be
administered in an amount sufficient to promote joint health;
improve joint health; maintain joint health; treat or manage joint
health; support joint health; support a normal and comfortable
range of motion and/or flexibility; improve range of motion and/or
flexibility; reduce the action of harmful enzymes that break down
protective joint tissues; alter the action of enzymes that affect
joint health; improve joint movement and/or joint function; improve
physical mobility; manage and/or maintain physical mobility;
alleviate joint pain and/or joint stiffness; improve joint physical
function; promote or enhance flexibility and comfortable movement;
promote healthy joint function and joint comfort; relieve joint
discomfort; relieve joint discomfort caused by exercise, work,
overexertion or any combination thereof; promote healthy joints by
protecting cartilage integrity; maintain joint cartilage; support
joint cartilage; treat, prevent, or manage cartilage degradation;
minimize cartilage degradation; promote joint health or comfort by
maintaining synovial fluid for joint lubrication; support joint
stability and joint flexibility; revitalize joints and promote
mobility; promote flexible joints and strong cartilage; maintain
steady blood flow to joints to support enhanced flexibility and/or
strength; promote joint comfort and a wide range of motion after
exercise, work, overexertion, or any combination thereof; or any
other associated indication described herein, and generally with
acceptable toxicity to a patient.
[0079] In certain other embodiments, compounds and compositions
(e.g., pharmaceutical, nutraceutical) of the present disclosure may
be administered in an amount sufficient to treat osteoarthritis,
rheumatoid arthritis, juvenile rheumatoid arthritis, Still's
disease, psoriatic arthritis, reactive arthritis, septic arthritis,
Reiter's syndrome, Behcet's syndrome, Felty's syndrome, systemic
lupus erythematosus, ankylosing spondylitis, diffuse idiopathic
skeletal hyperostosis (DISH), sacroiliac joint dysfunction,
polymyalgia rheumatic, carpal tunnel syndrome, gout, bursitis,
tendenitis, synovitis, SAPHO (synovitis, acne, pustulosis,
hyperostosis, osteitis) syndrome, patella chondromalacia,
repetitive strain injury, sprain, dislocation, or any other
associated indication, and generally with acceptable toxicity to a
patient.
[0080] Administration of the compounds of this disclosure, or their
pharmaceutically or nutraceutically acceptable salts, in pure form
or in an appropriate pharmaceutical or nutraceutical composition,
can be carried out via any of the accepted modes of administration
of agents for serving similar utilities. The pharmaceutical or
nutraceutical compositions of this disclosure can be prepared by
combining a compound of this disclosure with an appropriate
pharmaceutically or nutraceutically acceptable carrier, diluent or
excipient, and may be formulated into preparations in solid,
semi-solid, liquid or gaseous forms, such as tablets, capsules,
powders, granules, ointments, solutions, suppositories, injections,
inhalants, gels, microspheres, and aerosols. Typical routes of
administering such pharmaceutical or nutraceutical compositions
include oral, topical, transdermal, inhalation, parenteral,
sublingual, buccal, rectal, vaginal, or intranasal. The term
parenteral as used herein includes subcutaneous injections,
intravenous, intramuscular, intrasternal injection or infusion
techniques. Pharmaceutical or nutraceutical compositions of this
disclosure are formulated so as to allow the active ingredients
contained therein to be bioavailable upon administration of the
composition to a patient. In certain embodiments, compositions of
the present disclosure are administered to a subject or patient in
the form of one or more dosage units, where, for example, a tablet
may be a single dosage unit, and a container of a compound of this
disclosure in aerosol form may hold a plurality of dosage units.
Actual methods of preparing such dosage forms are known, or will be
apparent, to those skilled in this art; for example, see Remington:
The Science and Practice of Pharmacy, 20.sup.th Edition
(Philadelphia College of Pharmacy and Science, 2000). The
composition to be administered will, in any event, contain a
therapeutically effective amount of a compound of this disclosure,
or a pharmaceutically or nutraceutically acceptable salt thereof,
for treatment of a disease or condition of interest in accordance
with the teachings of this disclosure.
[0081] A pharmaceutical or nutraceutical composition of this
disclosure may be in the form of a solid or liquid. In one aspect,
the carrier(s) are particulate, so that the compositions are, for
example, in tablet or powder form. The carrier(s) may be liquid,
with the compositions being, for example, oral syrup, injectable
liquid or an aerosol, which is useful in, for example, inhalatory
administration.
[0082] When intended for oral administration, the pharmaceutical or
nutraceutical composition is in either solid or liquid form, where
semi-solid, semi-liquid, suspension and gel forms are included
within the forms considered herein as either solid or liquid.
[0083] As a solid composition for oral administration, the
pharmaceutical or nutraceutical composition may be formulated into
a powder, granule, compressed tablet, pill, capsule, chewing gum,
wafer, bar, or like form. Such a solid composition will typically
contain one or more inert diluents or edible carriers. In addition,
one or more of the following may be present: binders such as
carboxymethylcellulose, ethyl cellulose, cyclodextrin,
microcrystalline cellulose, gum tragacanth or gelatin; excipients
such as starch, lactose or dextrins, disintegrating agents such as
alginic acid, sodium alginate, Primogel, corn starch and the like;
lubricants such as magnesium stearate or Sterotex.RTM.; glidants
such as colloidal silicon dioxide; sweetening agents such as
sucrose or saccharin; a flavoring agent such as peppermint, methyl
salicylate or orange flavoring; and a coloring agent.
[0084] When the pharmaceutical or nutraceutical composition is in
the form of a capsule, for example, a gelatin capsule, it may
contain, in addition to materials of the above type, a liquid
carrier such as polyethylene glycol or oil.
[0085] The pharmaceutical or nutraceutical composition may be in
the form of a liquid, for example, an elixir, syrup, gel, solution,
emulsion or suspension. The liquid may be for oral administration
or for delivery by injection, as two examples. When intended for
oral administration, a useful composition contains, in addition to
the present compounds, one or more of a sweetening agent,
preservatives, dye/colorant and flavor enhancer. In a composition
intended to be administered by injection, one or more of a
surfactant, preservative, wetting agent, dispersing agent,
suspending agent, buffer, stabilizer and isotonic agent may be
included.
[0086] The liquid pharmaceutical or nutraceutical compositions of
this disclosure, whether they be solutions, suspensions or other
like form, may include one or more of the following adjuvants:
sterile diluents such as water for injection, saline solution, such
as physiological saline, Ringer's solution, isotonic sodium
chloride, fixed oils such as synthetic mono or diglycerides which
may serve as the solvent or suspending medium, polyethylene
glycols, glycerin, propylene glycol or other solvents;
antibacterial agents such as benzyl alcohol or methyl paraben;
antioxidants such as ascorbic acid or sodium bisulfite; chelating
agents such as ethylenediaminetetraacetic acid; buffers such as
acetates, citrates or phosphates and agents for the adjustment of
tonicity such as sodium chloride or dextrose. The parenteral
preparation can be enclosed in ampoules, disposable syringes or
multiple dose vials made of glass or plastic. Physiological saline
is a generally useful adjuvant. An injectable pharmaceutical or
nutraceutical composition is sterile.
[0087] A liquid pharmaceutical or nutraceutical composition of this
disclosure intended for either parenteral or oral administration
should contain an amount of a compound of this disclosure such that
a suitable dosage will be obtained.
[0088] The pharmaceutical or nutraceutical composition of this
disclosure may be intended for topical administration, in which
case the carrier may suitably comprise a solution, emulsion, cream,
lotion, ointment, or gel base. The base, for example, may comprise
one or more of the following: petrolatum, lanolin, polyethylene
glycols, bee wax, mineral oil, diluents such as water and alcohol,
and emulsifiers and stabilizers. Thickening agents may be present
in a pharmaceutical or nutraceutical composition for topical
administration. If intended for transdermal administration, the
composition may include a transdermal patch or iontophoresis
device.
[0089] The pharmaceutical or nutraceutical composition of this
disclosure may be intended for rectal administration, in the form,
for example, of a suppository, which will melt in the rectum and
release the drug. The composition for rectal administration may
contain an oleaginous base as a suitable nonirritating excipient.
Such bases include lanolin, cocoa butter and polyethylene
glycol.
[0090] The pharmaceutical or nutraceutical composition of this
disclosure may include various materials, which modify the physical
form of a solid or liquid dosage unit. For example, the composition
may include materials that form a coating shell around the active
ingredients. The materials that form the coating shell are
typically inert, and may be selected from, for example, sugar,
shellac, and other enteric coating agents. Alternatively, the
active ingredients may be encased in a gelatin capsule.
[0091] The pharmaceutical or nutraceutical composition of this
disclosure in solid or liquid form may include an agent that binds
to the compound of this disclosure and thereby assists in the
delivery of the compound. Suitable agents that may act in this
capacity include a monoclonal or polyclonal antibody, a protein or
a liposome.
[0092] The pharmaceutical or nutraceutical composition of this
disclosure in solid or liquid form may include reducing the size of
a particle to, for example, improve bioavailability. The size of a
powder, granule, particle, microsphere, or the like in a
composition, with or without an excipient, can be macro (e.g.,
visible to the eye or at least 100 .mu.m in size), micro (e.g., may
range from about 100 .mu.m to about 100 nm in size), nano (e.g.,
may no more than 100 nm in size), and any size in between or any
combination thereof to improve size and bulk density.
[0093] The pharmaceutical or nutraceutical composition of this
disclosure may consist of dosage units that can be administered as
an aerosol. The term aerosol is used to denote a variety of systems
ranging from those of colloidal nature to systems consisting of
pressurized packages. Delivery may be by a liquefied or compressed
gas or by a suitable pump system that dispenses the active
ingredients. Aerosols of compounds of this disclosure may be
delivered in single phase, bi-phasic, or tri-phasic systems in
order to deliver the active ingredient(s). Delivery of the aerosol
includes the necessary container, activators, valves,
subcontainers, and the like, which together may form a kit. One
skilled in the art, without undue experimentation, may determine
the most appropriate aerosol(s).
[0094] The pharmaceutical or nutraceutical compositions of this
disclosure may be prepared by methodology well known in the
pharmaceutical or nutraceutical art. For example, a pharmaceutical
or nutraceutical composition intended to be administered by
injection can be prepared by combining a compound of this
disclosure with sterile, distilled water so as to form a solution.
A surfactant may be added to facilitate the formation of a
homogeneous solution or suspension. Surfactants are compounds that
non-covalently interact with the compound of this disclosure so as
to facilitate dissolution or homogeneous suspension of the compound
in the aqueous delivery system.
[0095] The compounds of this disclosure, or their pharmaceutically
or nutraceutically acceptable salts, are administered in a
therapeutically effective amount, which will vary depending upon a
variety of factors including the activity of the specific compound
employed; the metabolic stability and length of action of the
compound; the age, body weight, general health, sex, and diet of
the patient; the mode and time of administration; the rate of
excretion; the drug combination; the severity of the particular
disorder or condition; and the subject undergoing therapy.
[0096] Compounds of this disclosure, or pharmaceutically or
nutraceutically acceptable derivatives thereof, may also be
administered simultaneously with, prior to, or after administration
of one or more other therapeutic agents. Such combination therapy
includes administration of a single pharmaceutical or nutraceutical
dosage formulation which contains a compound of this disclosure and
one or more additional active agents, as well as administration of
the compound of this disclosure and each active agent in its own
separate pharmaceutical or nutraceutical dosage formulation. For
example, a compound of this disclosure and another active agent can
be administered to the patient together in a single oral dosage
composition, such as a tablet or capsule, or each agent can be
administered in separate oral dosage formulations. Where separate
dosage formulations are used, the compounds of this disclosure and
one or more additional active agents can be administered at
essentially the same time, i.e., concurrently, or at separate
staggered times, i.e., sequentially; combination therapy is
understood to include all these regimens.
[0097] It is understood that in the present description,
combinations of substituents or variables of the depicted formulae
are permissible only if such contributions result in stable
compounds.
[0098] It will also be appreciated by those skilled in the art that
in the process described herein the functional groups of
intermediate compounds may need to be protected by suitable
protecting groups. Such functional groups include hydroxy, amino,
mercapto and carboxylic acid. Suitable protecting groups for
hydroxy include trialkylsilyl or diarylalkylsilyl (for example,
t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl),
tetrahydropyranyl, benzyl, and the like. Suitable protecting groups
for amino, amidino and guanidino include t-butoxycarbonyl,
benzyloxycarbonyl, and the like. Suitable protecting groups for
mercapto include --C(O)--R'' (where R'' is alkyl, aryl or
arylalkyl), p-methoxybenzyl, trityl and the like. Suitable
protecting groups for carboxylic acid include alkyl, aryl or
arylalkyl esters. Protecting groups may be added or removed in
accordance with standard techniques, which are known to one skilled
in the art and as described herein. The use of protecting groups is
described in detail in Green, T.W. and P.G.M. Wutz, Protective
Groups in Organic Synthesis (1999), 3.sup.rd Ed., Wiley. As one of
skill in the art would appreciate, a protecting group may also be a
polymer resin such as a Wang resin, Rink resin or a
2-chlorotrityl-chloride resin.
[0099] It will also be appreciated by those skilled in the art,
although such protected derivatives of compounds of this disclosure
may not possess pharmacological activity as such, they may be
administered to a mammal and thereafter metabolized in the body to
form compounds of this disclosure which are pharmacologically
active. Such derivatives may therefore be described as "prodrugs".
All prodrugs of compounds of this disclosure are included within
the scope of this disclosure.
[0100] Furthermore, all compounds of this disclosure which exist in
free base or acid form can be converted to their pharmaceutically
or nutraceutically acceptable salts by treatment with the
appropriate inorganic or organic base or acid by methods known to
one skilled in the art. Salts of the compounds of this disclosure
can be converted to their free base or acid form by standard
techniques.
[0101] In some embodiments, compounds of the present disclosure can
be isolated from plant sources, for example, from those plants
included in the Examples and elsewhere throughout the present
application. Suitable plant parts for isolation of the compounds
include leaves, bark, trunk, trunk bark, stems, stem bark, twigs,
tubers, root, root bark, bark surface (such as periderm or
polyderm, which may include phellem, phellogen, phelloderm, or any
combination thereof), young shoots, rhizomes, seed, fruit,
androecium, gynoecium, calyx, stamen, petal, sepal, carpel
(pistil), flower, or any combination thereof. In some related
embodiments, the compounds are isolated from plant sources and
synthetically modified to contain any of the recited substituents.
In this regard, synthetic modification of the compound isolated
from plants can be accomplished using any number of techniques that
are known in the art and are well within the knowledge of one of
ordinary skill in the art.
[0102] As noted herein, compounds of a Diels-Alder adduct of a
chalcone and a prenylphenyl moiety, prenylated flavonoids,
stilbenes, or any combination thereof may be obtained by chemical
synthesis or from a plant extract, such as a Morus or Milicia
extract. For example, Morus is a genus of flowering trees in the
family Moraceae, which comprises more than 30 species (known as
mulberries) that grow wild or under cultivation in many countries.
Exemplary Morus species include Morus alba L., Morus australis
Poir, Morus celtidifolia Kunth, Morus insignis, Morus mesozygia
Stapf, Morus microphylla, Morus nigra L., Morus rubra L., Morus
atropurpurea, Morus bombycis, Morus cathayana, Morus indica, Morus
thou, Morus japonica, Morus kagayamae, Morus laevigata, Morus
latifolia, Morus liboensis, Morus macroura, Morus mongolica, Morus
multicaulis, Morus notabilis, Morus rotundiloba, Morus serrate,
Morus heterophyllus, Morus tillaefolia, Morus trilobata, Morus
yunnanensis, and Morus wittiorum.
[0103] In certain embodiments, a Morus extract is from Morus alba,
or a Morus extract is a mixture of extracts from one, two, three,
four, or five different Morus species. A mixture of extracts may
include extracts from two or more Morus species or other sources
listed in Table A. For example, a composition comprising a
Diels-Alder adduct of a chalcone and a prenylphenyl moiety, a
prenylated flavonoid, a stilbene, or any combination thereof may be
made up of a Morus extract (e.g., Morus alba) and a Milicia extract
(e.g., Milicia excelsa). In certain embodiments, a Morus extract
enriched for prenylated flavonoids and stilbenes is from Morus alba
(a) root bark, (b) root bark and leaves, (c) rootbark and twigs,
(d) root bark, leaves and twigs, or (e) root bark, root wood, fine
roots, stem bark, branch, branch bark, branch wood, and twigs.
[0104] In some specific embodiments, compounds of a Diels-Alder
adduct of a chalcone and a prenylphenyl moiety may be any one or
more of the compounds provided in Table A.
TABLE-US-00001 TABLE A List of Exemplary Diels-Alder Adduct
Compounds Molecular Structure Name Species Formula M. W.
##STR00014## Albafuran C Morus alba C.sub.34H.sub.28O.sub.9 580.590
##STR00015## Albafuran C; 2- Epimer Morus australis
C.sub.34H.sub.28O.sub.9 580.590 ##STR00016## Albanin F Morus alba,
also from Morus australis, Morus bombycis, and Morus lhou
C.sub.40H.sub.36O.sub.11 692.718 ##STR00017## Albanin F (Moracenin
D); 12,13-Dihydro, 13-hydroxy Morus sp. C.sub.40E.sub.38O.sub.12
710.733 ##STR00018## Albanin G (Kuwanon H. Moracenin A.) Morus
alba; also isol. from Morus australis, Morus bombycis, and Morus
lhou C.sub.45H.sub.44O.sub.11 760.836 ##STR00019## Albanin G; 2'''-
Deoxy (Mongolicin D) Morus mongolica C.sub.45H.sub.44O.sub.10
744.837 ##STR00020## Albanol A (Mulberrofuran G.) Morus lhou
C.sub.34H.sub.26O.sub.8 562.575 ##STR00021## Albanol A; 3''-
(3-Methyl-2- butenyl), Mulberrofuran F Morus lhou
C.sub.39H.sub.34O.sub.8 630.693 ##STR00022## Albanol B Morus alba
C.sub.34H.sub.22O.sub.8 558.543 ##STR00023## Artonin C Artocarpus
heterophyllus (jackfruit) C.sub.40H.sub.38O.sub.10 678.734
##STR00024## Artonin D Artocarpus heterophyllus (jackfruit)
C.sub.40H.sub.36O.sub.10 676.718 ##STR00025## Artonin I Morus
heterophyllus C.sub.40H.sub.36O.sub.11 692.718 ##STR00026##
Australisin B Morus australis C.sub.39H.sub.34O.sub.9 646.692
##STR00027## Australisin C.; 2-Epimer Morus australis
C.sub.34H.sub.28O.sub.9 ##STR00028## Brosimone B Brosimopsis
oblongifolia (preferred genus name Brosimum)
C.sub.40H.sub.38O.sub.10 678.734 ##STR00029## Brosimone D
Brosimopsis oblongifolia (preferred genus name Brosimum)
C.sub.45H.sub.44O.sub.11 760.836 ##STR00030## Cathayanon A Morus
cathayana C.sub.40H.sub.36O.sub.12 708.717 ##STR00031## Cathayanon
A; 14-Epimer Morus cathayana C.sub.40H.sub.36O.sub.12 708.717
##STR00032## Cathayanon E Morus cathayana C.sub.40H.sub.36O.sub.12
708.717 ##STR00033## Chalcomoracin Morus alba and Morus mongolica
C.sub.39H.sub.36O.sub.9 648.708 ##STR00034## Chalcomoracin;
3'',5''-Diepimer Sorocea muriculata C.sub.39H.sub.36O.sub.9 648.708
##STR00035## Chalcomoracin; 3''-Epimer Morus mongolica
C.sub.39H.sub.36O.sub.9 648.708 ##STR00036## Dorstenone Dorstenia
barteri C.sub.40H.sub.38O.sub.8 646.735 ##STR00037## Guangsangon C
Morus macroura C.sub.35H.sub.30O.sub.10 610.616 ##STR00038##
Guangsangon D Morus macroura C.sub.35H.sub.30O.sub.10 610.616
##STR00039## Guangsangon D; 2'-Deoxy, 4',6'-dihydroxy Morus
macroura C.sub.35H.sub.30O.sub.11 626.615 ##STR00040## Guangsangon
D; 3-Deoxy, 4'- hydroxy Morus macroura and Morus wittiorum
C.sub.35H.sub.30O.sub.10 610.616 ##STR00041## Guangsangon D;
2-Epimer, 3- deoxy, 4'- hydroxy Morus macroura
C.sub.35H.sub.30O.sub.10 610.616 ##STR00042## Guangsangon E Morus
macroura C.sub.39H.sub.36O.sub.9 648.708 ##STR00043## Guangsangon
E; 3''-Epimer, 2'''',3''''-dihydro, 3''''-hydroxy Morus macroura
C.sub.39H.sub.38O.sub.10 666.723 ##STR00044## Guangsangon F Morus
macroura C.sub.40H.sub.36O.sub.10 676.718 ##STR00045## Guangsangon
G Morus macroura C.sub.35H.sub.28O.sub.10 608.600 ##STR00046##
Guangsangon G; 1''-Epimer, 2'-hydroxy Morus macroura
C.sub.35H.sub.28O.sub.11 624.600 ##STR00047## Guangsangon G;
2'-Hydroxy Morus macroura C.sub.35H.sub.28O.sub.11 624.600
##STR00048## Guangsangon G; 5-Hydroxy Morus wittiorum
C.sub.35H.sub.28O.sub.11 625.600 ##STR00049## Guangsangon H Morus
macroura C.sub.40H.sub.38O.sub.10 678.734 ##STR00050## Guangsangon
J Morus macroura C.sub.39H.sub.36O.sub.9 648.708 ##STR00051##
Guangsangon L Morus alba C.sub.27H.sub.24O.sub.8 476.482
##STR00052## Isobavachrome ne dimer Dorstenia zenkeri
C.sub.40H.sub.38O.sub.8 646.735 ##STR00053## Kuwanol A Morus
bombycis C.sub.34H.sub.28O.sub.8 564.590 ##STR00054## Kuwanol B
Morus bombycis C.sub.34H.sub.26O.sub.8 562.575 ##STR00055## Kuwanol
E Morus alba (white mulberry) C.sub.39H.sub.38O.sub.9 650.724
##STR00056## Kuwanol E; 2''',3'''-Dihydro, 3'''-hydroxy Sorocea
ilicifolia C.sub.39H.sub.40O.sub.10 668.739 ##STR00057## Kuwanon J
Morus alba and from Morus bombycus and Morus nigra
C.sub.40H.sub.38O.sub.10 678.734 ##STR00058## Kuwanon J; 16''-Deoxy
Morus alba (white mulberry) C.sub.40H.sub.38O.sub.9 662.735
##STR00059## Kuwanon J; 2- Deoxy Morus alba (white mulberry)
C.sub.40H.sub.38O.sub.9 662.735 ##STR00060## Kuwanon J,
.DELTA.21'',22''- Isomer, 2-deoxy Morus alba (white mulberry)
C.sub.40H.sub.38O.sub.9 662.735 ##STR00061## Kuwanon J;
2,16''-Dideoxy Morus alba (white mulberry) C.sub.40H.sub.38O.sub.8
646.735 ##STR00062## Kuwanon J; 2',3'-Dihydro Morus mongolica
C.sub.40H.sub.40O.sub.10 680.750 ##STR00063## Kuwanon J; 1''-
Epimer Morus alba and Morus bombycus C.sub.40H.sub.38O.sub.10
678.734 ##STR00064## Kuwanon J; .DELTA.21'',22''- Isomer, 2-deoxy
(Artonin X.) Artocarpus heterophyllus (jackfruit)
C.sub.40H.sub.38O.sub.9 662.735 ##STR00065## Kuwanon L Morus alba
(white mulberry) C.sub.35H.sub.30O.sub.11 626.615 ##STR00066##
Kuwanon L; 2,3-Didehydro, (3-methyl-2- butenyl) Morus alba (white
mulberry) C.sub.40H.sub.36O.sub.11 692.718 ##STR00067## Kuwanon N
Morus lhou C.sub.45H.sub.44O.sub.11 760.836 ##STR00068## Kuwanon O
Morus lhou C.sub.40H.sub.38O.sub.11 694.734 ##STR00069## Kuwanon P
Morus lhou C.sub.34H.sub.30O.sub.9 582.606 ##STR00070## Kuwanon P;
2- Deoxy Morus macroura C.sub.34H.sub.30O.sub.8 ##STR00071##
Kuwanon W Morus lhou C.sub.45H.sub.42O.sub.11 758.820 ##STR00072##
Kuwanon X Morus lhou C.sub.34H.sub.30O.sub.9 582.606 ##STR00073##
Kuwanon X; 3''- Epimer Morus alba (white mulberry)
C.sub.34H.sub.30O.sub.9 582.606 ##STR00074## Kuwanon Z Morus alba
(white mulberry) C.sub.34H.sub.26O.sub.10 594.573 ##STR00075##
Mongolicin C Morus mongolica C.sub.34H.sub.26O.sub.9 578.574
##STR00076## Moracenin C Morus sp. C.sub.45H.sub.44O.sub.11 760.836
##STR00077## Mulberrofuran C Morus bombycis (Moraceae) ##STR00078##
Mulberrofuran E Morus alba (white mulberry) (Moraceae)
C.sub.39H.sub.36O.sub.8 632.709 ##STR00079## Mulberrofuran I Morus
bombycis C.sub.34H.sub.24O.sub.8 560.559 ##STR00080## Mulberrofuran
J Morus lhou C.sub.34H.sub.28O.sub.9 580.590 ##STR00081##
Mulberrofuran J, 2-Epimer Morus bombycis ##STR00082## Mulberrofuran
O Morus alba 646.692 ##STR00083## Mulberrofuran P Morus alba (white
mulberry) C.sub.34H.sub.22O.sub.9 574.542 ##STR00084##
Mulberrofuran Q Morus alba (white mulberry)
C.sub.34H.sub.24O.sub.10 592.558 ##STR00085## Mulberrofuran S Morus
alba (white mulberry) C.sub.34H.sub.24O.sub.9 576.558 ##STR00086##
Mulberrofuran T Morus alba (white mulberry) C.sub.44H.sub.44O.sub.9
716.826 ##STR00087## Mulberrofuran U Morus insignis
C.sub.39H.sub.36O.sub.9 648.708 ##STR00088## Multicaulisin Morus
multicaulis C.sub.40H.sub.36O.sub.11 692.718 ##STR00089## Sanggenol
G Morus cathayana C.sub.30H.sub.34O.sub.7 694.734 ##STR00090##
Sanggenol J Morus cathayana C.sub.45H.sub.44O.sub.12 776.835
##STR00091## Sanggenol M Morus mongolica C.sub.44H.sub.44O.sub.11
748.825 ##STR00092## Sanggenon B Morus C.sub.33H.sub.30O.sub.9
570.595 ##STR00093## Sanggenon B; 7-O-(2,4- Dihydroxybenzoyl)
(Sanggenon S) Morus sp C.sub.40H.sub.34O.sub.12 706.701
##STR00094## Sanggenon D Morus cathayana C.sub.40H.sub.36O.sub.12
708.717 ##STR00095## Sanggenon E Morus Spp.
C.sub.45H.sub.44O.sub.12 776.835 ##STR00096## Sanggenon G Morus
alba C.sub.40H.sub.38O.sub.11 694.734 ##STR00097## Sanggenon G;
14,15-Dihydro, 15-hydroxy Morus sp. C.sub.40H.sub.40O.sub.12
712.749 ##STR00098## Sanggenon Q Morus mongolica
C.sub.40H.sub.36O.sub.12 708.717 ##STR00099## Sanggenon D;
3'-Epimer Morus cathayana C.sub.40H.sub.36O.sub.12 708.717
##STR00100## Sanggenon D; 2,3,3'- Triepimer Morus cathayana
C.sub.40H.sub.36O.sub.12 708.717
##STR00101## Sorocein B Sorocea bonplandii C.sub.40H.sub.34O.sub.9
658.703 ##STR00102## Sorocein H Sorocea bonplandii (Moraceae) and
Morus spp. C.sub.45H.sub.44O.sub.12 776.835 ##STR00103##
Wittiorumin B Morus wittiorum C.sub.40H.sub.36O.sub.12 708.717
##STR00104## Wittiorumin B; 1''-Epimer, 2'- deoxy Morus wittiorum
C.sub.40H.sub.36O.sub.11 692.718 ##STR00105## Wittiorumin E Morus
wittiorum C.sub.40H.sub.38O.sub.10 678.734 ##STR00106## Wittiorumin
F Morus wittiorum C.sub.39H.sub.36O.sub.9 648.708 ##STR00107##
Wittiorumin G Morus wittiorum C.sub.40H.sub.38O.sub.10 678.734
##STR00108## Yunanensin A Morus yunnanensis C.sub.39H.sub.28O.sub.8
624.645 ##STR00109##
[0105] Compounds in Table A and Examples 3, 5, 6 and 68 can be
extracted, isolated or purified from the indicated plant species or
certain plant parts (e.g., from the bark, trunk, trunk bark, stem
bark, root, root bark, bark surface (such as periderm or polyderm,
which may include phellem, phellogen, phelloderm, or any
combination thereof), leaves, fruits, flowers, other plant parts,
or any combination thereof) or can be prepared synthetically or
semi-synthetically as described in more detail in PCT Application
No. PCT/US2013/43188, which methods of synthesis are incorporated
herein by reference. In certain embodiments, one or more compounds
of Table A and Examples 3, 5, 6 and 68 are enriched for or are the
major active ingredients in an extract of the indicated plant
species, wherein the enriched extract is obtained from a whole
plant or certain plant parts, such as leaves, bark, trunk, trunk
bark, stems, stem bark, twigs, tubers, root, root bark, bark
surface (such as periderm or polyderm, which may include phellem,
phellogen, phelloderm, or any combination thereof), young shoots,
rhizomes, seed, fruit, androecium, gynoecium, calyx, stamen, petal,
sepal, carpel (pistil), flower, or any combination thereof.
[0106] In further embodiments, major active ingredients in an
extract of Morus comprise prenylated flavonoids and stilbenes (such
as those provided in Table A and Examples 3, 5, 6 and 68), wherein
the extract is enriched for these active ingredients from root
bark, leaves, twigs, or a combination thereof. In certain
embodiments, a Morus extract is enriched for prenylated flavonoids
and stilbenes, wherein the extract comprises from about 1% to about
25% prenylated flavonoids and from about 1% to about 25% stilbenes,
or wherein the extract comprises from about 2% to about 6%
prenylated flavonoids and from about 2% to about 6% stilbenes, or
wherein the extract comprises at least 3% prenylated flavonoids and
at least 3% stilbenes (weight to weight).
[0107] In certain embodiments, provided herein are Morus extracts
enriched for one or more prenylated flavonoids or chalconoids and
one or more stilbenes, wherein the one or more prenylated
flavonoids are compounds having a structure of Formula (III) or
(IV):
##STR00110##
or a pharmaceutically or nutraceutically acceptable salt, tautomer,
glycoside, prodrug or stereoisomer thereof, wherein
R.sub.1-R.sub.12 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkyl carbonyl, aralkylcarbonyl or a bond to a compound of
structure (III) or (IV); or one of R.sub.1-R.sub.12 joins with
another one of R.sub.1-R.sub.12 to form a ring, and the remaining
R.sub.1-R.sub.12 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkylcarbonyl, aralkylcarbonyl or a bond to a compound of
structure (III) or (IV), provided that all valencies are
satisfied;
[0108] the chalcanoid is a compound of structure (V):
##STR00111##
or a pharmaceutically or nutraceutically acceptable salt, tautomer,
glycoside, prodrug or stereoisomer thereof, wherein
R.sub.1-R.sub.10 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkyl carbonyl, or aralkylcarbonyl, provided that all
valencies are satisfied; and
[0109] the one or more stilbenes are compounds having a structure
of Formula (I) or (II):
##STR00112##
[0110] wherein R.sub.1-R.sub.10 are each independently a H,
hydroxyl, glycoside, prenyl, flavonoid, chalcone, halogen,
sulfhydryl, amino, aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkenyl,
C.sub.1-12 alkoxy, C.sub.1-12 alkthio, C.sub.1-12 alkyamino, aryl,
heteroaryl, aralkyl, alkylcarbonyl, or aralkylcarbonyl.
[0111] In further embodiments, the one or more prenylayted
flavonoids are compounds having a structure of Formula (III), (IV)
or (V), wherein the optional double bond is present in ring C,
R.sub.11 and R.sub.12 are absent, and R.sub.10 is a prenyl group.
In still further embodiments, the one or more prenylayted
flavonoids are compounds having a structure of Formula (III), (IV)
or (V), wherein the at least one of R.sub.1-R.sub.9 is a prenyl
group and R.sub.10-R.sub.12 are independently H or hydroxyl. In
certain specific embodiments, the prenylated flavonoids include
Albanin G, Kuwanon G, Morusin, morusinol, Sanggenon, isoxanthoumol,
glabridin, cathayanon A, or any combination thereof. In certain
embodiments, the one or more stilbenes are compounds having a
structure of Formula (I) or (II), wherein R.sub.1-R.sub.10 are each
independently a H, hydroxyl, glycoside, or C.sub.1-4 alkoxy. In
further embodiments, the one or more stilbenes are compounds having
a structure of Formula (I) or (II), wherein R.sub.1, R.sub.5,
R.sub.6 and R.sub.10 are H. In still further embodiments, the one
or more stilbenes are compounds having a structure of Formula (I)
or (II), wherein R.sub.2 is a glucoside, or R.sub.2 and R.sub.8 are
glycosides, and one or more of R.sub.4, R.sub.9, and R.sub.10 are
hydroxyl. In yet further embodiments, the one or more stilbenes are
compounds having a structure of Formula (I) or (II), wherein
R.sub.1, R.sub.5, and R.sub.6 are H, and one or more of
R.sub.2-R.sub.4 and R.sub.7-R.sub.10 are independently hydroxyl,
C.sub.1-3 alkoxy, or any combination thereof. In certain specific
embodiments, a stilbene compound includes oxyresveratrol,
resveratrol, piceatannol, pinosylvin, 3,4'-dihydroxystilbene,
combretastatin A-1, pterostilbene, rhapontigenin, and a stilbene
glycoside includes mulberroside A, rhaponticin, piceid, astringin,
or any combination of these stilbenes or stilbene glycosides.
[0112] In some embodiments, the flavonoid is a compound of
structure (III) and in other embodiments the flavonoid is a
compound of structure (IV). In some of the embodiments, at least
one of R.sub.1-R.sub.12, such as R.sub.10 is prenyl. In other
embodiments, polyflavonoids are provided and at least one of
R.sub.1-R.sub.12 in the compounds of structure (III) or (IV) is a
bond to a compounds of structure of (III) or (IV) (i.e., the
compound comprises more than one flavonoid of structure (III)
and/or (IV)).
[0113] In some other embodiments of the compounds of structure
(III) or (IV), R.sub.1-R.sub.12 is H, hydroxyl, a prenyl group or
cycloalkyl. For example, in some embodiments the cycloalkyl is
substituted and/or comprises one or more carbon-carbon double bonds
(i.e., is unsaturated). The optional substitutents are typically
selected from aryl, such as phenyl, and aryl carbonyl. Accordingly,
in some further embodiments, the flavonoid has one of the following
structures (IIIa) or (IVa):
##STR00113##
wherein R.sup.4a is, at each occurrence, independently H, hydroxyl
or a prenyl group.
[0114] In certain embodiments of the compounds of structure (IIIa)
or (IVa), R.sub.1-R.sub.3 and R.sub.5-R.sub.12 are each
independently selected from H, hydroxyl and a prenyl group. In
certain embodiments, at least one one of R.sub.1-R.sub.3, R.sub.4a
or R.sub.5-R.sub.12 is prenyl, for example in some embodiments,
R.sub.10 is prenyl. In other embodiments of the compounds of
structure (IIIa) or (IVa), at least two of R.sub.1-R.sub.3,
R.sub.4a or R.sub.5-R.sub.12 is hydroxyl.
[0115] In some more specific embodiments, the flavonoid has one of
the following structures:
##STR00114##
[0116] In other embodiments, one of R.sub.1-R.sub.12 joins with
another one of R.sub.1-R.sub.12 to form a ring and the remaining
R.sub.1-R.sub.12 are H, hydroxyl or a prenyl group. In certain of
these embodiments, the ring is a heterocyclic ring, for example a
cyclic ether ring. Accordingly, in certain embodiments the
flavonoid has one of the following structures (IIIb) or (IVb):
##STR00115##
[0117] In certain embodiments of the compounds of structure (IIIb)
or (IVb), R.sub.1, R.sub.2 and R.sub.5-R.sub.12 are each
independently selected from H, hydroxyl and a prenyl group. In
certain embodiments, at least one one of R.sub.1, R.sub.2 or
R.sub.5-R.sub.12 is prenyl, for example in some embodiments,
R.sub.10 is prenyl. In other embodiments of the compounds of
structure (IIIb) or (IVb), at least two of R.sub.1, R.sub.2 or
R.sub.5-R.sub.12 is hydroxyl. In certain embodiments, the flavonoid
has the following structure:
##STR00116##
[0118] In various other embodiments, R.sub.1-R.sub.10 of the
chalcanoid of structure (V) are each independently selected from H,
hydroxyl, a prenyl group, and C.sub.1-12 alkoxy.
[0119] The biologically active flavans of this disclosure may be
obtained by synthetic methods or extracted from one or more plants,
such as Acacia, Uncaria, or both. In certain embodiments, an Acacia
plant species is selected from A. angustifolia, A. ataxacantha, A.
berlandieri, A. bonariensis, A. brevispica, A. catechu, A. chundra,
A. concinna, A. floribunda, A. greggii, A. interior, A. macilenta,
A. mellifera, A. merrallii, A. occidentalis, A. peninsularis, A.
pennata, A. pennatula, A. polyacantha, A. polyphylla, A. riparia,
A. roemeriana, A. senegal, A. sinuata, A. tamarindifolia, A.
tenuifolia, A. victoriae, A. visco, or any any combination thereof
(for exemplary Acacia extracts and flavans, see U.S. Pat. No.
8,124,134). In certain embodiments, an Uncaria plant species is
selected from U. acida, U. africana, U. attenuate, U. bernaysii, U.
borneensis, U. callophylla, U. cordata, U. elliptica, Uncaria
gambir, U. guianensis, U. hirsute, U. homomalla, U. lanosa, U.
longiflora, U. macrophylla, U. orientalis, U. rhynchophylla, U.
scandens, U. sessilifructus, U. setiloba, U. sinensis, U.
sterrophylla, U. tomentosa, U. wangii, or any any combination
thereof (for exemplary Uncaria extracts and flavans, see U.S.
Patent Publication No. 2007/0264361).
[0120] In further embodiments, a composition of this disclosure
comprises an Acacia catechu extract enriched for flavans containing
catechin, epicatechin, or a combination thereof. In still further
embodiments, a composition of this disclosure comprises an Uncaria
gambir extract enriched for flavans containing catechin,
epicatechin, or a combination thereof. In yet further embodiments,
an Acacia extract enriched for flavans is from Acacia catechu, or
an Acacia extract enriched for flavans is a mixture of extracts
from one, two, three, four, five or more different Acacia species,
Uncaria species, or from other sources. In other embodiments, an
Uncaria extract enriched for flavans is from Uncaria gambir, or an
Uncaria extract enriched for flavans is a mixture of extracts from
one, two, three, four, five or more different Uncaria species,
Acacia species, other sources (e.g., different plant such as green
tea, synthetic), or any combination thereof. For example, a
composition of this disclosure comprises a mixture of an Acacia
catechu extract enriched for flavans containing catechin,
epicatechin, or both and an Uncaria gambir extract enriched for
flavans containing catechin, epicatechin, or both.
[0121] In certain embodiments, major active ingredients in an
extract of Acacia comprise flavans containing catechin,
epicatechin, or both, wherein the extract is enriched for these
active ingredients from roots, bark, or a combination thereof. In
certain embodiments, major active ingredients in an extract of
Uncaria comprise flavans containing catechin, epicatechin, or both,
wherein the extract is enriched for these active ingredients from
leaves.
[0122] In certain embodiments, provided herein are Acacia or
Uncaria extracts enriched for one or more flavans containing
catechin, epicatechin, or both, wherein the flavans are compounds
having a structure of Formula (VI):
##STR00117##
wherein R.sub.21, R.sub.22, R.sub.23, R.sub.24 and R.sub.25 are
independently selected from a H, --OH, --SH, --OCH.sub.3,
--SCH.sub.3, --OR, --SR, --NH.sub.2, --NRH, --NR.sub.2,
--NR.sub.3.sup.+X.sup.-, esters of substitution groups,
independently selected from the group consisting of gallate,
acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl
esters and caffeoyl esters; a carbon, oxygen, nitrogen or sulfur
glycoside of a single or a combination of multiple sugars including
aldopentose, methyl aldopentose, aldohexose, ketohexose; dimer,
trimer or other polymerized flavans; [0123] wherein R is a
C.sub.1-10 alkyl group; and
[0124] X is a pharmaceutically acceptable counter anion of
hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride,
or carbonate.
[0125] In certain embodiments, there are provided herein Curcuma
extracts comprising curcuminoids. In further embodiments, a Curcuma
longa extract is enriched for curcuminoids, such as curcumin
(diferuloylmethane), demethoxy-curcumin, bisdemethoxy-curcumin,
casumunin A, cassumunin B, or any combination thereof. The
biologically active curcuminoids and analogues thereof of this
disclosure may be obtained by synthetic methods (see Anand et al.,
Biochem. Pharmacol. 76:1590, 2008) or extracted from one or more
plants, such as Curcuma plants, Zingiber plants, or both.
[0126] Exemplary species of the Curcuma genus of the instant
disclosure include C. aeruginosa, C. albicoma, C. albiflora, C.
alismatifolia, C. amada, C. amarissima, C. americana, C.
angustifolia, C. aromatics, C. attenuata, C. aurantiaca, C.
australasica, C. bakeriana, C. bicolor, C. bhatii, C. brog, C.
burttii, C. caesia, C. candida, C. cannanorensis, C. caulina, C.
careyana, C. ceratotheca, C. chuanezhu, C. chuanhuangjiang, C.
chuanyujin, C. coccinea, C. cochinchinensis, C. codonantha, C.
coerulea, C. colorata, C. comosa, C. cordata, C. cordifolia, C.
coriacea, C. decipiens, C. domestica, C. ecalcarata, C. ecomata, C.
elata, C. erubescens, C. euchroma, C. exigua, C. ferruginea, C.
flaviflora, C. glans, C. glaucophylla, C. gracillima, C.
grahamiana, C. grandiflora, C. haritha, C. harmandii, C. heyneana,
C. inodora, C. karnatakensis, C. kuchoor, C. kudagensis, C.
kunstleri, C. kurzii, C. kwangsiensis, C. lanceolata, C. larsenii,
C. latiflora, C. latifolia, C. leucorhiza, C. leucorrhiza, C.
loerzingii, C. longa, C. longiflora, C. longispica, C. lutea, C.
malabarica, C. mangga, C. meraukensis, C. montana, C. musacea, C.
mutabilis, C. neilgherrensis, C. nilamburensis, C. ochrorhiza, C.
officinalis, C. oligantha, C. ornata, C. pallida, C. parviflora, C.
parvula, C. peethapushpa, C. petiolata, C. phaeocaulis, C. picta-C.
pierreana, C. plicata, C. porphyrotaenia, C. prakasha, C.
pseudomontana, C. purpurascens, C. purpurea, C. raktakanta, C.
ranadei, C. reclinata, C. rhabdota, C. rhomba, C. roscoeana, C.
rotunda, C. rubescens, C. rubricaulis, C. rubrobracteata, C.
sattayasaii, C. sessilis, C. sichuanensis, C. singularis, C.
soloensis, C. sparganiifolia, C. speciosa, C. spicata, C.
stenochila, C. strobilifera, C. sulcata, C. sumatrana, C.
sylvatica, C. sylvestris, C. thalakaveriensis, C. thorelii, C.
trichosantha, C. vamana, C. vellanikkarensis, C. viridiflora, C.
vitellina-C. wenchowensis, C. wenyujin, C. xanthorrhiza, C.
yunnanensis, C. zedoaria, C. zedoaroides, C. zerumbet.
[0127] In certain embodiments, a Curcuma extract enriched for
curcuminoids is from Curcuma longa, or a Curcuma extract enriched
for curcuminoids is a mixture of extracts from one, two, three,
four, five or more different Curcuma species or from other sources.
For example, a composition comprising curcuminoids may be a a
Curcuma extract (e.g., Curcuma longa) mixed with synthetic
curcuminoids, or a mixture of a Curcuma extract (e.g., Curcuma
longa) enriched for curcuminoids with a Zingiber cassumunar extract
enriched for curcuminoids, Curcuma phaeocaulis extract enriched for
curcuminoids, Curcuma. xanthorrhiza extract enriched for
curcuminoids, or any combination thereof. In other embodiments, a
Curcuma extract enriched for one or more curcuminoids (e.g.,
curcumin, demethoxy-curcumin, bisdemethoxy-curcumin, casumunin A,
cassumunin B, or any combination thereof) may be from root,
rhizome, or a combination thereof.
[0128] In certain embodiments, a composition of this disclosure
comprises an Acacia extract containing or enriched for one or more
flavans as described herein or in U.S. Pat. No. 8,124,134, and a
Morus extract containing or enriched for at least one Diels-Alder
adduct of a chalcone and a prenylphenyl moiety, prenylated
flavonoid, stilbene, or any combination thereof. In certain
embodiments, a composition comprises an Acacia extract containing
or enriched for one or more flavans as described herein or in U.S.
Pat. No. 8,124,134 and a Morus extract containing or enriched for
one or more compounds listed in Table A and Examples 3, 5, 6 and
68. In still further embodiments, a composition comprises an Acacia
extract containing or enriched for catechin, epicatichin, or both,
and a Morus extract containing or enriched for one or more
prenylated flavonoids, one or more stilbenes, or any combination
thereof. In other embodiments, a composition comprises a mixture of
a Morus extract enriched for one or more prenylated flavonoids and
one or more stilbenes, and an Acacia extract enriched for
flavans.
[0129] In further embodiments, a composition of this disclosure
comprises a mixture of a Morus extract enriched for one or more
prenylated flavonoids and one or more stilbenes, and an Acacia
extract enriched for one or more flavans,
[0130] wherein the one or more prenylated flavonoids are compounds
having a structure of Formula (III) or (IV):
##STR00118##
or a pharmaceutically or nutraceutically acceptable salt, tautomer,
glycoside, prodrug or stereoisomer thereof, wherein
R.sub.1-R.sub.12 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkyl carbonyl, aralkylcarbonyl or a bond to a compound of
structure (III) or (IV); or one of R.sub.1-R.sub.12 joins with
another one of R.sub.1-R.sub.12 to form a ring, and the remaining
R.sub.1-R.sub.12 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkylcarbonyl, aralkylcarbonyl or a bond to a compound of
structure (III) or (IV), provided that all valencies are
satisfied;
[0131] the chalcanoid is a compound of structure (V):
##STR00119##
or a pharmaceutically or nutraceutically acceptable salt, tautomer,
glycoside, prodrug or stereoisomer thereof, wherein
R.sub.1-R.sub.10 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkylcarbonyl, or aralkylcarbonyl, provided that all
valencies are satisfied; and
[0132] the one or more stilbenes are compounds having a structure
of Formula (I) or (II):
##STR00120##
[0133] wherein R.sub.1-R.sub.10 are each independently a H,
hydroxyl, glycoside, prenyl, flavonoid, chalcone, halogen,
sulfhydryl, amino, aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkenyl,
C.sub.1-12 alkoxy, C.sub.1-12 alkthio, C.sub.1-12 alkyamino, aryl,
heteroaryl, aralkyl, alkylcarbonyl, or aralkylcarbonyl; and
[0134] wherein the flavans are compounds having a structure of
Formula (VI):
##STR00121##
[0135] wherein R.sub.21, R.sub.22, R.sub.23, R.sub.24 and R.sub.25
are independently selected from a H, --OH, --SH, --OCH.sub.3,
--SCH.sub.3, --OR, --SR, --NH.sub.2, --NRH, --NR.sub.2,
--NR.sub.3.sup.+X.sup.-, esters of substitution groups,
independently selected from the group consisting of gallate,
acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl
esters and caffeoyl esters; a carbon, oxygen, nitrogen or sulfur
glycoside of a single or a combination of multiple sugars including
aldopentose, methyl aldopentose, aldohexose, ketohexose; dimer,
trimer or other polymerized flavans;
[0136] wherein R is a C.sub.1-10 alkyl group; and
[0137] X is a pharmaceutically acceptable counter anion of
hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride,
or carbonate.
[0138] In any of the aforementioned compositions, a Morus extract
is from Morus alba, and an Acacia extract is from Acacia catechu.
In further embodiments of these compositions, a major active
ingredient in a Morus extract is Albanin G, Kuwanon G, Morusin,
oxyresveratrol, mulberroside A or any combination thereof, and a
major active ingredient in an Acacia extract is catechin,
epicatechin, or both.
[0139] In further embodiments, any of the aforementioned
compostions comprise one or more prenylayted flavonoids are
compounds having a structure of Formula (III), (IV) or (V), wherein
the optional double bond is present in ring C, R.sub.11 and
R.sub.12 are absent, and R.sub.10 is a prenyl group. In still
further embodiments, any of the aforementioned compostions comprise
one or more prenylayted flavonoids are compounds having a structure
of Formula (III), (IV) or (V), wherein the at least one of
R.sub.1-R.sub.9 is a prenyl group and R.sub.10-R.sub.12 are
independently H or hydroxyl. In certain embodiments, any of the
aforementioned compostions comprise one or more stilbenes having a
structure of Formula (I) or (II), wherein R.sub.1-R.sub.10 are each
independently a H, hydroxyl, glycoside, or C.sub.1-4 alkoxy. In
certain other embodiments, any of the aforementioned compostions
comprise one or more stilbenes are compounds having a structure of
Formula (I) or (II), wherein R.sub.1-R.sub.10 are each
independently a H, hydroxyl, glycoside, or C.sub.1-4 alkoxy. In
further embodiments, any of the aforementioned compostions comprise
one or more stilbenes are compounds having a structure of Formula
(I) or (II), wherein R.sub.1, R.sub.5, R.sub.6 and R.sub.10 are H.
In still further embodiments, any of the aforementioned compostions
comprise one or more stilbenes are compounds having a structure of
Formula (I) or (II), wherein R.sub.2 is a glucoside, or R.sub.2 and
R.sub.8 are glycosides, and one or more of R.sub.4, R.sub.9, and
R.sub.10 are hydroxyl. In yet further embodiments, any of the
aforementioned compostions comprise one or more stilbenes are
compounds having a structure of Formula (I) or (II), wherein
R.sub.1, R.sub.5, and R.sub.6 are H, and one or more of
R.sub.2-R.sub.4 and R.sub.7-R.sub.10 are independently hydroxyl,
C.sub.1-3 alkoxy, or any combination thereof. In certain specific
embodiments, a stilbene compound includes oxyresveratrol,
resveratrol, piceatannol, pinosylvin, 3,4'-dihydroxystilbene,
combretastatin A-1, pterostilbene, rhapontigenin, and a stilbene
glycoside includes mulberroside A, rhaponticin, piceid, astringin,
or any combination of these stilbenes or stilbene glycosides.
[0140] Any of the aforementioned Morus extract mixed with Acacia
extract compositions are useful for promoting, managing or
improving joint health, or for treating a joint disorder or disease
(e.g., osteoarthritis, rheumatoid arthritis, juvenile rheumatoid
arthritis, Still's disease, psoriatic arthritis, reactive
arthritis, septic arthritis, Reiter's syndrome, Behcet's syndrome,
Felty's syndrome, systemic lupus erythematosus, ankylosing
spondylitis, diffuse idiopathic skeletal hyperostosis (DISH),
sacroiliac joint dysfunction, polymyalgia rheumatic, carpal tunnel
syndrome, gout, bursitis, tendenitis, synovitis, SAPHO (synovitis,
acne, pustulosis, hyperostosis, osteitis) syndrome, patella
chondromalacia, repetitive strain injury, sprain, dislocation).
[0141] In certain aspects, a composition of this disclosure
comprises a mixture of a Morus extract enriched for one or more
prenylated flavonoids and one or more stilbenes, and an Acacia
extract enriched for flavans, wherein the composition inhibits
cartilage degradation. Cartialge degradation is measured as the
level of sulphated GAGs (e.g., released from proteoglycans)
released into a medium at the end of a GAG release assay reaction,
which reflects the amount of articular cartilage degradation
"Inhibition of cartilage degradation" is established when there is
a statistically significant reduction in sulphated GAG release as
measured in, for example, a Blyscan.TM. assay (Accurate Chemical
and Scientific Corp., Westbury, N.Y.) and described herein in
Example 27.
[0142] In certain embodiments, a composition of this disclosure
comprises an Uncaria extract containing or enriched for one or more
flavans as described herein or in U.S. Pat. No. 8,034,387, and a
Morus extract containing or enriched for at least one Diels-Alder
adduct of a chalcone and a prenylphenyl moiety, prenylated
flavonoid, stilbene, or any combination thereof. In certain
embodiments, a composition comprises an Uncaria extract containing
or enriched for one or more flavans as described herein or in U.S.
Pat. No. 8,034,387 and a Morus extract containing or enriched for
one or more compounds listed in Table A and Examples 3, 5, 6 and
68. In still further embodiments, a composition comprises an Acacia
extract containing or enriched for catechin, epicatichin, or both,
and a Morus extract containing or enriched for one or more
prenylated flavonoids, one or more stilbenes, or any combination
thereof. In other embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, and an Uncaria
extract enriched for flavans.
[0143] In further embodiments, a composition of this disclosure
comprises a mixture of a Morus extract enriched for one or more
prenylated flavonoids and one or more stilbenes, and an Uncaria
extract enriched for one or more flavans,
[0144] wherein the one or more prenylated flavonoids are compounds
having a structure of Formula (III) or (IV):
##STR00122##
or a pharmaceutically or nutraceutically acceptable salt, tautomer,
glycoside, prodrug or stereoisomer thereof, wherein
R.sub.1-R.sub.12 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkyl carbonyl, aralkylcarbonyl or a bond to a compound of
structure (III) or (IV); or one of R.sub.1-R.sub.12 joins with
another one of R.sub.1-R.sub.12 to form a ring, and the remaining
R.sub.1-R.sub.12 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkylcarbonyl, aralkylcarbonyl or a bond to a compound of
structure (III) or (IV), provided that all valencies are
satisfied;
[0145] the chalcanoid is a compound of structure (V):
##STR00123##
or a pharmaceutically or nutraceutically acceptable salt, tautomer,
glycoside, prodrug or stereoisomer thereof, wherein
R.sub.1-R.sub.10 are each independently H, hydroxyl, a prenyl
group, flavonoid, chalcone, glycoside, halogen, sulfhydryl, amino,
aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkthio,
C.sub.1-12 alkyamino, cycloalkyl, heterocyclyl, aryl, heteroaryl,
aralkyl, alkyl carbonyl, or aralkylcarbonyl, provided that all
valencies are satisfied; and
[0146] the one or more stilbenes are compounds having a structure
of Formula (I) or (II):
##STR00124##
[0147] wherein R.sub.1-R.sub.10 are each independently a H,
hydroxyl, glycoside, prenyl, flavonoid, chalcone, halogen,
sulfhydryl, amino, aldehyde, C.sub.1-12 alkyl, C.sub.1-12 alkenyl,
C.sub.1-12 alkoxy, C.sub.1-12 alkthio, C.sub.1-12 alkyamino, aryl,
heteroaryl, aralkyl, alkylcarbonyl, or aralkylcarbonyl; and
[0148] wherein the flavans are compounds having a structure of
Formula (VI):
##STR00125##
[0149] wherein R.sub.21, R.sub.22, R.sub.23, R.sub.24 and R.sub.25
are independently selected from a H, --OH, --SH, --OCH.sub.3,
--SCH.sub.3, --OR, --SR, --NH.sub.2, --NRH, --NR.sub.2,
--NR.sub.3.sup.+X.sup.-, esters of substitution groups,
independently selected from the group consisting of gallate,
acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl
esters and caffeoyl esters; a carbon, oxygen, nitrogen or sulfur
glycoside of a single or a combination of multiple sugars including
aldopentose, methyl aldopentose, aldohexose, ketohexose; dimer,
trimer or other polymerized flavans;
[0150] wherein R is a C.sub.1-10 alkyl group; and
[0151] X is a pharmaceutically acceptable counter anion of
hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride,
or carbonate.
[0152] In any of the aforementioned compositions, the Morus extract
is from Morus alba, and the Uncaria extract is from Uncaria gambir.
In further embodiments, a major active ingredient in the Morus
extract is Albanin G, Kuwanon G, Morusin, oxyresveratrol,
mulberroside A or any combination thereof, and a major active
ingredient in the Uncaria extract is catechin, epicatechin, or a
combination thereof.
[0153] In further embodiments, the one or more prenylayted
flavonoids are compounds having a structure of Formula (III), (IV)
or (V), wherein the optional double bond is present in ring C,
R.sub.11 and R.sub.12 are absent, and R.sub.10 is a prenyl group.
In still further embodiments, the one or more prenylayted
flavonoids are compounds having a structure of Formula (III), (IV)
or (V), wherein the at least one of R.sub.1-R.sub.9 is a prenyl
group and R.sub.10-R.sub.12 are independently H or hydroxyl. In
certain specific embodiments, the prenylated flavonoids include
Albanin G, Kuwanon G, Morusin, morusinol, Sanggenon, isoxanthoumol,
glabridin, cathayanon A, or any combination thereof. In certain
embodiments, the one or more stilbenes are compounds having a
structure of Formula (I) or (II), wherein R.sub.1-R.sub.10 are each
independently a H, hydroxyl, glycoside, or C.sub.1-4 alkoxy. In
further embodiments, the one or more stilbenes are compounds having
a structure of Formula (I) or (II), wherein R.sub.1, R.sub.5,
R.sub.6 and R.sub.10 are H. In still further embodiments, the one
or more stilbenes are compounds having a structure of Formula (I)
or (II), wherein R.sub.2 is a glucoside, or R.sub.2 and R.sub.8 are
glycosides, and one or more of R.sub.4, R.sub.9, and R.sub.10 are
hydroxyl. In yet further embodiments, the one or more stilbenes are
compounds having a structure of Formula (I) or (II), wherein
R.sub.1, R.sub.5, and R.sub.6 are H, and one or more of
R.sub.2-R.sub.4 and R.sub.7-R.sub.10 are independently hydroxyl,
C.sub.1-3 alkoxy, or any combination thereof. In certain specific
embodiments, a stilbene compound includes oxyresveratrol,
resveratrol, piceatannol, pinosylvin, 3,4'-dihydroxystilbene,
combretastatin A-1, pterostilbene, rhapontigenin, and a stilbene
glycoside includes mulberroside A, rhaponticin, piceid, astringin,
or any combination of these stilbenes or stilbene glycosides.
[0154] In some embodiments, the flavonoid is a compound of
structure (III) and in other embodiments the flavonoid is a
compound of structure (IV). In some of the embodiments, at least
one of R.sub.1-R.sub.12, such as R.sub.10 is prenyl. In other
embodiments, polyflavonoids are provided and at least one of
R.sub.1-R.sub.12 in the compounds of structure (III) or (IV) is a
bond to a compounds of structure of (III) or (IV) (i.e., the
compound comprises more than one flavonoid of structure (III)
and/or (IV)).
[0155] In some other embodiments of the compounds of structure
(III) or (IV), R.sub.1-R.sub.12 is H, hydroxyl, a prenyl group or
cycloalkyl. For example, in some embodiments the cycloalkyl is
substituted and/or comprises one or more carbon-carbon double bonds
(i.e., is unsaturated). The optional substitutents are typically
selected from aryl, such as phenyl, and aryl carbonyl. Accordingly,
in some further embodiments, the flavonoid has one of the following
structures (IIIa) or (IVa):
##STR00126##
wherein R.sup.4a is, at each occurrence, independently H, hydroxyl
or a prenyl group.
[0156] In certain embodiments of the compounds of structure (IIIa)
or (IVa), R.sub.1-R.sub.3 and R.sub.5-R.sub.12 are each
independently selected from H, hydroxyl and a prenyl group. In
certain embodiments, at least one one of R.sub.1-R.sub.3, R.sub.4a
or R.sub.5-R.sub.12 is prenyl, for example in some embodiments,
R.sub.10 is prenyl. In other embodiments of the compounds of
structure (IIIa) or (IVa), at least two of R.sub.1-R.sub.3,
R.sub.4a or R.sub.5-R.sub.12 is hydroxyl.
[0157] In some more specific embodiments, the flavonoid has one of
the following structures:
##STR00127##
[0158] In other embodiments, one of R.sub.1-R.sub.12 joins with
another one of R.sub.1-R.sub.12 to form a ring and the remaining
R.sub.1-R.sub.12 are H, hydroxyl or a prenyl group. In certain of
these embodiments, the ring is a heterocyclic ring, for example a
cyclic ether ring. Accordingly, in certain embodiments the
flavonoid has one of the following structures (IIIb) or (IVb):
##STR00128##
[0159] In certain embodiments of the compounds of structure (IIIb)
or (IVb), R.sub.1, R.sub.2 and R.sub.5-R.sub.12 are each
independently selected from H, hydroxyl and a prenyl group. In
certain embodiments, at least one one of R.sub.1, R.sub.2 or
R.sub.5-R.sub.12 is prenyl, for example in some embodiments,
R.sub.10 is prenyl. In other embodiments of the compounds of
structure (IIIb) or (IVb), at least two of R.sub.1, R.sub.2 or
R.sub.5-R.sub.12 is hydroxyl. In certain embodiments, the flavonoid
has the following structure:
##STR00129##
[0160] In various other embodiments, R.sub.1-R.sub.10 of the
chalcanoid of structure (V) are each independently selected from H,
hydroxyl, a prenyl group, and C.sub.1-12 alkoxy.
[0161] Any of the aforementioned Morus extract mixed with Uncaria
extract compositions are useful for promoting, managing or
improving joint health, or for treating a joint disorder or disease
(e.g., osteoarthritis, rheumatoid arthritis, juvenile rheumatoid
arthritis, Still's disease, psoriatic arthritis, reactive
arthritis, septic arthritis, Reiter's syndrome, Behcet's syndrome,
Felty's syndrome, systemic lupus erythematosus, ankylosing
spondylitis, diffuse idiopathic skeletal hyperostosis (DISH),
sacroiliac joint dysfunction, polymyalgia rheumatic, carpal tunnel
syndrome, gout, bursitis, tendenitis, synovitis, SAPHO (synovitis,
acne, pustulosis, hyperostosis, osteitis) syndrome, patella
chondromalacia, repetitive strain injury, sprain, dislocation). In
certain embodiments, a composition of this disclosure comprises a
mixture of a Morus extract enriched for one or more prenylated
flavonoids and one or more stilbenes, and an Uncaria extract
enriched for flavans, wherein the composition inhibits cartilage
degradation.
[0162] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, an Uncaria
extract enriched for flavans, and an Acacia extract enriched for
flavans. In further embodiments, a composition comprises a mixture
of a Morus extract enriched for one or more prenylated flavonoids
and one or more stilbenes, an Uncaria extract enriched for flavans
including catechin, epicatechin or both, and an Acacia extract
enriched for flavans including catechin, epicatechin or both. In
certain embodiments, the Morus extract is from Morus alba, the
Uncaria extract is from Uncaria gambir, and the Acacia extract is
from Acacia catechu. In further embodiments, a major active
ingredient in the Morus extract is Albanin G, Kuwanon G, Morusin,
oxyresveratrol, mulberroside A or any combination thereof, and a
major active ingredient in the Uncaria and Acacia extracts is
catechin, epicatechin, or a combination thereof. Any of these three
extract compositions (Morus, Uncaria, Acacia) are useful for
promoting, managing or improving joint health, or for treating a
joint disorder or disease (e.g., osteoarthritis, rheumatoid
arthritis, juvenile rheumatoid arthritis, Still's disease,
psoriatic arthritis, reactive arthritis, septic arthritis, Reiter's
syndrome, Behcet's syndrome, Felty's syndrome, systemic lupus
erythematosus, ankylosing spondylitis, diffuse idiopathic skeletal
hyperostosis (DISH), sacroiliac joint dysfunction, polymyalgia
rheumatic, carpal tunnel syndrome, gout, bursitis, tendenitis,
synovitis, SAPHO (synovitis, acne, pustulosis, hyperostosis,
osteitis) syndrome, patella chondromalacia, repetitive strain
injury, sprain, dislocation).
[0163] In certain embodiments, a composition of this disclosure
comprises a mixture of a Morus extract containing or enriched for
at least one Diels-Alder adduct of a chalcone and a prenylphenyl
moiety, prenylated flavonoid, stilbene or any combination thereof,
and a Curcuma extract enriched for curcuminoids. In further
embodiments, a composition comprises a mixture of a Morus extract
containing or enriched for one or more compounds listed in Table A
and Examples 3, 5, 6 and 68, and a Curcuma extract enriched for one
or more curcuminoids. In still further embodiments, a composition
comprises a Morus extract containing or enriched for one or more
prenylated flavonoids, one or more stilbenes or any combination
thereof, and a Curcuma extract enriched for one or more
curcuminoids. In certain embodiments, the Morus extract is from
Morus alba, and the Curcuma extract is from Curcuma longa. In any
of the aforementioned compositions, a major active ingredient in
the Morus extract is Albanin G, Kuwanon G, Morusin, oxyresveratrol,
mulberroside A or any combination thereof, and a major active
ingredient in the Curcuma extract is curcumin, demethoxy-curcumin,
bisdemethoxy-curcumin or any combination thereof.
[0164] Any of the aforementioned Morus extract mixed with Curcuma
extract compositions are useful for promoting, managing or
improving joint health, or for treating a joint disorder or disease
(e.g., osteoarthritis, rheumatoid arthritis, juvenile rheumatoid
arthritis, Still's disease, psoriatic arthritis, reactive
arthritis, septic arthritis, Reiter's syndrome, Behcet's syndrome,
Felty's syndrome, systemic lupus erythematosus, ankylosing
spondylitis, diffuse idiopathic skeletal hyperostosis (DISH),
sacroiliac joint dysfunction, polymyalgia rheumatic, carpal tunnel
syndrome, gout, bursitis, tendenitis, synovitis, SAPHO (synovitis,
acne, pustulosis, hyperostosis, osteitis) syndrome, patella
chondromalacia, repetitive strain injury, sprain, dislocation). In
certain embodiments, a composition of this disclosure comprises a
mixture of a Morus extract enriched for one or more prenylated
flavonoids and one or more stilbenes, and an Curcuma extract
enriched for one or more curcuminoids, wherein the composition
inhibits cartilage degradation.
[0165] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, an Acacia
extract enriched for flavans, and a Curcuma extract enriched for
curcuminoids. In further embodiments, a composition comprises a
mixture of a Morus extract enriched for one or more prenylated
flavonoids and one or more stilbenes, an Acacia extract enriched
for flavans including catechin, epicatechin or both, and a Curcuma
extract enriched for one or more curcuminoids. In certain
embodiments, the Morus extract is from Morus alba, the Acacia
extract is from Acacia catechu, and the Curcuma extract is from
Curcuma longa. In further embodiments, a major active ingredient in
the Morus extract is Albanin G, Kuwanon G, Morusin, oxyresveratrol,
mulberroside A or any combination thereof, and a major active
ingredient in the Curcuma extract is curcumin (diferuloylmethane),
demethoxy-curcumin, bisdemethoxy-curcumin or any combination
thereof.
[0166] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, an Uncaria
extract enriched for flavans, and a Curcuma extract enriched for
curcuminoids. In further embodiments, a composition comprises a
mixture of a Morus extract enriched for one or more prenylated
flavonoids and one or more stilbenes, an Uncaria extract enriched
for flavans including catechin, epicatechin or both, and a Curcuma
extract enriched for one or more curcuminoids. In certain
embodiments, the Morus extract is from Morus alba, the Uncaria
extract is from Uncaria gambir, and the Curcuma extract is from
Curcuma longa.
[0167] Any of these three extract compositions (Morus, Morus,
Acacia, Curcuma or Morus, Uncaria, Curcuma) are useful for
promoting, managing or improving joint health, or for treating a
joint disorder or disease (e.g., osteoarthritis, rheumatoid
arthritis, juvenile rheumatoid arthritis, Still's disease,
psoriatic arthritis, reactive arthritis, septic arthritis, Reiter's
syndrome, Behcet's syndrome, Felty's syndrome, systemic lupus
erythematosus, ankylosing spondylitis, diffuse idiopathic skeletal
hyperostosis (DISH), sacroiliac joint dysfunction, polymyalgia
rheumatic, carpal tunnel syndrome, gout, bursitis, tendenitis,
synovitis, SAPHO (synovitis, acne, pustulosis, hyperostosis,
osteitis) syndrome, patella chondromalacia, repetitive strain
injury, sprain, dislocation).
[0168] In any of the aforementioned compositions, a Morus extract
is enriched for prenylated flavonoids, such as Albanin G, Kuwanon
G, Morusin, or any combination thereof. In certain embodiments, a
Morus extract is enriched for stilbenes, such as oxyresveratrol,
mulberroside A, or any combination thereof. In further embodiments,
a Morus extract is enriched for prenylated flavonoids and
stilbenes, including Albanin G, Kuwanon G, Morusin, oxyresveratrol,
mulberroside A, or any combination thereof. In still further
embodiments, a Morus extract is enriched for prenylated flavonoids
and stilbenes, wherein the extract comprises from about 2% to about
25% prenylated flavonoids and from about 1% to about 8% stilbenes,
or wherein the extract comprises at least 3% prenylated flavonoids
and at least 3% stilbenes (weight to weight). In other embodiments,
prenylated flavonoids, stilbenes, or both are isolated or purified
from a Morus extract and used in the compositions of this
disclosure. Exemplary active ingredients that can be isolated or
purified from a Morus extract and used in the compositions of this
disclosure include Albanin G, Kuwanon G, Morusin, oxyresveratrol,
mulberroside A, or any combination thereof. In any of the
aforementioned compositions, the Morus extract is from Morus
alba.
[0169] In any of the aforementioned embodiments, the compositions
comprising mixtures of extracts or compounds may be mixed at a
particular ratio by weight. For example, a Morus extract and an
Acacia extract may be blended in a 2:1 weight ratio, respectively.
In certain embodiments, the ratio (by weight) of two extracts or
compounds of this disclosure ranges from about 0.5:5 to about
5:0.5. Similar ranges apply when more than two extracts or
compounds (e.g., three, four, five) are used. Exemplary ratios
include 0.5:1, 0.5:2, 0.5:3, 0.5:4, 0.5:5, 1:1, 1:2, 1:3, 1:4, 1:5,
2:1, 2:2, 2:3, 2:4, 2:5, 3:1, 3:2, 3:3, 3:4, 3:5, 4:1, 4:2, 4:3,
4:4, 4:5, 5:1, 5:2, 5:3, 5:4, 5:5, 1:0.5, 2:0.5, 3:0.5, 4:0.5, or
5:0.5. In certain embodiments, Morus and Acacia extracts are
blended in a 1:1, 2:1, 3:1, 4:1, 5:1, 1:2, 1:3, 1:4, or 1:5 weight
ratio, respectively. In further embodiments, Morus and Acacia
extracts are blended in a range of 1:2 to 4:1 weight ratio,
respectively. In certain embodiments, Morus and Uncaria extracts
are blended in a 1:1, 2:1, 3:1, 4:1, 5:1, 1:2, 1:3, 1:4, or 1:5
weight ratio, respectively. In further embodiments, Morus and
Uncaria extracts are blended in a range of 1:4 to 4:1 weight ratio,
respectively. In certain embodiments, Morus and Curcuma extracts
are blended in a 1:1, 2:1, 3:1, 4:1, 5:1, 1:2, 1:3, 1:4, or 1:5
weight ratio, respectively. In further embodiments, Morus and
Curcuma extracts are blended in a range of 1:1 to 4:1 weight ratio,
respectively.
[0170] In any of the aforementioned embodiments, the compositions
comprising mixtures of extracts or compounds may be present at
certain percentage levels or ratios. In certain embodiments, a
composition comprising a Morus extract can include 0.1% to 49.9% or
about 1% to about 10% or about 0.5% to about 3% of prenylated
flavonoids, 0.1% to 49.9% or about 1% to about 10% or about 0.5% to
about 3% of stilbenes, or a combination thereof. In certain
embodiments, a composition comprising an Acacia extract can include
from about 0.01% to about 99.9% flavans or include at least 1%, 2%,
3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%,
18%, 19%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or
80% flavans (e.g., catechin, epicatechin, or both)
[0171] In certain examples, a composition of this disclosure may be
formulated to further comprise a pharmaceutically or
nutraceutically acceptable carrier, diluent, or excipient, wherein
the pharmaceutical or nutraceutical formulation comprises from
about 0.5 weight percent (wt %) to about 90 wt % of active or major
active ingredients of an extract mixture. In further embodiments,
the pharmaceutical or nutraceutical formulation comprises from
about 0.5 weight percent (wt %) to about 90 wt %, about 0.5 wt % to
about 80 wt %, about 0.5 wt % to about 75 wt %, about 0.5 wt % to
about 70 wt %, about 0.5 wt % to about 50 wt %, about 1.0 wt % to
about 40 wt %, about 1.0 wt % to about 20 wt %, about 1.0 wt % to
about 10 wt %, about 3.0 wt % to about 9.0 wt %, about 5.0 wt % to
about 10 wt %, about 3.0 wt % to about 6 wt % of the major active
ingredients in an extract mixture, or the like. In any of the
aforementioned formulations, a composition of this disclosure is
formulated as a tablet, hard capsule, softgel capsule, powder, or
granule.
[0172] In certain embodiments, a composition comprising a Morus
extract with a pharmaceutically or nutraceutically acceptable
carrier, diluent, or excipient will contain at least 6 wt % or at
least 5 wt % or at least 3 wt % or at least 2 wt % or at least 1 wt
% active Morus ingredients, such as prenylated flavonoids,
stilbenes, or a combination thereof. For example, a pharmaceutical
or nutraceutical composition comprising a Morus extract will
include at least 3 wt % prenylated flavonoids or from about at
least 0.5 wt % to about at least 2.5 wt % or from about at least 1
wt % to about at least 2.5 wt % or from about at least 1.5 wt % to
about at least 2.5 wt % (e.g., Albanin G, Kuwanon G, Morusin, or
any combination thereof) and at least 3% stilbenes (e.g.,
oxyresveratrol, mulberroside A, or both). In certain embodiments, a
composition comprising an Acacia or Uncaria extract with a
pharmaceutically or nutraceutically acceptable carrier, diluent, or
excipient will contain at least 20 wt % active Acacia or Uncaria
ingredients, such as flavans. For example, a pharmaceutical or
nutraceutical composition comprising an Acacia or Uncaria extract
will include at least about 3.5 wt % to about at least 14 wt % or
at least about 6 wt % to about at least 16.5 wt % (e.g., catechin,
epicatechin, or both). In certain embodiments, a composition
comprising a Curcuma extract with a pharmaceutically or
nutraceutically acceptable carrier, diluent, or excipient will
contain at least 25 wt % active Curcuma ingredients, such as
cucuminoids. For example, a pharmaceutical or nutraceutical
composition comprising a Curcuma extract will include at least
about 4.5 wt % to at least about 13 wt % curcuminoids (e.g.,
curcumin, demethoxy-curcumin, bisdemethoxy-curcumin, or any
combination thereof). In any of the aforementioned formulations, a
composition of this disclosure is formulated as a tablet, hard
capsule, softgel capsule, powder, or granule.
[0173] In certain embodiments, a composition of this disclosure
comprises Morus and Acacia extracts, wherein the composition
comprises from about 1 wt % to about 2.5 wt % prenylated flavonoids
including Albanin G, Kuwanon G and Morusin, from about 1 wt % to
about 2.5 wt % stilbenes including oxyresveratrol and mulberroside
A, and about 3.5 wt % to about 14 wt % flavans including catechin
and epicatechin. In certain other embodiments, a composition of
this disclosure comprises Morus and Uncaria extracts, wherein the
composition comprises from about 0.5 wt % to about 2.5 wt %
prenylated flavonoids including Albanin G, Kuwanon G and Morusin,
from about 0.5 wt % to about 2.5 wt % stilbenes including
oxyresveratrol and mulberroside A, and about 6 wt % to about 16.5
wt % flavans including catechin and epicatechin. In certain further
embodiments, a composition of this disclosure comprises Morus and
Curcuma extracts, wherein the composition comprises from about 1.5
wt % to about 2.5 wt % prenylated flavonoids including Albanin G,
Kuwanon G and Morusin, from about 1.5 wt % to about 2.5 wt %
stilbenes including oxyresveratrol and mulberroside A, and about
4.5 wt % to about 13 wt % curcuminoids including curcumin.
[0174] Any of these compositions may be used to promote joint
health; improve joint health; maintain joint health; treat or
manage joint health; support joint health; support a normal and
comfortable range of motion and/or flexibility; improve range of
motion and/or flexibility; reduce the action of harmful enzymes
that break down protective joint tissues; alter the action of
enzymes that affect joint health; improve joint movement and/or
joint function; improve physical mobility; manage and/or maintain
physical mobility; alleviate joint pain and/or joint stiffness;
improve joint physical function; promote or enhance flexibility and
comfortable movement; promote healthy joint function and joint
comfort; relieve joint discomfort; relieve joint discomfort caused
by exercise, work, overexertion or any combination thereof; promote
healthy joints by protecting cartilage integrity; maintain joint
cartilage; support joint cartilage; treat, prevent, or manage
cartilage degradation; minimize cartilage degradation; promote
joint health or comfort by maintaining synovial fluid for joint
lubrication; support joint stability and joint flexibility;
revitalize joints and promote mobility; promote flexible joints and
strong cartilage; maintain steady blood flow to joints to support
enhanced flexibility and/or strength; promote joint comfort and a
wide range of motion after exercise, work, overexertion, or any
combination thereof.
[0175] In other embodiments, any of these compositions may be used
to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid
arthritis, Still's disease, psoriatic arthritis, reactive
arthritis, septic arthritis, Reiter's syndrome, Behcet's syndrome,
Felty's syndrome, systemic lupus erythematosus, ankylosing
spondylitis, diffuse idiopathic skeletal hyperostosis (DISH),
sacroiliac joint dysfunction, polymyalgia rheumatic, carpal tunnel
syndrome, gout, bursitis, tendenitis, synovitis, SAPHO (synovitis,
acne, pustulosis, hyperostosis, osteitis) syndrome, patella
chondromalacia, repetitive strain injury, sprain, dislocation, or
any other associated indication, and generally with acceptable
toxicity to a patient.
[0176] In other embodiments of the present disclosure, a
composition can also include an adjuvant or a carrier. Adjuvants
include substances that generally enhance the function of the
formula in promoting, maintaining, or improving joint health.
Suitable adjuvants include Freund's adjuvant; other bacterial cell
wall components; aluminum-based salts; calcium-based salts; silica;
boron, histidine, glucosamine sulfates, Chondroitin sulfate, copper
gluconate, polynucleotides; vitamin D, vitamin K, toxoids; shark
and bovine cartilage; serum proteins; viral coat proteins; other
bacterial-derived preparations; .gamma.-interferon; block copolymer
adjuvants, such as Hunter's Titermax adjuvant (Vaxcel.TM., Inc.
Norcross, Ga.); Ribi adjuvants (available from Ribi ImmunoChem
Research, Inc., Hamilton, Mont.); and saponins and their
derivatives, such as Quil A (available from Superfos Biosector A/S,
Denmark). Carriers include compounds that increase the half-life of
a therapeutic or neutraceutical composition in a treated subject.
Suitable carriers include polymeric controlled release
formulations, biodegradable implants, liposomes, bacteria, viruses,
oils, esters, or glycols.
[0177] Additional adjunctive agents useful with the compositions of
this dislclosure include glucosamine (including glucosamine
sulfate, glucosamine hydrochloride, N-acetylglucosamine),
glycosaminoglycans (GAGs), hyaluronic acid (HA), elastin, collagen,
chicken collagen Type II, hyaluronic acid and collagen blend,
chondroitin sulfate, methylsulfonylmethane (MSM), bovine cartilage,
amino acids (including desmosine, isodesmosine, L-glutamine),
Boswellia serrata extract, piperine (e.g., Piper nigrum L (black
pepper) extract or Piper longum L (long pepper) extract), bromelain
(pineapple extract), trypsin, rutin, emu oil, transforming growth
factor(TGF)-.beta., carotenoids (such as lutein, carotene,
canthaxanthin); vitamins (such as Vitamin D3), .omega.-3 fatty
acids (such as eicosapentaenoic acid, EPA; docosahexaenoic acid,
DHA), calcium fructoborate, eggshell membrane, astaxanthin,
Hydrilla verticillata extract (leaf and bud), ginger extract
(root), grapefruit extract (seed), non-steroidal anti-inflammatory
drugs (NSAIDs), or any combination thereof.
[0178] Exemplary NSAIDS include salicylates, such as aspirin
(acetylsalicylic acid), diflusinal, salsalate; propionic acid
derivatives, such as ibuprofen, dexibuprofen, naproxen, fenoprofen,
ketoprofen, dexketoprofen, flurbiprofen, oxprozin, loxoprofen;
acetic acid derivatives, such as indometacin, tolmetin, sulindac,
etodolac, ketorolac, diclofenac, nabumetone; enolic acid
derivatives, such as piroxicam, meloxicam, tenoxicam, droxicam,
lornoxicam, isoxicam; fenamic acid derivatives, such as mefenamic
acid, meclofenamic acid, flufenamic acid, tolfenamic acid;
selective COX-2 inhibitors, such s celecoxib, parecoxib,
lumiracoxib, etoricoxib, firocoxib, paracetamol, H-harpagide;
suphonanilides, such as nimesulide; nicotinic acid derivatives,
such as lysine clonixinate; dual COX/LX inhibitors, such as
licofelone. A related drug, paracetamol or "acetaminophen" is often
considered in the same category as NSAIDS due to its use as a
non-narcotic analgesic and fever-reducing agent, but is not
classified as a NSAID because it only exerts weak
anti-inflammatory.
[0179] In certain embodiments, compositions of the instant
disclosure further comprise an injectable anticoagulant, an oral
anticoagulant, an antiplatelet agent, an anti-angina agent, or a
COX-2 selective inhibitor. Exemplary injectable anticoagulants
include heparin, dalteparin, enoxaparin and tinzaparin. Examples of
oral anticoagulants include, but are not limited to warfarin,
vitamin K antagonists and vitamin K reductase inhibitors. Examples
of antiplatelet agents include aspirin, clodipogrel and
dipyridamole. Exemplary anti-angina drugs include nitrates,
beta-blockers, calcium blockers, angiotensin-converting enzyme
inhibitors, and potassium channel activators. Finally, examples of
COX-2 selective inhibitors include rofecoxib, celecoxib, etodolac
and meloxicam.
[0180] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for one or more prenylated flavonoids and
one or more stilbenes, an Acacia extract enriched for flavans, and
a glucosamine-type compound. In further embodiments, the Morus
extract is a Morus alba extract, the Acacia extract is an Acacia
catechu extract, and the glucosamine-type compound is glucosamine
sulfate, glucosamine hydrochloride, N-acetylglucosamine,
chondroitin sulfate, methylsulfonylmethane, or hyaluronic acid. In
certain embodiments, Morus extract, Acacia extract, and NAG are
blended in a 1:1:1, 2:1:1, 3:1:1, 4:1:1, 5:1:1, 1:2:1, 1:3:1,
1:4:1, 1:5:1, 1:1:2, 1:1:3, 1:1:4, or 1:1:5 weight ratio,
respectively. In certain embodiments, Morus extract, Uncaria
extract, and NAG are blended in a 1:1:1, 2:1:1, 3:1:1, 4:1:1,
5:1:1, 1:2:1, 1:3:1, 1:4:1, 1:5:1, 1:1:2, 1:1:3, 1:1:4, or 1:1:5
weight ratio, respectively. In certain embodiments, Morus extract,
Curcuma extract, and NAG are blended in a 1:1:1, 2:1:1, 3:1:1,
4:1:1, 5:1:1, 1:2:1, 1:3:1, 1:4:1, 1:5:1, 1:1:2, 1:1:3, 1:1:4, or
1:1:5 weight ratio, respectively. In certain embodiments, a
composition comprises a mixture of a Morus extract enriched for
prenylated flavonoids, an Uncaria extract enriched for flavans, and
a glucosamine-type compound. In further embodiments, the Morus
extract is a Morus alba extract, the Uncaria extract is an Uncaria
gambir extract, and the glucosamine-type compound is glucosamine
sulfate, glucosamine hydrochloride, N-acetylglucosamine,
chondroitin sulfate, methylsulfonylmethane, or hyaluronic acid.
[0181] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, a Curcuma
extract enriched for curcuminoids, and a glucosamine-type compound.
In further embodiments, the Morus extract is a Morus alba extract,
the Curcuma extract is a Curcuma longa extract, and the
glucosamine-type compound is glucosamine sulfate, glucosamine
hydrochloride, N-acetylglucosamine, chondroitin sulfate,
methylsulfonylmethane, or hyaluronic acid.
[0182] In any of the aforementioned compositions, the compositions
may additionally comprise Mentha extract enriched for rosmarinic
acid, eriocitrin, or both. Rosmarinic acid accumulation is found
most notably in many plants of the Lamiaceae family (dicotyledons),
especially in the subfamily Nepetoideae, including plants commonly
used as culinary herbs, such as Ocimum basilicum (basil), Ocimum
tenuiflorumcum (holy basil), Melissa officinalis (lemon balm),
Rosmarinus officinalis (rosemary), Origanum majorana (marjoram),
Salvia officinalis (sage), Thymus vulgaris (thyme) and Mentha
piperita (peppermint). Rosmarinic acid is also found in plants with
medicinal properties, such as common self-heal (Prunella vulgaris)
or species in the genus Stachy. Other exemplary plants that contain
rosmarinic acid include Heliotropium foertherianum (a plant in the
family Boraginaceae), species in the genera Maranta (Maranta
leuconeura, Maranta depressa, which are plants in the family
Marantaceae, monocotyledons), species in the genera Thalia (Thalia
geniculata), and Anthoceros agrestis (hornwort).
[0183] Exemplary mint plants containing rosmarinic acid or
eriocitrin or both include Mentha aquatica (Water mint or Marsh
mint); Mentha arvensis (Corn Mint, Wild Mint, Japanese Peppermint,
Field Mint, Pudina, Banana mint); Mentha asiatica (Asian Mint);
Mentha australis (Australian mint); Mentha canadensis; Mentha
cervina (Hart's Pennyroyal); Mentha citrata (Bergamot mint, Orange
mint); Mentha crispata (Wrinkled-leaf mint); Mentha dahurica
(Dahurian Thyme); Mentha diemenica (Slender mint); Mentha laxiflora
(Forest mint); Mentha longifolia (Mentha sylvestris, Horse Mint);
Mentha piperita (Peppermint); Mentha pulegium (Pennyroyal); Mentha
requienii (Corsican mint); Mentha sachalinensis (Garden mint);
Mentha satureioides (Native Pennyroyal); Mentha spicata (M.
viridis, syn M. cordifolia Spearmint, Curly mint); Mentha
suaveolens (Apple mint, Pineapple mint (a variegated cultivar of
Apple mint)); Mentha vagans (Gray mint).
[0184] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, an Acacia
extract enriched for flavans, and a Mentha extract enriched for
rosmarinic acid, eriocitrin, or both. In further embodiments, the
Morus extract is a Morus alba extract, the Acacia extract is an
Acacia catechu extract, and the Mentha extract is a Mentha piperita
extract. In certain embodiments, Morus, Acacia and Mentha extracts
are blended in a 1:1:0.5, 2:1:0.5, 3:1:0.5, 4:1:0.5, 5:1:0.5,
1:2:0.5, 1:3:0.5, 1:4:0.5, 1:5:0.5, 1:1:1, 1:1:2, 1:1:3, 1:1:4, or
1:1:5 weight ratio, respectively.
[0185] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, an Uncaria
extract enriched for flavans, and a Mentha extract enriched for
rosmarinic acid, eriocitrin, or both. In further embodiments, the
Morus extract is a Morus alba extract, the Uncaria extract is an
Uncaria gambir extract, and the Mentha extract is a Mentha piperita
extract. In certain embodiments, Morus, Uncaria and Mentha extracts
are blended in a 1:1:0.5, 2:1:0.5, 3:1:0.5, 4:1:0.5, 5:1:0.5,
1:2:0.5, 1:3:0.5, 1:4:0.5, 1:5:0.5, 1:1:1, 1:1:2, 1:1:3, 1:1:4, or
1:1:5 weight ratio, respectively.
[0186] In certain embodiments, a composition comprises a mixture of
a Morus extract enriched for prenylated flavonoids, a Curcuma
extract enriched for curcuminoids, and a Mentha extract enriched
for rosmarinic acid, eriocitrin, or both. In further embodiments,
the Morus extract is a Morus alba extract, the Curcuma extract is a
Curcuma longa extract, and the Mentha extract is a Mentha piperita
extract. In certain embodiments, Morus, Curcuma and Mentha extracts
are blended in a 1:1:0.5, 2:1:0.5, 3:1:0.5, 4:1:0.5, 5:1:0.5,
1:2:0.5, 1:3:0.5, 1:4:0.5, 1:5:0.5, 1:1:1, 1:1:2, 1:1:3, 1:1:4, or
1:1:5 weight ratio, respectively.
[0187] Any of the aforementioned compositions are useful for
promoting joint health; improving joint health; maintaining joint
health; treating or managing joint health; supporting joint health;
supporting a normal and comfortable range of motion and/or
flexibility; improving range of motion and/or flexibility; reducing
the action of harmful enzymes that break down protective joint
tissues; altering the action of enzymes that affect joint health;
improving joint movement and/or joint function; improving physical
mobility; managing and/or maintaining physical mobility;
alleviating joint pain and/or joint stiffness; improving joint
physical function; promoting or enhancing flexibility and
comfortable movement; promoting healthy joint function and joint
comfort; relieving joint discomfort; relieving joint discomfort
caused by oxidative stress, harmful free radicals, aging, wear and
tear, exercise, work, overexertion or any combination thereof;
managing or reducing joint damage caused by oxidative stress,
harmful free radicals, aging, wear and tear, exercise, work,
overexertion or any combination thereof; promoting healthy joints
by protecting cartilage integrity; maintaining joint cartilage;
supporting joint cartilage; treating, preventing, or managing
cartilage degradation; minimizing cartilage degradation; promoting
joint health or comfort by maintaining synovial fluid for joint
lubrication; supporting joint stability and joint flexibility;
revitalizing joints and promoting mobility; promoting flexible
joints and strong cartilage; maintaining steady blood flow to
joints to support enhanced flexibility and/or strength; promoting
joint comfort and a wide range of motion after exercise, work,
overexertion or any combination thereof; or any combination
thereof.
[0188] In further embodiments, any of the aforementioned
compositions are useful for treating, preventing, or ameliorating
joint disorders or disease, such as osteoarthritis, rheumatoid
arthritis, juvenile rheumatoid arthritis, Still's disease,
psoriatic arthritis, reactive arthritis, septic arthritis, Reiter's
syndrome, Behcet's syndrome, Felty's syndrome, systemic lupus
erythematosus, ankylosing spondylitis, diffuse idiopathic skeletal
hyperostosis (DISH), sacroiliac joint dysfunction, polymyalgia
rheumatic, carpal tunnel syndrome, gout, bursitis, tendenitis,
synovitis, SAPHO (synovitis, acne, pustulosis, hyperostosis,
osteitis) syndrome, patella chondromalacia, repetitive strain
injury, sprain, dislocation, or any combination thereof.
EXAMPLES
Example 1
Preparation of Organic and Aqueous Extracts from Morus alba
[0189] Plant material from Morus alba L. root barks was ground to a
particle size of no larger than two millimeters (mm). Dried ground
plant material (60 grams (g) was then transferred to an Erlenmeyer
flask and Methanol:Dichloromethane (1:1 volume ratio) (600
milliliters (mL)) was added. The mixture was shaken for one hour,
filtered and the biomass was extracted again with
Methanol:Dichloromethane (1:1 volume ratio) (600 mL). These organic
extracts were combined and evaporated under vacuum to provide 3.55
g of organic extract (OE). After organic extraction, the biomass
was air dried and extracted once with ultrapure water (600 mL). The
aqueous solution was filtered and freeze-dried to provide 4.44 g of
aqueous extract (AE).
[0190] Similar results were obtained using the same procedure or
reflex in flasks, but with the organic solvent being replaced with
methanol or ethanol to provide a methanol extract (ME) or ethanol
extract (EE), respectively. Other species and parts of plants and
marine sample were extracted using this same procedure.
Example 2
High Throughput Purification (HTP) of Active Plant Extracts
[0191] Organic extract material (400 mg) from the Morus alba root
bark extract obtained in Example 1 was loaded onto a prepacked (2
cm ID.times.8.2 cm, 10 g silica gel) column. The column was then
eluted using a Hitachi.RTM. High Throughput Purification (HTP)
system with a gradient mobile phase of (A) 50:50 volume ratio of
EtOAc:Hexane and (B) Methanol from 100% A to 100% B in 30 minutes
at a flow rate of 5 mL/min. The separation was monitored using a
broadband wavelength UV detector and the fractions were collected
in a 96-deep-well plate at 1.9 mL/well using a Gilson fraction
collector. The sample plate was dried under low vacuum and
centrifugation and then the samples were dissolved with 1.5 mL
dimethyl sulfoxide (DMSO) per well. A portion (100 .mu.L) was taken
and combined (based on UV trace) for the function assay. Column
fractions having significant biological activity were retained for
further testing.
Example 3
Isolation, Purification, and Identification of Prenylated
Flavonoids from Morus alba Extracts
[0192] An organic extract (11 g) from the root barks of Morus alba,
obtained as described in Example 1, was divided and loaded
separately onto two pre-packed flash columns (120 g silica,
particle size 32-60 .mu.m, 4 cm.times.19 cm), and then eluted with
Hexane, EtOAc and Methanol (as the mobile phase) at a flow rate of
20 mL/minutes. The gradients started with 95% Hexane/EtOAC for 5
minutes, then increased EtOAC from 5% to 100% over the duration of
25 minutes, and then held at 100% EtOAc for additional five
minutes, before increasing MeOH from 0% to 50% MeOH/EtOAC over a
next period of 15 minutes, finally changed the elution solution to
100% MeOH and eluted the column for another 16 minutes. The total
run time was 66 minutes and 88 fractions were generated for each
column. The fractions were analyzed by silica gel thin layer
chromatography (TLC) and pooled together to generate eight column
eluent pools.
[0193] The resulting best active pool (containing 300 mg of
material) was fractionated on a preparative C18 column (30
cm.times.250 cm) with a gradient mobile phase of water (A) and
methanol (B) over 60 minutes at a flow rate of 20 mL/minute to
generate 22 fraction pools. Mass Spectrometry (MS) analysis showed
that these pooled fractions of material contain three related
compounds, described in more detail below.
[0194] Compound 1 (28.2 mg) was identified as a Diels-Alder adduct
of a chalcone and prenylphenyl moiety called Kuwanon G, also known
as Moracenin B or Albanin F, by High Resolution Electron Spray
Ionization Mass Spectroscopy (HRESIMS) (m/z) [M+H].sup.-=693.2329;
UV .lamda..sub.max (MeOH): 265, 320 nm; .sup.1H NMR (600 MHz,
DMSO-d.sub.6, 100.degree. C.) .delta. ppm 1.44 (s, 3H) 1.52 (br.
s., 3H) 1.58 (s, 3H) 1.92 (m, 2H) 3.08 (d, 3H) 3.56 (m, 2H) 4.29
(d, J=10.02 Hz, 1H) 4.48 (m, 1H) 5.07 (m, 1H) 5.14 (br. s, 1H) 5.93
(s, 2H) 5.96 (dd, J=8.35, 2.23 Hz, 1H) 6.02 (br s, 1H) 6.11 (d,
J=2.23 Hz, 1H) 6.41 (dd, J=8.35, 2.23 Hz, 1H) 6.51 (s, 1H) 6.60 (m,
1H) 7.13 (d, J=8.35 Hz, 1H) 7.28 (br s, 1H); .sup.13C NMR (126 MHz,
METHANOL-d.sub.4) .delta. ppm 16.35 (1C) 21.78 (1C) 23.35 (1C)
24.53 (1C) 37.72 (1C) 97.14 (1C) 101.57 (1C) 102.22 (1C) 102.33
(1C) 104.28 (1C) 106.55 (2C) 107.00 (1C) 107.21 (1C) 112.37 (1C)
114.47 (1C) 120.27 (1C) 121.62 (2C) 123.27 (1C) 131.05 (1C) 131.35
(2C) 132.62 (1C) 132.99 (1C) 155.16 (1C) 155.56 (1C) 156.38 (1C)
159.66 (1C) 160.39 (2C) 161.13 (1C) 161.88 (1C) 164.51 (1C) 164.63
(1C) 182.46 (1C) 208.68 (1C).
##STR00130##
[0195] Compound 2 (10.5 mg) was identified as Albanin G, also known
as Kuwanon H or Moracenin A, another Diels-Alder adduct of a
chalcone and prenylphenyl moiety by HRESIMS (m/z) [M-H].sup.-=759;
UV .lamda..sub.max (MeOH): 265, 320 nm; .sup.13C NMR (126 MHz,
METHANOL-d.sub.4) .delta. ppm 16.35 (1C) 16.47 (1C) 20.96 (1C)
21.79 (1C) 23.32 (1C) 24.51 (1C) 24.53 (1C) 33.74 (1C) 35.61 (1C)
36.81 (1C) 37.77 (1C) 97.19 (1C) 102.27 (1C) 102.33 (1C) 104.24
(1C) 106.07 (1C) 106.53 (2C) 107.34 (1C) 112.37 (1C) 113.94 (1C)
114.35 (1C) 120.17 (1C) 121.60 (2C) 122.31 (2C) 123.25 (1C) 130.21
(2C) 131.33 (2C) 132.96 (1C) 156.37 (3C) 157.07 (1C) 159.59 (1C)
160.37 (1C) 161.23 (1C) 161.77 (1C) 161.96 (1C) 162.21 (1C) 182.45
(1C) 208.82 (1C).
##STR00131##
[0196] Compound 3 (12.9 mg) was identified as Morusinol by ESIMS
(m/z) [M-H].sup.-=437; UV .lamda..sub.max (MeOH): 269, 317 nm;
.sup.1H NMR (500 MHz, METHANOL-d.sub.4) .delta. ppm 1.08 (s, 6H)
1.43 (s, 6H) 1.60 (m, 2H) 2.43 (m, 2H) 5.59 (d, J=9.97 Hz, 1H) 6.16
(s, 1H) 6.43 (m, 2H) 6.59 (d, J=10.26 Hz, 1H) 7.15 (d, J=9.09 Hz,
1H); .sup.13C NMR (126 MHz, METHANOL-d.sub.4) .delta. ppm 21.52 (t,
1C) 28.54 (q, 2C) 28.88 (q, 2C) 43.19 (t, 1C) 71.56 (s, 1C) 79.28
(s, 1C) 100.28 (d, 1C) 102.35 (s, 1C) 104.06 (d, 1C) 106.05 (s, 1C)
108.26 (d, 1C) 113.14 (s, 1C) 115.89 (d, 1C) 122.99 (s, 1C) 128.36
(d, 1C) 132.37 (d, 1C) 153.97 (s, 1C) 157.96 (s, 1C) 160.62 (s, 1C)
162.13 (s, 1C) 162.88 (s, 1C) 163.63 (s, 1C) 184.09 (s, 1C)
##STR00132##
[0197] Another best active pool (containing 538 mg of material) was
fractionated on a preparative C18 column (30 cm.times.250 cm) with
a gradient mobile phase of water (A) and methanol (B) over 60
minutes at a flow rate of 20 mL/minute to generate 16 fraction
pools. A prenylphenylated Compound 4, called Morusin (80 mg), also
known as Mulberrochromene was isolated. The structure and
spectroscopy data were as follows: ESIMS (m/z) [M-H].sup.- 419; UV
.lamda.max (MeOH): 269.4 nm; 1H NMR (500 MHz, METHANOL-d4) .delta.
ppm 1.41 (m, 9H) 1.58 (s, 3H) 3.10 (d, J=7.15 Hz, 2H) 5.09 (m, 1H)
5.57 (d, J=10.49 Hz, 1H) 6.14 (s, 1H) 6.40 (m, 2H) 6.59 (d, J=10.01
Hz, 1H) 7.10 (d, J=8.11 Hz, 1H); 13C NMR (126 MHz, METHANOL-d4)
.delta. ppm 16.25 (q, 1C) 23.48 (t, 1C) 24.42 (q, 1C) 26.99 (q, 2C)
77.70 (s, 1C) 98.69 (d, 1C) 100.79 (s, 1C) 102.43 (d, 1C) 104.51
(s, 1C) 106.63 (d, 1C) 111.67 (s, 1C) 114.35 (d, 1C) 120.63 (s, 1C)
121.30 (d, 1C) 126.73 (d, 1C) 131.02 (d, 1C) 131.42 (s, 1C) 152.36
(s, 1C) 156.51 (s, 1C) 159.04 (s, 1C) 160.61 (s, 1C) 161.27 (s, 1C)
162.14 (s, 1C) 182.44 (s, 1C).
##STR00133##
Example 4
Preparation of Organic 70% ETOH Extracts from Morus alba
[0198] 2 kg of dried Morus alba roots and root barks were cut,
crushed, and then extracted with approximately ten-fold volume (20
L) of 70% ethyl alcohol in water (v/v); the extraction was carried
on at 80.degree. C. for 5 hrs. The ethanol solution was filtered to
obtain the supernatant which was then concentrated with an
evaporator under vacuum at 40.degree. C. This extraction and
concentration procedure was repeated two times. The extraction
solutions were then combined together and concentrated until the
volume become 1/25 of the original volume. The concentrated
solution was dried by vacuum freeze-drying to obtain 283.5 g of
Morus alba 70% EtOH extract powder 1-01. The extraction yield was
about 14.7% (w/w).
Example 5
Isolation of Mulberroside a from Morus alba ETOH Extracts
[0199] A 20 g amount of Morus alba 70% ethyl alcohol extract 1-01
from Example 4 was loaded onto silica gel column and the column was
eluted with a stepwise application of solvent mixture containing
linear gradient of hexane:EtOAc (5:1 to 1:5) to give eight
subfractions. Among the eight subfractions, the 8.sup.th fraction
was subjected to a RP-HPLC column (YMC-ODS) 5 .mu.m, C18
(250.times.30 mm) by injection onto a preparative HPLC system (JAI,
LC-9104, Japan) eluted with 15% Acetonitrile in H.sub.2O in 16.2
min with UV wavelength 330 nm to afford Compound 5 (mulberroside A)
(191 mg).
[0200] Compound 5 (mulberroside A, C.sub.26H.sub.32O.sub.14):
APCI-MS (m/z) [M+H]' 569.58; UV .lamda..sub.max (MeOH): 217.9,
325.6 nm; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 6.34
(brs, 1H) 6.52 (dd, J=8.6, 2.4 Hz, 1H) 6.54 (d, J=2.4 Hz, 1H) 6.57
(s, 1H) 6.64 (s, 1H) 6.94 (d, J=16.4 Hz, 1H) 7.22 (d, J=16.4 Hz,
1H) 7.45 (d, J=8.6 Hz, 1H); .sup.13C NMR (125 MHz, DMSO-d.sub.6)
.delta. ppm 60.58 (t, G-6') 60.62 (d, G-6) 69.56 (d, G-4) 69.63 (d,
G-4' 73.20 (d, G-2') 73.29 (d, G-2) 76.61 (d, G-3') 76.61 (d, G-3)
77.00 (d, G-5') 77.04 (d, G-5) 100.39 (s, G-1') 100.76 (s, G-1)
102.65 (d, C-2') 103.86 (d, C-3) 105.35 (d, C-4' 106.52 (d, C-5)
107.46 (d, C-6') 117.86 (s, C-1) 123.47 (d, C-6) 126.00 (d, a)
127.27 (d, b) 139.77 (s, C-1') 155.86 (s, C-2) 157.96 (s, C-4)
158.40 (s, C-5') 158.92 (s, C-3')
##STR00134##
Example 6
Compounds Purified from Milicia excelsa (African Teak)
[0201] The organic extract (8 g) from the stem barks of Milicia
excelsa, obtained using the methods described in Example 1, was
divided and loaded separately onto two pre-packed flash columns
(120 g silica, particle size 32-60 .mu.m, 4 cm.times.19 cm), then
the column was eluted with the gradient as described in Example 4.
A prenylated flavonoid--Compound 6--was isolated from one of the
active fractions and identified as Sanggenon C/D/O.
[0202] The structure and spectroscopy data of Compound 6 was as
follows: ESIMS (m/z) [M-2H].sup.- 706; UV .lamda..sub.max (MeOH):
265, 320 nm; .sup.1H NMR (500 MHz, METHANOL-d.sub.4) ppm 1.55 (s,
CH.sub.3, 3 H) 1.58 (s, CH.sub.3, 3 H) 1.82 (m, CH.sub.3, 3 H) 2.28
(dd, J=18.65, 5.09 Hz, 1H) 2.39 (dd, J=17.80, 5.09 Hz, 1H) 2.69 (m,
1H) 2.94 (m, 1H) 3.87 (d, J=6.78 Hz, CH, 1H) 4.16 (br. s., CH, 1H)
4.49 (br. s., CH, 1H) 5.19 (br. s., 1H) 5.45 (br. s., 1H) 5.64 (s,
1H) 6.11 (d, J=2.26 Hz, 1H) 6.17 (dd, J=8.48, 2.26 Hz, 1H)
6.23-6.34 (m, 3H) 6.42 (dd, J=8.20, 1.70 Hz, 1H) 6.86 (d, J=8.19
Hz, 1H) 7.21 (d, J=8.48 Hz, 1H) 8.08 (d, J=8.76 Hz, 1H).
##STR00135##
Example 7
Preparation of Various Milicia excelsa Extracts
[0203] Milicia EtOAc extract fraction 7 was produced as follows: 5
kg of dried Milicia excelsa stem barks were cut, crushed, and
extracted with approximately 4-fold volume (20 L) of ethyl alcohol
(Food grade, Korea Ethanol Supplies Company, Korea) in water (v/v).
The extraction solvent was treated at 80.degree. C., for 4 hrs and
the resulting extraction was filtered to obtain a supernatant that
was concentrated with evaporator at 40.degree. C. The
above-described extraction procedure was repeated two times. The
resulting extraction solutions were combined together and
concentrated until the volume become 1/25 of the original volumes.
The concentrated solution was then dried by vacuum freeze-drying to
obtain 200 g of crude Milicia excelsa EtOH extract powder.
[0204] 196 g of crude Milicia excelsa EtOH extract powder prepared
in the above procedure was suspended in 2 L of distilled water and
the suspension was vigorously mixed with 2 L of n-hexane to obtain
an n-hexane soluble fraction and water-soluble fraction. The
n-hexane soluble fraction was collected and the residual solution
was subjected to a second n-hexane extraction. The above-described
procedure was repeated four times and the resulting n-hexane
soluble fractions were combined and evaporated under vacuum to
obtain 74.8 g of n-hexane soluble extract 7-1 of Milicia excelsa
stem bark.
[0205] The water-soluble fraction of Milicia excelsa stem bark
prepared in the above procedure was vigorously mixed with an
equivalent volume of ethyl acetate to obtain an ethyl acetate
soluble fraction and a water-soluble fraction. The ethyl acetate
soluble fraction was collected and the residual solution was
subjected to the ethyl acetate extraction again. This procedure was
repeated four times. The ethyl acetate soluble fractions and
water-soluble fractions were respectively evaporated under vacuum
to obtain 63.9 g of ethyl acetate soluble extract fraction 7 and
35.34 g of water-soluble extract 7-2 of Milicia excelsa stem
bark.
Example 8
Preparation and HPLC Quantification of Extracts from Morus
Plants
[0206] Morus samples were collected from different plant parts in
different geological locations in S. Korea. The dry plant materials
were ground into powder. Mixed 20 grams of Morus plant powder with
enough Diatomaceous earth to fill up a 100 mL extraction cell, and
extracted with 70% Ethanol/water by using ASE 350 Extractor
(Extraction condition: Heat=5 minutes, Static=5 minutes, Flush=80
volume, Purge=900 seconds, Cycles=3, Pressure=1500 psi,
Temperature=60.degree. C.). After extraction, the solution was
concentrated with an evaporator at 50.degree. C. to produce a solid
extract.
[0207] The target components Mulberroside A, Oxyresveratrol,
Kuwanon G, Albanin G and Morusin in the Moms extracts were
quantified with a Luna C18 reversed-phase column (Phenomenex, 10
.mu.m, 250 mm.times.4.6 mm) in a Hitachi HPLC system at 325 nm. The
column was eluted with a binary gradient of 0.1% Formic acid in
water (mobile phase A) and acetonitrile (mobile phase B) at 1
ml/min flow rate and 30.degree. C. column temperature.
TABLE-US-00002 TABLE 1 Gradient Table of HPLC Analytical Method
Time (min) Mobile phase A Mobile phase B 0.0 90 10 8.0 85 15 35.0
10 90 35.1 0 100 38.0 0 100 38.1 90 10 45.0 90 10
[0208] Reference Standard Material 72-1 (Morus 70% EtOH extract
1-01) produced according to Example 4 was utilized as the
quantification standard. All extract samples were prepared in a
concentration around 5 mg/ml in MeOH. After sonicating for
approximately 15 minutes, the sample solution was cooled in a flask
to room temperature and filtered through a 0.45 um nylon syringe
filter and 20 .mu.l of the sample was injected into the column.
[0209] Morus plants were collected from South Korea and China from
different geological locations in both countries. The HPLC
quantification of Mulberroside A, Oxyresveratrol, Kuwanon G,
Albanin G and Morusin content in different species, different plant
parts, collected from different locations, and at different age of
plants, are listed in Tables 2 and 3. The actives have been
qualified from Morus root bark, root wood, fine roots, stem bark,
branch, branch bark, branch wood, and twigs. There are small
amounts of stilbene-type compounds--Mulberroside A and
Oxyresveratrol--detected in Morus leaf.
TABLE-US-00003 TABLE 2 Quantification of Active Compounds in Morus
Collected from S. Korea. Active Content in Extract (%) Morus Plant
Mulberroside Oxy- Kuwanon Albanin Extraction No. Part A resveratrol
G G Morusin Yield (%) MK-1 Root bark 10.93 0.07 1.66 0.82 0.55 23%
MK-2 Root bark 11.58 0.75 2.79 1.18 1.21 19% MK-3 Root wood 6.40
2.26 0.58 0.20 0.24 8% MK-4 Fine root 9.58 2.15 2.98 1.73 1.35 15%
MK-5 Stem bark 2.89 0.16 0.27 0.42 0.48 19% MK-6 Root bark 0.36
0.16 0.23 0.00 0.09 18% MK-7 Root bark 13.28 0.00 0.25 0.00 0.00
27% MK-8 Root bark 11.71 0.08 0.63 0.25 0.15 21% MK-9 Root bark
17.63 0.48 2.80 0.66 1.56 21% MK10 Root bark 0.28 0.19 1.70 0.06
0.05 16% MK-11 Leaves 0.54 0.06 0.00 0.00 0.00 23% MK-12 Fruit 0.00
0.00 0.00 0.00 0.00 35% MK-13 Branch 3.31 4.07 0.14 0.00 0.18 9%
MK-14 Root bark 12.51 0.39 5.73 2.48 2.42 22% MK-15 Root wood 1.58
2.52 0.36 0.14 0.12 7% MK-16 Branch 22.46 0.09 0.58 0.00 0.57 15%
bark MK-17 Branch 4.95 1.78 0.17 0.00 0.00 5% wood MK-18 Root bark
0.41 0.28 3.36 0.11 0.18 14%
TABLE-US-00004 TABLE 3 Quantification of Active Compounds in Morus
Collected from China Active Content in Extract (%) Morus Plant
Mulberroside Oxy- Kuwanon Albanin Extraction No. Part A resveratrol
G G Morusin Yield (%) MC-1 Root bark 1.74 0.10 7.29 6.31 5.38 17%
MC-2 Root bark 3.42 0.37 4.69 1.00 1.97 18% MC-3 Root bark 0.04
0.05 0.34 0.00 0.12 8% MC-4 Root bark 0.11 0.60 0.39 0.00 0.14 8%
MC-5 Root bark 0.24 0.22 0.73 0.00 0.18 9% MC-6 Root bark 14.07
0.36 2.06 1.29 1.42 20% MC-7 Root bark 9.96 1.01 2.51 0.73 0.78 12%
MC-8 Root bark 0.21 2.64 0.06 0.46 1.40 12% MC-9 Root bark 5.85
1.44 5.11 2.41 8.70 19% MC-10 Root bark 2.81 0.76 11.43 4.21 3.82
11% MC-11 Root bark 0.03 0.01 0.40 0.75 0.10 11% MC-12 Fruit 0.00
0.00 0.00 0.00 0.00 74% MC-13 Leaves 0.00 0.00 0.13 0.00 0.00 20%
MC-14 Twigs 2.67 0.90 0.06 0.17 0.03 4%
Example 9
HPLC Quantification of Extracts from Morus Root Bark
[0210] Ethanol extracts of Morus root barks were obtained from
different geological locations in China. The contents of four
active components--Mulberroside A, Kuwanon G, Albanin G and
Morusin--in those Morus extracts were quantified with the HPLC
method described in Example 8. As shown in the Table 4, two Morus
extracts (ME-10 and ME-12) contained none of the four active
compounds. Three Morus extracts (ME-6, ME-7 and ME-8) contained no
Mulberroside A and very small amounts of prenylated flavonoids
(less than 4% as a total of the 3 compounds present). Another four
Morus extracts (ME-3, ME-4, ME-5, and ME-14) contained small
amounts of prenylated flavonoids (less than 2% as a total of the 3
compounds present) and variable amount of Mulberroside A. This
example clearly demonstrates the lack of enrichment and
standardization of stilbene and prenylated flavonoids in regular
Morus root bark extracts.
TABLE-US-00005 TABLE 4 Quantification of Active Compounds in Morus
Extracts from China Morus Active Content in Extract (%) Extract
Mulberroside A Kuwanon G Albanin G Morusin ME-1 20.4 2.17 0.77 1.31
ME-2 22.26 2.57 0.83 1.49 ME-3 10.86 0.42 0.17 0.22 ME-4 1.07 0.22
0.13 0.13 ME-5 2.3 0.54 0.27 0.23 ME-6 0 0.45 0.15 0.95 ME-7 0 0.47
0.16 0.99 ME-8 0 1.32 0.35 2.08 ME-9 6.7 2.29 0.99 0.91 ME-10 0 0 0
0 ME-11 6.13 2.15 1.02 0.93 ME-12 0 0 0 0 ME-13 8 2.8 1.01 1.06
ME-14 6.49 0.85 0.22 0.21
Example 10
Preparation of Morus alba 70% ETOH Extract 10
[0211] Dried Morus alba roots and root barks (93.3 kg) were cut,
crushed, and then extracted with approximately seven-fold volume
(700 L) of 70% ethyl alcohol in water (v/v); the extraction was
carried out at 100.degree. C. for 4 hrs. The ethanol solution was
filtered to obtain the supernatant, which was then concentrated
with an evaporator under vacuum at 40.degree. C. This extraction
and concentration procedure was repeated two times. The extraction
solutions were then combined together and concentrated until the
volume become 1/25 of the original volume. The concentrated
solution was dried by vacuum freeze-drying to obtain 18.3 kg of
Morus alba 70% EtOH extract powder 10. The extraction yield was
about 19.6% (w/w). The major active component content is listed in
Table 4 of Example 14.
Example 11
Preparation of Morus alba ETOAC Fraction 11
[0212] Morus alba EtOH extract produced according to Example 10 was
extracted with approximately two-fold volume of ethyl alcohol (EP
grade, Ducksan Chemical, Korea) from 4 kg of dried Morus alba root
bark yielded 570 g of Morus alba EtOH extract powder. The EtOH
extract was partitioned with hexane and water followed by
extraction with ethyl acetate. Extraction was performed by
homogenization of the extraction solution at 15,000 rpm for five
minutes with homogenizer (IKA T25D, Germany). The well homogenized
extraction solution was then separated by centrifuge (Beckman
J-20XP, Germany) at 3,000 rpm (rotor# JLA 8.1000) for five minutes.
Corresponding n-hexane soluble and water soluble extracts were
prepared from 570 g of the crude Morus alba EtOH powder. This
resulted in production of 80.5 g of the n-hexane soluble extract
and 156 g of the water-soluble extract of Morus alba. After solvent
partition with EtOAc, the upper layer (EtOAc soluble layer) was
filtered by filter paper (Hyundai Micro, No. 20, Korea) and the
EtOAc solution was collected. The residue (precipitate material)
collected from the centrifugation was re-extracted with two-fold
volume (300 L) of ethyl acetate (EP grade, Ducksan Chemical,
Korea). The re-extracted solution was agitated at 150 rpm for 2
hours. The resulting mixture was then filtered (Hyundai Micro, No.
20, Korea) to obtain an additional EtOAc extract solution. The
above-described procedure was repeated two times. The three
resulting EtOAc extract solutions were combined and concentrated by
evaporator at 40.degree. C. to obtain the final EtOAc extract 11.
The final amount of Morus alba EtOAc fraction 11, obtained from
this process was 327 g. The major active component content is
provided in Table 4 (Example 14).
Example 12
Preparation of Morus alba 70% ETOH Precipitate Extract 12
[0213] Morus alba EtOH precipitate extract 12 was produced by
follows; 634 kilograms (KG) of dried Morus alba roots and root
barks were cut, crushed and extracted with approximately 7 fold
volume (3600 liters (L)) of 70% ethyl alcohol in water (v/v); the
extraction solvent was treated at 80.degree. C., for 4 hrs; the
residue was filtered to obtain the supernatant which was then
concentrated with an evaporator at 40.degree. C. The
above-described procedure was repeated three times. The extraction
solutions were then concentrated until the volume become about 1/30
the original starting volumes. Then the concentrated solutions were
combined to evaporate again in order to reduce volume of
concentrated solution until 1/90 volume of the original extraction
solution. The concentrated solution was rested at room temperature
for 24 hours (hr) to allow separation into two layers (supernatant
and precipitate-layer). The precipitate was filtered and dried by
vacuum freeze-drying to obtain M alba 70% EtOH precipitate powder.
A total of 24 kg of the resulting product was obtained from 634 kg
of raw plant material. The extraction yield was about 3.79% (w/w).
The major active component content is listed in Table 4 (Example
14).
Example 13
Preparation of Morus alba 70% ETOH Extract (13-1), Precipitate
(13-2), and Supernatant (13-3) Extracts
[0214] Morus alba EtOH precipitate extract was produced as follows:
465 kg of dried Morus alba roots and root bark were cut, crushed,
and extracted with approximately 10-fold volume (4500 L) of 70%
ethyl alcohol in water (v/v); the extraction solvent was treated at
80.degree. C. for 4 hrs; the residue was filtered to obtain the
supernatant which was concentrated with an evaporator at 40.degree.
C. Above-described procedure was repeated three times. The
extraction solutions were concentrated until the volume become 1/30
the original volume. The concentrated solutions were then combined
and evaporated again to reduce the volume of the concentrated
solution until 1/90 volume of the original extraction solution was
achieved. The concentrated solution was left at room temperature
for 24 hr to allow separation into a supernatant and precipitate
layer. The precipitate layer was then dried by vacuum to obtain 12
kg of Morus alba 70% EtOH precipitate powder 13-2. The precipitate
yield from Moms root barks was about 2.6% (w/w). The supernatant
layer was dried by vacuum drying to obtain 24 kg Morus alba 70%
EtOH supernatant powder 13-3. The extraction yield for the
supernatant 13-3 was about 5.2%.
[0215] Morus alba 70% EtOH combination extract (13-1) was obtained
by blending 2 kg of precipitate (13-2) and 4 kg of supernatant
(13-3)). The major active component content in both Morus alba EtOH
extract 13-1, precipitate 13-2 and supernatant 13-3 is listed in
Table 4 (Example 14).
Example 14
HPLC Quantification of Active Content in Different Morus alba
Extracts
[0216] The detailed HPLC quantification method for Mulberroside A,
Oxyresveratrol, Kuwanon G, Albanin G and Morusin content was
described in Example 8. Table 4 listed the active contents in
different Morus root bark extracts as prepared in the Examples 10,
11,12 and 13.
TABLE-US-00006 TABLE 5 Quantification of Active Compounds in Morus
Extracts Prenylated Flavonoid in Extract (%) Stilbene in Extract
(%) Total Morus Mulberroside Oxy- Total Kuwanon Albanin Prenylated
Extracts A resveratrol Stilbenes G G Morusin Flavonoids 10 2.88
1.64 11 1.55 0.33 1.89 9.31 6.74 6.84 22.89 12 1.27 0 1.27 5.30
4.28 4.25 13.83 13-1 7.31 0.26 7.57 3.12 1.71 2.01 6.84 13-2 0.76 0
0.76 5.51 3.98 4.48 13.97 13-3 7.50 0 7.50 1.27 0.36 0.48 2.11
Example 15
Preparation of Organic Extracts from Curcuma longa
[0217] A total of 20 grams of dried rhizome powder of Curcuma longa
were loaded into two 100 ml stainless steel tube and extracted
twice with an organic solvent mixture (methylene chloride/methanol
in a ratio of 1:1) using an ASE 300 automatic extractor at
80.degree. C. and under 1,500 psi of pressure. The extract solution
was filtered, collected, and evaporated with a rotary evaporator to
give crude organic extract (OE) (6.04 g, 30.2% yield).
Example 16
High Throughput Purification (HTP) of Curcuma longa Organic
Extracts
[0218] The Curcuma longa organic extract (OE, 400 mg) as described
in Example 15 was loaded onto a pre-packed flash column (2 cm
ID.times.8.2 cm, 25 ml, 10 g silica gel), eluted using a Hitachi
high throughput purification (HTP) system with an unique gradient
mobile phase of (A) 50:50 EtOAc:hexanes and (B) methanol from 100%
A to 100% B in 30 minutes at a flow rate of 5 mL/min. A total of 88
fractions were collected in a 96-deep-well plate at 1.9 mL per well
using a Gilson fraction collector. The sample plate was dried under
low vacuum and centrifugation, and then the dried samples were
resuspended in 1.5 mL dimethyl sulfoxide (DMSO) per well. A portion
(100 .mu.L) from each well was taken and combined (based on UV
trace) for the BKB1 inhibition assay.
Example 17
Bradykinin B1 Radioligand Binding Assay of Curcuma Extracts and
Fractions Thereof
[0219] Bradykinin B1 (BKB1) radioligand binding assay was conducted
to determine the inhibition activity of Curcuma longa OE and
extract fractions on BKB1 binding to BKB1 receptor (BKB1R).
Membranes from human IMR-90 lung fibroblasts, stimulated with
IL-1.beta. in modified HEPES buffer (PH=7.4), were incubated with a
test sample in the presence of 0.9 nM
[.sup.3H](Des-Arg.sup.10)-Kallidin for 60 minutes at room
temperature. After incubation, membranes were filtered and washed
five times with modified DPBS buffer (pH=7.4). Samples were
scintillation counted to determine the amount of specifically bound
to the BKB1 receptor containing membrane.
[0220] The Curcuma longa OE was tested at a concentration of 166
.mu.g/mL and IC.sub.50 values were determined using the same method
with serial dilutions at concentrations ranging from 400 .mu.g/mL
and 5 ng/mL to obtain a dose-response curve. Data showing
inhibition of BKB1 binding to BKB1R by Curcuma longa OE extracts is
provided in Table 6.
TABLE-US-00007 TABLE 6 Inhibition of BKB1Receptor Binding by
Curcuma longa OE Sample BKB1(166 .mu.g/ml) POC (%) BKB1 IC.sub.50
(.mu.g/mL) OE extract -0.14 9.6
[0221] Curcuma longa OE showed strong inhibition of BKB1 binding
with an IC.sub.50 of about 9.6 .mu.g/mL. Furthermore, HTP fractions
of the Curcuma longa OE were examined in the BKB1 binding assay
(see FIG. 1). The activity profile of the HTP fractions indicates
that fractions 11-22, 34, and 38 had the most potent BKB1 receptor
binding inhibition, with a mean percentage of control (POC) below
10%. Curcuminoids were found to be the major active compounds
associated with the activity of HTP fractions 11-22.
Example 18
BKB1 and BKB2R Binding Activity of Curcuma Compounds
[0222] BKB1 binding assay, as described in Example 17, was used to
test curcumin compound isolated from a Curcuma longa extract
(Compound 11), as well as commercially available curcumin purchased
from Sigma-Aldrich (C1386). Curcumin was tested at final
concentrations ranging from 200 .mu.M to 5 nM. Binding curves were
plotted by non-linear regression fit (using GraphPad Prizm
software). K.sub.i values were computed using Cheng-Prusoff
algorithm. In addition, inhibition of BKB2 receptor binding
activity by curcumin was examined with methods similar to those
described in Example 17 for the BKB1 receptor with some
modifications. Bradykinin Radioligand Binding Assay (BKB2) was
conducted using a standard assay under the following conditions:
[0223] 1. Composition of Assay Buffer: 24 mM TES, pH 6.8, 1 mM
1.10-Phenanthrioline, 0.3% BSA. [0224] 2. Source of BKb2R: CHO-K1
cells expressing recombinant human BKb2R [0225] 3. Ligand:
[.sup.3H]-Bradykinin: 0.2 nM. [0226] 4. Incubation time: 90 min RT.
[0227] 5. Reading: TopCount.
[0228] Commercial curcumin (Sigma, C1386) was tested at
concentrations ranging from 200 .mu.M to 5 nM. Binding curves for
commercial curcumin does not conform to mass action law for
competitive inhibitor. K.sub.i was manually calculated by using
Cheng-Prusoff equation. The inhibition activity for BKB1 and BKB2
by curcumin is provided in Table 7.
TABLE-US-00008 TABLE 7 Inhibition of BKB1 and BKB2 by Curcumin
Compound BKB1 Ki (.mu.g/ml) BKB2 Ki (.mu.g/ml) Curcumin 2.173
58
[0229] The data indicate that curcumin is a selective BKB1
antagonist since it shows much stronger inhibition of BKB1 binding
activity as compared to BKB2 binding.
Example 19
Preparation of Curcuma longa Ethyl Alcohol Extract 19
[0230] Curcuma EtOH extract was produced as follows: 20 kg of dried
Curcuma longa rhizomes (roots) were pulverized, and extracted with
approximately 4-fold volume (80 L) of 100% ethyl alcohol and the
extraction solvent held at 80-85.degree. C. for 30 hrs. The residue
was filtered to obtain a supernatant that was concentrated with an
evaporator at 85-90.degree. C. The extraction solutions were then
concentrated until the volume was 1/25 of the original volume. The
concentrated solution was dried by spray dry process (temperature
I/P 200.degree. C. and O/P 95.degree. C.) to obtain about 1 kg of
25% Curcuma in EtOH extract powder 19 with reddish-orange color.
The extraction yield was about 5% (w/w).
Example 20
Quantification of Curcumin in Curcuma Rhizome Extract
[0231] The following analytical method was used to determine the
amount of Curcumin in the Curcuma longa rhizome extracts. An
Agilent HPLC/PDA system was used with a C18 reversed-phase column
(Phenomenex, USA, Luna 5 um, 250 mm.times.4.6 mm) for detection and
quantitation of Curcumin and minor components. A binary 0.1% acetic
acid in purified water (mobile phase A) and acetonitrile (mobile
phase B) gradient was used for elution of Curcumin components as
described in Table 7. The flow rate was set to 1 ml/min passing
through the Luna C18 column with a column temperature of 35.degree.
C. The UV detector was set to read absorbance at 407 nm.
TABLE-US-00009 TABLE 7 Curcumin HPLC Gradient Elution Scheme Time
(min) Mobile phase A % Mobile phase B % 0 55 45 10.0 55 45 10.1 10
90 25.0 10 90 25.1 55 45 30.0 55 45
[0232] The quantification standard--Curcumin was purchased from
Sigma-Aldrich Co. The highest concentration level of Curcumin was
0.05 mg/ml and diluted to L5 from L1 (0.0031 mg/ml) using methanol.
Concentration of Curcuma longa rhizome extract samples were
adjusted to about 1 mg/ml in methanol in a volumetric flask and
sonicated until dissolved (approximately 20 minutes), then cooled
to room temperature, mixed well and filtered through a 0.45 .mu.m
nylon syringe filter. Then 10 .mu.l of sample was quantified by
HPLC, which results for Curcuma longa rhizome extract are provided
in Table 8.
TABLE-US-00010 TABLE 8 HPLC Quantification of Curcuma longa Rhizome
Extract Curcumin Curcuminoids Sample % (total) % 110 16.34 30.04
210 14.71 27.93 310 13.08 26.53
Example 21
Preparation of Gambir (Uncaria gambir) Extract 21
[0233] Uncaria gambir water extract was produced as follows. 100 kg
of dried leaves of Uncaria gambir was cut, crushed, and extracted
with 15-fold volume (1500 L) of 70% ethyl alcohol and the
extraction solvent treated at 80.degree. C. for 7 hrs. The
resulting residue was filtered to obtain a supernatant. The
above-described procedure was repeated for second time. The
extraction supernatant solutions were combined together and
concentrated with an evaporator at 46.degree. C. under vacuum
condition until the volume became 1/30.sup.th of the original
volume. The concentrated solution was evaporated further to reduce
volume of concentrated solution until 1/90 volume of the original
solution. The resulting concentrated solution was then rested at
room temperature for 24 hrs to allow precipitate to form in the
concentrated solution. The precipitate was filtered and dried under
vacuum to obtain precipitate powder as Uncaria gambir extract
powder 21. The yield from 100 kg of dried leaves of Uncaria gambir
was about 6 kg of extract powder, so the extraction yield was about
6% (w/w).
Example 22
HPLC Quantification of Uncaria Gambir Extracts
[0234] The following analytical method was used to determine the
amount of catechin in the Uncaria gambir leaf extracts. An Agilent
HPLC/PDA system with a C18 reversed-phase column (Phenomenex, USA,
Luna 5 um, 250 mm.times.4.6 mm) was used for the detection and
quantitation of catechin compound in Gambir extracts. A binary
column gradient was used for elution of material from the column.
Mobile Phase A: 0.1% phosphoric acid in purified water, and Mobile
Phase B: acetonitrile gradient was used for elution (Table 9). The
flow rate was set to 1.0 ml/min passing through the Luna C18 column
with a column temperature of 35.degree. C. The UV detector was set
to record absorbance at 275 nm.
TABLE-US-00011 TABLE 9 Gradient Table of HPLC Analytical Method
Time (min) Mobile Phase A Mobile Phase B 0.0 85.0 15.0 7.0 85.0
15.0 12.0 10.0 90.0 16.5 10.0 90.0 16.6 85.0 15.0 24.0 85.0
15.0
[0235] Pure catechin reference sample was purchased from
Sigma-Aldrich Co. The reference sample was dissolved in MeOH:0.1%
H.sub.3PO.sub.4 (1:1). Highest level concentration range of
catechin was 0.5 mg/ml and diluted to L5 from L1 (0.003 mg/ml)
using 50% methanol in 0.1% H.sub.3PO.sub.4. Concentration of the
Gambir extract samples were adjusted to 2 mg/ml in 50% methanol in
0.1% H.sub.3PO.sub.4 in a volumetric flask and sonicated until
dissolved (approximately 10 minutes), and then cooled to room
temperature, mixed well and filtered through a 0.45 .mu.m nylon
syringe filter. HPLC analysis was performed by injecting a 20 .mu.l
sample into the HPLC.
TABLE-US-00012 TABLE 10 HPLC Quantification of Gambir Extract
Sample Catechin % 210 20.0 212 18.5
Example 23
Preparation of Acacia catechu 65% Catechin Extract
[0236] Acacia catechu 65% catechin extract was produced as follows:
500 kg of Acacia catechu (KATHA) was put into 750 L of 50% ethyl
alcohol and stirred at room temperature for 90 min. After 500 L of
ethyl acetate was put into the homogenized KATHA slurry, it was
stirred smoothly for 30 min. The slurry was allowed to separate
into two layers for 1 hr. The ethyl acetate layer was moved into a
new bottle, and the partition was repeated with the water layer.
Both the 1st and 2nd ethyl acetate layers were combined and
concentrated at 60-62.degree. C. until TDS 30%, and then spray
dried (temp. I/P 190.degree. C.--O/P 90.degree. C.). A total of
72.5 kg Acacia catechu extract was obtained from 500 kg of raw
material with catechin and epicatechin total content at not less
than 65%. The extraction yield was 14.5% (w/w).
Example 24
Fractionation, Purification and Identification of Active Compounds
from Mentha piperita Extracts
[0237] A Mentha piperita methanol extract (ME) (10.6 g) as prepared
in Example 26 was partitioned between hexane (100 mL) and water
(150 mL) three times. The combined hexane solutions were vacuum
dried to give a hexane extract (HE) of 2.19 g. The aqueous layer
was extracted with ethyl acetate (100 mL) three times. The combined
ethyl acetate layers were dried under vacuum to give an ethyl
acetate extract (EA) of 1.26 g. The aqueous layer was then further
extracted with butanol (100 mL) three times to give a butanol
extract (BU) of 1.91 g. The remaining aqueous layer was
freeze-dried to give an aqueous extract (WA) of 3.91 g. Each of the
ME, HE, EA, BU and WA was tested for anti-nociceptive activity in
an acetic acid-induced abdominal constriction model in mice. The
active compounds partitioned into the EA and BU layers were further
investigated.
[0238] In vivo activity guided isolation led to the discovery of
three active compounds. The EA fraction (653.5 mg) was subjected to
a RP-HPLC column (Phenomex) 10 .mu.m Luna C18 (250.times.30 mm) by
two injections on a HPLC system L6200A starting with 40% MeOH (B)
in H.sub.2O (A) to 60% B in 8 min, from 60% to 100% MeOH in 27 min,
and finally washed with 100% B for another 15 minutes at a flow
rate of 20 mL/min with UV wavelength 230 nm to give Compound 1
(Rosmarinic acid) (136.3 mg).
[0239] Compound 7 (Rosmarinic acid): ESIMS (m/z) [M-H].sup.- 359;
UV .lamda..sub.max (MeOH): 284, 328.6 nm; .sup.1H NMR (500 MHz,
MeOH-d.sub.4) .delta. ppm 3.00 (dd, J=14.31, 8.44 Hz, 1H) 3.09 (dd,
J=14.43, 4.16 Hz, 1H) 5.18 (dd, J=8.44, 4.28 Hz, 1H) 6.26 (d,
J=15.65 Hz, 1H) 6.61 (dd, J=7.95, 1.83 Hz, 1H) 6.70 (d, J=7.83 Hz,
1H) 6.75 (d, J=1.71 Hz, 1H) 6.78 (d, J=8.07 Hz, 1H) 6.95 (dd,
J=8.31, 1.96 Hz, 1H) 7.04 (d, J=1.96 Hz, 1H) 7.55 (d, J=15.90 Hz,
1H); .sup.13C NMR (126 MHz, MeOH-d.sub.4) .delta. ppm 36.51 (t, 1C)
73.23 (d, 1C) 113.00 (d, 1C) 113.81 (d, 1C) 114.88 (d, 1C) 115.09
(d, 1C) 116.16 (d, 1C) 120.38 (d, 1C) 121.73 (d, 1C) 126.24 (s, 1C)
127.86 (s, 1C) 143.84 (s, 1C) 144.73 (s, 1C) 145.38 (s, 1C) 146.30
(d, 1C) 148.30 (s, 1C) 167.05 (s, 1C) 172.13 (s, 1C)
##STR00136##
[0240] Separation of the BU fraction (1.1 g) was performed by
RP-HPLC on the same column with two injections as described above
starting with 30% MeOH (B) in H.sub.2O (A) for 5 min, 30% B to 50%
B in 15 min, from 50% to 100% B in 20 min, and washed with 100% B
for 15 minutes at a flow rate of 20 mL/min with UV wavelength 320
nm to give Compound 2 (Eriocitrin) (192.0 mg) and compound 3 (87.4
mg).
[0241] Compound 8 (Eriocitrin): ESIMS (m/z) [M-H].sup.- 595; UV
.lamda.max (MeOH): 228.4, 289.2, 335.5 nm; .sup.1H NMR (500 MHz,
MeOH-d4) .delta. ppm 1.21 (m, 3H) 2.76 (d, J=15.41 Hz, 1H) 3.10 (m,
1H) 3.48 (m, 2H) 3.63 (m, 3H) 3.71 (m, 1H) 3.91 (m, 1H) 4.00 (d,
J=9.54 Hz, 1H) 4.71 (br. s., 2H) 4.95 (d, J=6.11 Hz, 2H) 5.33 (m,
1H) 6.19 (d, J=7.58 Hz, 2H) 6.80 (br. s., 2H) 6.96 (m, 1H);
.sup.13C NMR (126 MHz, MeOH-d4) .delta. ppm 16.53 (q, 1C) 42.62 (t,
1C) 66.01 (t, 1C) 68.37 (d, 1C) 69.90 (d, 1C) 70.63 (d, 1C) 70.98
(d, 1C) 72.68 (d, 1C) 73.23 (d, 1C) 75.68 (d, 1C) 76.42 (d, 1C)
79.13 (d, 1C) 95.70 (d, 1C) 96.54 (d, 1C) 99.71 (d, 1C) 100.71 (d,
1C) 103.55 (s, 1C) 113.51 (d, 1C) 114.92 (d, 1C) 117.97 (d, 1C)
130.11 (s, 1C) 145.06 (s, 1C) 145.51 (s, 1C) 162.99 (s, 1C) 163.51
(s, 1C) 165.41 (s, 1C) 197.10 (s, 1C)
[0242] The in vivo activity of rosmarinic acid and eriocitrin were
further confirmed in a carrageenan-induced paw edema and pain
sensitivity model in rats. Rosmarinic acid and eriocitrin showed
significant anti-inflammatory and analgesic activities at a dose of
200 mg/kg and 100 mg/kg level, respectively.
##STR00137##
[0243] Compound 9 was assigned as Skolimoside: ESIMS (m/z)
[M-H].sup.- 593; UV .lamda.max (MeOH): 228.4, 258.1, 347.0 nm;
.sup.1H NMR (500 MHz, METHANOL-d4) .delta. ppm 1.19 (d, J=6.11 Hz,
3H) 3.41 (br. s., 1H) 3.50 (br. s., 2H) 3.60-3.71 (m, 3H) 3.74 (dd,
J=9.54, 3.18 Hz, 1H) 3.87-3.96 (m, 1H) 4.06 (d, J=9.78 Hz, 1H) 4.72
(s, 1H) 5.04 (br. s., 1H) 6.52 (s, 1H) 6.60 (s, 1H) 6.75 (br. s.,
1H) 6.93 (d, J=8.07 Hz, 1H) 7.41 (br. s., 2H); .sup.13C NMR (126
MHz, METHANOL-d4) .delta. ppm 16.48 (q, 1C) 66.07 (t, 1C) 68.39 (d,
1C) 69.91 (d, 1C) 70.67 (d, 1C) 71.01 (d, 1C) 72.64 (d, 1C) 73.33
(d, 1C) 75.74 (d, 1C) 76.40 (d, 1C) 94.73 (d, 1C) 99.72 (d, 1C)
100.19 (d, 1C) 100.68 (d, 1C) 102.84 (d, 1C) 105.69 (s, 1C) 112.92
(d, 1C) 115.48 (d, 1C) 119.20 (d, 1C) 122.11 (s, 1C) 145.58 (s, 1C)
149.76 (s, 1C) 157.49 (s, 1C) 161.52 (s, 1C) 163.31 (s, 1C) 165.54
(s, 1C) 182.60 (s, 1C)
##STR00138##
Example 25
Preparation of Ethanol Extracts from Mentha piperita
[0244] Peppermint (Mentha piperita) 90% EtOH extract (lot#
RM604-13002) was produced as follows: 73.4 kg of dried Mentha
piperita was cut, crushed, and extracted with a 15-fold volume
(1100 L) of 90% ethyl alcohol (v/v) at 85.degree. C. for 3 hrs. The
resulting residue was filtered to obtain a supernatant that was
concentrated with a vacuum evaporator at 40.degree. C. The
resulting residue was extracted a second time with 13-fold volume
(950 L) of 90% ethyl alcohol (v/v) at 40.degree. C. for 1 hrs and
filtered to obtain a second supernatant which was concentrated with
a vacuum evaporator at 40.degree. C. The resulting concentrated
cake was dried under vacuum to obtain 19.3 kg of Peppermint 90%
EtOH extract powder designated as Extract 25. The extraction yield
was 25.3% (w/w).
Example 26
Preparation of Methanol and Other Organic Extracts from Mentha
piperita
[0245] Dried ground peppermint leaf powder (Mentha piperita) (21.7
g) loaded into two 100 ml stainless steel tubes and extracted twice
with an organic solvent mixture (methanol) using an ASE 300
automatic extractor at 80.degree. C. under a pressure of 1,500 psi.
The extract solution was automatically filtered, collected, and
evaporated with a rotary evaporator to give a crude organic extract
(ME 26-1) (4.48 g, 20.64% yield).
[0246] Alternatively, 252.3 g of dried ground leaf powder of Mentha
piperita was extracted with methanol three times by refluxing one
hour each time. The organic solution was combined and evaporated
under vacuum to provide methanol extract (ME 26-2) 40.88 g with a
yield of 16.20%.
[0247] Similar results were obtained using the same procedure, but
with the organic solvent being replaced with methanol or ethanol to
provide a methanol extract (ME) or ethanol extract (EE),
Ethanol:H.sub.2O (7:3) extracts, Ethanol:H.sub.2O (1:1) extracts,
Ethanol:H.sub.2O (3:7) extracts and water extracts
respectively.
Example 27
Ex Vivo Glycosaminoglycans (GAG) Release Assay
[0248] Articular cartilage from hock joints of rabbits (2.5 kg body
weight) was removed immediately after each animal was sacrificed
and articular cartilage explants were obtained by following the
method described by Sandy et al. (Biochem. Biophy Acta 543:36,
1978). Briefly, after the articular surfaces were surgically
exposed under sterile conditions, approximately 200-220 mg
articular surfaces per joint were dissected and submerged into
complete medium (DMEM, supplemented with heat inactivated 5% FBS;
penicillin 100 U/ml; streptomycin 100 ug/ml). They were then rinsed
several times with the complete medium and incubated for 1 to 2
days at 37.degree. C. in a humidified 5% CO.sub.2/95% air incubator
for stabilization. The complete medium was replaced with a basal
medium (DMEM, supplemented with heat-inactivated 1% FBS, 10 mM
HEPES, and penicillin 100 U/ml streptomycin 100 .mu.g/ml).
Approximately 30 mg cartilage pieces (2.times.3.times.0.35
mm/piece) were placed in 24-well plates and treated with given
concentrations of test agents. After pretreatment for 1 h, 5 ng/ml
of rhIL-1.alpha. was added to the culture medium and further
incubated at 37.degree. C. in a humidified 5% CO.sub.2/95% air
incubator. The culture medium was collected 24 h later and stored
at -20.degree. C. until assay.
[0249] The amount of sulphated GAGs (e.g., released from
proteoglycans) in the medium at the end of the reaction reflects
the amount of articular cartilage degradation, which was determined
using the commercially available 1,9-dimethy-methylene blue method
according to the instructions of the manufacturer (Blyscan.TM.
assay, Accurate Chemical and Scientific Corp., Westbury, N.Y.).
Example 28
Effect of Purified Compounds from Morus on Ex Vivo GAG Release
[0250] Rabbit cartilage explants were cultured with rhIL-1.alpha.
(5 ng/ml) in the absence or presence of purified Morus compounds
isolated according to Example 3 to examine the protective effects
on proteoglycan (PG) degradation. Purified compound inhibited
rhIL-1.alpha.-mediated degradation of PG in a concentration
dependent manner. Especially, Mulberroside A, Oxyresveratrol and
Morusin showed a strong inhibitory effect when compared with
diclofenac treated group.
TABLE-US-00013 TABLE 12 Effect of Morus Compounds on Ex Vivo GAG
Release Sample Dose % GAG release Normal -- 36.6 IL-1.alpha. 5
ng/ml 100 Diclofenac 300 .mu.g/ml 34.6 Mulberoside A 25 .mu.g/ml
73.1 50 .mu.g/ml 75.8 100 .mu.g/ml 70.5 Kuwanon G 25 .mu.g/ml 56.6
50 .mu.g/ml 48 100 .mu.g/ml 44.4 Oxyresveratrol 25 .mu.g/ml 59.8
Morusin 25 .mu.g/ml 48.4 50 .mu.g/ml 49.9 100 .mu.g/ml 33.6
Example 29
Morus Extract Reduces Ex Vivo GAG Release
[0251] Rabbit cartilage explants were cultured with rhIL-1.alpha.
(5 ng/ml) in the absence or presence of Morus extracts to examine
the protective effects on PG degradation. Morus extracts inhibited
rhIL-1.alpha.-mediated degradation of PG in a concentration
dependent manner. All samples showed a strong effect as compared to
that of IL-la treated group.
TABLE-US-00014 TABLE 13 Effect of Morus Extracts on Ex Vivo GAG
Release Sample Dose % GAG release Normal / 36.6 IL-1.alpha. 5 ng/ml
100 Diclofenac 300 .mu.g/ml 34.6 13-1 100 .mu.g/ml 50.2 200
.mu.g/ml 41.9 11 100 .mu.g/ml 49.9 200 .mu.g/ml 37.3 13-3 100
.mu.g/ml 67.20 200 .mu.g/ml 61.3
Example 30
Effect of Curcuma and Uncaria Extracts on Ex Vivo GAG Release
[0252] Rabbit cartilage explants were cultured with rhIL-1.alpha.
(5 ng/ml) in the absence or presence of Curcuma extract from
Example 19 or Uncaria extract from Example 21 to examine the
protective effect on PG degradation. Curcuma extract 19 decreased
rhIL-1.alpha.-mediated degradation of PG in a concentration
dependent manner, while Uncaria extract 21 showed a weak protective
effect on PG degradation.
TABLE-US-00015 TABLE 14 Effect of Curcuma and Gambir Extracts on Ex
Vivo GAG Release Sample Dose % GAG release (-) -- 39.0 IL-1.alpha.
5 ng/ml 100.0 Diclofenac 300 .mu.g/ml 45.6 19 30 .mu.g/ml 88.9
(Curcuma) 50 .mu.g/ml 65.0 66.7 .mu.g/ml 59.2 100 .mu.g/ml 38.2 300
.mu.g/ml 50.4 21 66.7 .mu.g/ml 97.7 (Gambir) 80 .mu.g/ml 81.0 100
.mu.g/ml 78.0 120 .mu.g/ml 86.4 200 .mu.g/ml 88.4 300 .mu.g/ml
88.4
Example 31
Effect of Peppermint Extract on Ex Vivo GAG Release
[0253] Rabbit cartilage explants were cultured with rhIL-1.alpha.
(5 ng/ml) in the absence or presence of Peppermint extract from
Examples 25 and 26 to examine the protective effects on PG
degradation.
TABLE-US-00016 TABLE 15 Effect of Peppermint Extracts on Ex Vivo
GAG Release Sample Dose % GAG release Normal -- 34.5 IL-1.alpha. 5
ng/ml 100 Diclofenac 300 .mu.g/ml 22.6 191-8 150 .mu.g/ml 110.9 250
.mu.g/ml 84.1 500 .mu.g/ml 73.0 622-9 150 .mu.g/ml 91.5 250
.mu.g/ml 79.2 500 .mu.g/ml 68.7
[0254] Peppermint extract inhibited rhIL-1.alpha.-mediated
degradation of PG in a concentration dependent manner, although the
effect of Peppermint extracts on PG degradation were weaker than
the diclofenac treated group.
Example 32
Effect of N-Acetyl Glucosamine (NAG) on Ex Vivo GAG Release
[0255] Rabbit cartilage explants were cultured with rhIL-1.alpha.
(5 ng/ml) in the absence or presence of NAG to examine the
protective effects on PG degradation. NAG reduced
rhIL-1.alpha.-mediated degradation of PG in a concentration
dependent manner. However, the effects from NAG are marginal on the
PG degradation when compared to the diclofenac treated group.
TABLE-US-00017 TABLE 16 Effect of N-Acetyl glucosamin on the Ex
Vivo GAG releasing model Sample Dose % GAG release Normal -- 40.7
IL-1.alpha. 5 ng/ml 100.0 Diclofenac 300 .mu.g/ml 30.1 NAG 25
.mu.g/ml 95.7 50 .mu.g/ml 99.2 100 .mu.g/ml 187.5 150 .mu.g/ml
181.2
Example 33
Effect of Curcuma Longa (C):Morus (M) Compositions on Ex Vivo GAG
Release
[0256] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in the absence or presence of a mixture of
Curcuma and Morus extracts to examine the protective effects on PG
degradation. The plant extracts from Morus and Curcuma were
produced according Examples 10 and 19, respectively. Curcuma and
Morus extracts were combined at different ratios, including 4:1,
2:1, 1:1, 1:2 and 1:4, respectively. The compositions were tested
at four doses--50, 100, 200 and 300 .mu.g/ml. As shown in Table 17,
all compositions of plant extracts prevented rhIL-1.alpha. mediated
degradation of articular cartilage in a concentration dependent
manner.
TABLE-US-00018 TABLE 17 Effect of Morus/Curcuma Compositions on Ex
Vivo GAG Release Sample Dose (.mu.g/ml) % GAG release (-) -- 51.9
IL-1.alpha. 0.005 100.0 Diclofenac 300 36.8 4C:1M 50 80.5 100 58.1
200 49.1 300 61.8 2C:1M 50 82.0 100 57.5 200 47.4 300 68.4 1C:1M 50
88.7 100 62.0 200 54.2 300 59.7 1C:2M 50 81.6 100 59.5 200 58.0 300
57.2 1C:4M 50 62.6 100 63.3 200 56.7 300 32.7
Example 34
Evaluation of Curcuma (C):Morus (M) Composition Synergy on Ex Vivo
GAG Release
[0257] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in the absence or presence of compositions
of Curcuma extract, Morus extract, or a mixture thereof to examine
the presence of a protective effect on PG degradation. The plant
extracts from Morus and Curcuma were produced according Examples 10
and 19, respectively. Curcuma and Moms extracts were combined at
different ratios, including 1:2 and 1:4. The compositions were
tested at two doses--200 and 300 .mu.g/ml, or at one dose--75
.mu.g/ml to examine whether the combined extracts worked
synergistically or additively. The individual extract compositions
were tested at concentrations that were in proportion to the weight
content of those extracts in the mixed composition.
TABLE-US-00019 TABLE 18 Synergistic Effect of C:M Composition
versus C or M Alone % % Cmpsn .mu.g/ml Inhibition Cmpsn .mu.g/ml
Inhibition Remark 1C:4M 200 85.1 1C:4M 300 97.8 Theoretical value
1C:4M 200 87.8 1C:4M 300 100 Experimental result C 40 49.1 C 60
72.6 Individual M 160 70.7 M 240 92 Individual 1C:2M 200 81.7 1C:2M
300 95.6 Theoretical value 1C:2M 200 95.8 1C:2M 300 100
Experimental result C 66.7 59.9 C 100 85 Individual M 133.3 54.3 M
200 70.6 Individual 1C:1M 75 53 Theoretical value 1C:1M 75 57.5
Experimental result C 37.5 33 Individual M 37.5 29.9 Individual
[0258] Compositions of Curcuma and Morus extracts interfered with
the rhIL-1.alpha.-mediated degradation of PG in a concentration
dependent and synergistic manner. Especially, compositions 1C:4M (5
wt % curcuminoids, 2.4 wt % prenylated flavonoids, 2.4 wt %
stilbenes) and 1C:2M (8.3 wt % curcuminoids, 2 wt % prenylated
flavonoids, 2 wt % stilbenes) showed a synergistic effect at 200
and 300 .mu.g/ml. Composition 1C:1M (12.5 wt % curcuminoids, 1.5 wt
% prenylated flavonoids, 1.5 wt % stilbenes) also showed a
synergistic effect at 75 .mu.g/ml. Synergyvalues were calculated by
using the COLBY formular (Colby, Weeds 15:20, 1967).
Example 35
Effect of Curcuma (C):Morus (M):N-acetyl glucosamin (NAG)
Compositions on Ex Vivo GAG Release
[0259] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in absence or presence of composition of
Curcuma and Morus extract to examine the protective effects on PG
degradation. The plant extracts from Morus and Curcuma were
produced according to Examples 10 and 19, respectively. Curcuma and
Morus extracts were combined with N-Acetyl Glucosamine (NAG) at a
ratio 1C:1M:2NAG. The compositions were tested at four doses-50,
100, 200 and 300 .mu.g/ml. The individual extracts in the
compositions were tested at concentrations that were in proportions
of the weight contents of those extracts in the compositions.
Synergy values were calculated by using the Colby formular (Colby,
Weeds 15:20, 1967).
TABLE-US-00020 TABLE 19 Effect of Curcuma, Morus, and NAG
Compositions Sample Dose % GAG release Normal -- 40.7 IL-1.alpha. 5
ng/ml 100.0 Diclofenac 300 .mu.g/ml 30.1 1C:1M:2NAG 50 .mu.g/ml
83.2 100 .mu.g/ml 59.7 200 .mu.g/ml 52.7 300 .mu.g/ml 46.4 Curcuma
12.5 .mu.g/ml 71.8 25 .mu.g/ml 74.9 50 .mu.g/ml 50.8 75 .mu.g/ml
58.4 Morus 12.5 .mu.g/ml 76.3 25 .mu.g/ml 77.7 50 .mu.g/ml 70.9 75
.mu.g/ml 70.9 NAG 25 .mu.g/ml 95.7 50 .mu.g/ml 99.2 100 .mu.g/ml
87.5 150 .mu.g/ml 81.2
[0260] As shown in the Table 19, the composition of plant extracts
prevented with the rhIL-1.alpha. mediated degradation of articular
cartilage in a concentration dependent manner. In particular, a
1C:1M:2NAG composition showed an unexpected synergistic effect at
300 .mu.g/ml as compared to the three individual extracts alone
(Table 20).
TABLE-US-00021 TABLE 20 Synergistic Effect of C:M:NAG Compositions
Sample Dose % Inhibition Remark 1C:1M:2NAG 300 .mu.g/ml 89.6
Theoretical value 1C:1M:2NAG 300 .mu.g/ml 90.5 Experimental result
C 75 .mu.g/ml 70.1 Individual M 75 .mu.g/ml 49.2 Individual NAG 150
.mu.g/ml 31.8 Individual
Example 36
Effect of Curcuma (C):Morus (M): Peppermint (P) Compositions on Ex
Vivo GAG Release
[0261] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in absence or presence of composition of
Curcuma and Morus extract to examine the protective effects on PG
degradation. The plant extracts from Morus, Curcuma, and Peppermint
were produced according Examples 10, 19, and 24, respectively.
Curcuma, Morus, and Peppermint extracts were combined at ratios of
1C:1M:0.5P, 1C:1M:1P, 1C:1M:1.5P, and 1C:1M:2P. The compositions
were tested at four doses--50, 100, 200 and 300 .mu.g/ml.
TABLE-US-00022 TABLE 21 Effect of C:M:P Compositions on Ex Vivo GAG
Release Sample Dose (.mu.g/ml) % GAG release (-) -- 39.5
IL-1.alpha. 0.005 100.0 Diclofenac 300 34.9 1C:1M:0.5P 50 77.5 100
67.1 200 67.9 300 39.2 1C:1M:1P 50 76.7 100 65.0 200 51.7 300 47.8
1C:1M:1.5P 50 90.8 100 90.6 200 57.3 300 49.1 1C:1M:2P 50 105.2 100
81.5 200 64.3 300 54.2
[0262] As shown in Table 21, all compositions of plant extracts
prevented rhIL-1.alpha. induced degradation of articular cartilage
in a concentration dependent manner.
Example 37
Animal Care and Housing
[0263] Animals were acclimated upon arrival for a week before being
assigned randomly to their respective groups. CD-1mice (5/cage) and
Lewis rats (3/cage) were housed in a polypropylene cage and
individually identified by numbers on their tail. Each cage was
covered with wire bar lid and filtered top (Allentown, N.J.).
Individual cage was identified with a cage card indicating project
number, test article, dose level, group, and an animal number. The
Harlan T7087 soft cob beddings was used and changed at least twice
weekly. Animals were provided with fresh water and rodent chow diet
# T2018 (Harlan Teklad, 370 W, Kent, Wash.) ad libitum and were
housed in a temperature controlled room (22.2.degree. C.) on a 12
hour light-dark cycle. All animal experiments were conducted
according to institutional guidelines congruent with guide for the
care and use of laboratory animals.
Example 38
In Vivo Nociceptive Behavior Model Elicited by Intraplantar
Injection of Formalin
[0264] Mice (n=6 per group) were habituated under inverted
Plexiglas observation chamber for 30 minutes to allow them to
acclimatize to their surroundings. Animals were treated orally with
respective treatment group 30 minutes before intraplantar injection
of formalin (20 .mu.l of 2.5% solution) into the right hind paw of
restrained mice using a Hamilton syringe (Hamilton Company, Reno,
Nev.) (Dubuisson et al., Pain 4:161, 1977). Mice were immediately
transferred to their individual observational chamber. The duration
of time spent flinching and/or licking of the inflamed hind paw was
monitored and recorded over a period of 40 minutes in 10 minute
time blocks. Mirrors positioned behind the chambers enabled
observation of the right hind paw when it was obscured from direct
view.
Example 39
Visceral Pain Perception Model (Writhing's Test)
[0265] Mice (n=6 per group) were habituated under an inverted
Plexiglas observation chamber for 30 minutes to allow them to
acclimatize to their surroundings. Animals were orally administered
treatment articles at different doses, 100 mg/kg of ibuprofen, or
vehicle control (propylene glycol) 30 minutes before
intraperitoneal administration of freshly made acetic acid solution
(0.7% in 0.9% NaCl) at 10 ml/kg using a 26 gauge needle. The
experiment was carried out at room temperature. After the
challenge, each animal was placed back into its own individual
section of the observation chamber and the number of constrictions
of the abdominal muscle together with stretching was counted
cumulatively over a period of 30 minutes (Collier et al., Br. J.
Pharmacol. Chemother. 32:295, 1968).
Example 40
Carrageenan-Induced Rat Paw Edema Model
[0266] Local inflammation was induced by intraplantar injection of
carrageenan .lamda. (Sigma, St. Louis, Mo.; 100 .mu.l of 1% [w/v]
in saline) into the plantar surface of right hind paw of sedated
rat (with 2.5% isoflurane) at time 0 (T=0) (Gamache et al., J
Neurosurg. 65:679, 1986; Guay et al., J. Biol. Chem. 279:24866,
2004; Chou et al., Anesth. Analg. 97:1724, 2003). Rats were
acclimated in a procedure room for 20-30 minutes before each
measurement was taken. Allodynia was evaluated by measuring
responsiveness to the tip of a Randell-Selitto paw pressure test
applied perpendicular to the central plantar surface of the right
hind paw. A positive response to the applied pressure, noted by
sharp withdrawal of the paw, was recorded automatically by an
electronic Von Frey Anesthesiometer (2390 series Electrovonfrey,
IITC, Woodland Hills, Calif.) (Vivancos et al., Braz. J. Med. Biol.
Res. 37:391, 2004). Mechanical allodynia was evaluated before
carrageenan inoculation, and thereafter at 1 hr, 2 hr, 4 hr and 6
hr. Paw edema volume was measured with the use of Plethysmometer
(IITC, Woodland Hills, Calif.; Model 520) at time 0 (before
carrageenan), and then 1 hr, 2 hr, 4 hr, and 6 hr after carrageenan
injection. Animals (N=5 per group) were orally gavaged with a
positive control ibuprofen (Spectrum Chemical MFG, Gardena, Calif.)
(100 or 200 mg/kg); test articles such as: extracts, and
combinations of extracts at various doses from 100, 200, 300 to 400
mg/kg and vehicle control (propylene glycol) were given 1 hour
after carrageenan inoculation unless specified otherwise.
Example 41
Effect of Purified Curcumin in Nociceptive Behavior Model
[0267] Intraplantar injection of formalin (2.5%) in CD-1 mice
elicited a biphasic nociceptive response compromising flinching,
leg raising, biting and licking of the injected paw. These
behavioral reactions observed for the first five minutes are due to
direct action of the irritant on sensory nerve endings where is
believed to be as a result of inflammation in the later phase. In
this study, greater than 50% reduction in pain perception were
observed for animals treated with single oral dose of curcumin
isolated from organic extract of Curcuma longa as prepared in
Example 16 (Compound 11) or ibuprofen in the inflammatory phase
(Table 22). Mice were treated with curcumin (50, 100, 150 or 200
mg/kg) or ibuprofen (200 mg/kg) orally half an hour before
intraplantar formalin injection.
TABLE-US-00023 TABLE 22 Dose Related Iinhibition of Pain
Sensitivity by Curcumin Pain Sensitivity Rx Dose 20-40 Minutes
after Formalin Injection groups: (mg/kg) % .dwnarw. vs. Vehicle
P-value Ibuprofen 200 63.5 0.03 Curcumin 200 74.6 0.01 150 60.3
0.07 100 52.5 0.24 50 53.1 0.15
[0268] Dose related inhibition in pain sensitivity was observed for
curcumin treated mice at a dose range of 200 mg/kg to 100 mg/kg.
There was little to no difference in the level of pain inhibition
between animals treated with curcumin at 50 mg/kg and 100 mg/kg.
Pain inhibition at 200 mg/kg curcumin or ibuprofen was
statistically significant (Table 22). Furthermore, greater pain
inhibition was observed in mice treated with curcumin at 200 mg/kg
(74.6%) than with ibuprofen at 200 mg/kg (63.5%).
Example 42
Effect of Curcuma Formulated in 13-Cyclodextrin in Nociceptive
Behavior Model
[0269] To increase absorption and maximize efficacy, Curcuma
extract, prepared as described in Example 20, was formulated with
.beta.-cyclodextrin at various ratios and tested in an abdominal
constriction assay. CD-1 mice (N=6) were treated (gavaged) with 50
mg/kg or 100 mg/kg of these formulations or ibuprofen (100 mg/kg)
half an hour before intraperitoneal injection of acetic acid.
TABLE-US-00024 TABLE 23 Effect of Curcuma Compostions on Visceral
Pain Sensitivity Total Curcumin curcuminoid Dose % .dwnarw. vs. P-
Formulation content content (mg/kg) Vehicle values Ibuprofen -- --
100 56.1 0 401 12.57% 29.06% 50 19.2 0.02 100 38.2 0.001 203-1
6.69% 14.74% 50 27.9 0.01 100 33.3 0.003 601 8.11% 25.74% 50 10.9
0.07 100 24.9 0.02 403-1 4.46% 13.40% 50 9.0 0.44 100 16.0 0.12 201
72.99% 96.58% 50 23.7 0.03 100 28.1 0.001 101-1 9.68% 12.50% 50
26.9 0.07 100 32.8 0.0005
[0270] Ibuprofen treated animals showed 56.1% reduction in pain
sensitivity (Table 23). Other than formulation 403-1 (which has the
lowest curcumin and total curcuminoid content), all other
formulations showed statistically significant inhibition in
visceral pain sensitivity (Table 23).
Example 43
Effect of Mentha Piperita Extract in Nociceptive Behavior Model
[0271] Plants with historical anti-inflammatory usage were screened
for their anti-pain activity using writhing's animal model. Among
these extracts, mice treated with a single oral dose of peppermint
plant (Mentha piperita) methanol extract ME, as described in the
Example 26, showed 29.8% visceral pain inhibition when administered
at 300 mg/kg in CD-1 mice. Following ethyl acetate fractionation,
an enhanced, statistically significant inhibition (i.e., 47.2%)
compared to the methanol extract was observed for peppermint
fractions administered at 126 mg/kg (Table 24). Comparable
inhibition was also observed for ibuprofen treated animals (i.e.,
67.6%).
TABLE-US-00025 TABLE 24 Percent Inhibition of Visceral Pain
Sensitivity by Peppermint Extracts Dose Max % P- Compound/Spp
(mg/kg) Fraction inhibition value Reproducibility Ibuprofen 100 --
67.6 0.00026 Yes Mentha piperita 126 EA 47.2 0.0005 Yes 300 ME 29.8
0.0895 Yes CD-1 mice (N = 6) were gaveged with ibuprofen (100
mg/kg) or peppermint (126 or 300 mg/kg) half an hour before acetic
acid injection.
Example 44
In Vivo Efficacy of Peppermint Extracts in Carrageenan-Induced Rat
Paw Edema Model
[0272] Carrageenan-induced rat paw edema model was utilized to
evaluate different grades of peppermint ethanol extracts described
in Example 26, which were gavaged at 200 mg/kg one hour after
disease induction. As seen in Table 25 activity of extract
decreases proportionally as the percentage of ethanol used for
extraction decreased. Maximum inhibition in pain and inflammation
was observed when rats were gavaged with a 100% ethanol extract of
peppermint at a dose of 200 mg/kg followed by 90%. As a result, the
90% ethanol extract was selected for subsequent use. These
percentage reductions were statistically significant at each time
point analyzed against vehicle control.
TABLE-US-00026 TABLE 25 Anti-Pain and Anti-Inflammatory Activity of
Peppermint Extracts Percent change vs. Vehicle Dose Paw Edema Pain
sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen
200 5 43.5* 58.0* 50.3* 55.6* 62.7* 44.6* 100% Ethanol Extract 200
5 27.5* 49.5* 37.6* 33.8* 43.4* 36.3* 90% Ethanol Extract 200 5
26.6* 45.1* 36.0* 28.9* 41.4* 33.3* 70% Ethanol Extract 200 5 31.7*
25.9* 12.1 24.6* 32.3* 21.0* 30% Ethanol Extract 200 5 32.8* 27.9*
18.6** 24.1* 40.6* 16.5** Peppermint-Water 200 5 20.2* 26.2* 18.2**
8.6 26.0* 10.2** extract Data are presented as a percent change as
compared to vehicle alone. Lewis rats (N = 5) were treated with
ibuprofen (200 mg/kg), peppermint (200 mg/kg), or vehicle an hour
after carrageenan inoculation. *P .ltoreq. 0.001 vs vehicle. **P
.ltoreq. 0.05 vs vehicle.
Example 45
Efficacy of Rosmarinic Acid in Carrageenan-Induced Rat Paw Edema
Model
[0273] Documenting efficacy from abdominal constriction assay and
carrageenan-induced rat paw edema models, subsequent activity
guided fractionation and compound isolation was carried out to
determine the active marker compounds in a peppermint extract.
Rosmarinic acid (RA) and eriocitrin were confirmed as the active
markers of peppermint and tested at doses of 200 mg/kg and 100
mg/kg, respectively, in carrageenan-induced rat paw edema model. As
shown in Table 26, RA showed 29.9%, 35.7% and 34.6% reductions, and
eriocitrin showed 17.2%, 36.0% and 30.0% reductions in paw edema
after 1, 3 and 5 hours of treatment, respectively. Similarly, RA
showed 38.9%, 45.0% and 30.6% reductions and eriocitrin showed
20.4%, 36.4% and 25.2% reductions in pain sensitivity after 1, 3
and 5 hours of treatment, respectively. The positive control
ibuprofen showed 39.5%, 50.4% and 46.6% reduction in paw edema and
55.1%, 701.3% and 50.8% reduction in pain sensitivity after 1, 3
and 5 hours of treatment, respectively (Table 26). The measured
inhibition in pain and inflammation was statistically significant
for both RA and eriocitrin at each time point examined except 1
hour after eriocitrin treatment.
TABLE-US-00027 TABLE 26 Analgesic and Anti-Inflammatory Activity of
Compounds Purified from Peppermint MeOH Extract Percent change of
vehicle Dose Paw Edema Pain sensitivity Group (mg/kg) N 1 hr 3 hr 5
hr 1 hr 3 hr 5 hr Ibuprofen 200 5 39.5* 50.4* 46.6* 55.1* 70.3*
50.8* RA 200 5 29.9* 35.7* 34.6* 38.9* 45.0* 30.6* Eriocitrin 100 5
17.2 36.0* 30.0* 20.4* 36.4* 25.2* Data are presented as a percent
change as compared to vehicle alone. Lewis rats (N = 5) were
treated with ibuprofen (200 mg/kg), rosmarinic acid (200 mg/kg),
eriocitrin 100 mg/kg or vehicle an hour after carrageenan
inoculation. *P .ltoreq. 0.001 vs vehicle.
Example 46
In Vivo Dose Response Effect of Peppermint Extract in
Carrageenan-Induced Rat Paw Edema Model
[0274] To determine what dose would induce maximum inhibition in
pain and inflammation, a dose-response curve was conducted using
the carrageenan-induced rat paw edema model. Rats were gavaged with
90% ethanol extract of peppermint, made as described in Example 25,
at dose ranging from 300 mg/kg to 50 mg/kg. As illustrated in Table
27, a correlation in pain and inflammation reduction was observed
when rats were administered with peppermint at 200 mg/kg to 50
mg/kg. In this particular study, rats treated with 300 mg/kg of 90%
ethanol extract peppermint didn't show greater inhibition than 200
mg/kg treated rats, probably due to issues associated with
solubility of the higher dose.
TABLE-US-00028 TABLE 27 Analgesic and Anti-Inflammatory Activity of
Peppermint Extract 25 Percent Change of Vehicle Dose Inflammation
Analgesia Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibu- 200 5
44.6* 54.9* 50.0* 52.9* 62.5* 48.8* profen 25 300 5 8.5 32.8* 29.8*
27.2* 37.0* 30.8* 25 200 5 32.8* 46.1* 34.8* 38.0* 47.1* 34.2* 25
100 5 22.6* 23.3* 10.9 27.8* 21.9* 19.1** 25 50 5 15.8** 12.3 8.4
22.7* 13.4** 13.5** Data are presented as a percent change as
compared to vehicle alone. Female Lewis rats (N = 5) were treated
with ibuprofen (200 mg/kg) and 90% ethanol extract peppermint (300
mg/kg, 200 mg/kg, 100 mg/kg and 50 mg/kg), or vehicle an hour after
carrageenan inoculation. *P .ltoreq. 0.001 vs vehicle. **P .ltoreq.
0.05 vs vehicle.
Example 47
Effect of Morus Extract on Nociceptive Behavior Model
[0275] Writhing's animal model was employed to evaluate
anti-nociceptive activity of plant extracts of this disclosure.
When CD-1 mice were treated with a single oral dose of 25, 50 or
300 mg/kg of ethanol extract of Morus alba from Example 11, 30.7%,
45.3% and 48.4%, respectively, visceral pain inhibition was
observed as compared to vehicle treated CD-1 mice (Table 28).
TABLE-US-00029 TABLE 28 Percent inhibition of visceral pain
sensitivity by Morus Extract Dose Mean .+-. % Inhibition Compound
Spp. Part (mg/kg) N SD P Value Vehicle 0 6 82.3 .+-. 24.3 -- -- 300
6 42.5 .+-. 10.2 48.4 0.004 11 M. alba Root 50 6 45.0 .+-. 11.5
45.3 0.001 bark 25 6 57.2 .+-. 14.3 30.7 0.05 CD-1 mice (N = 6)
were gaveged with vehicle (0 mg/kg) or Morus alba (25, 50 or 300
mg/kg) half an hour before acetic acid injection.
Example 48
Dose Response of Carrageenan-Induced Rat Paw Edema Model to Morus
Extract
[0276] Analgesic and anti-inflammatory activity of Morus alba were
also confirmed by using carrageenan induced rat paw edema model.
Lewis rats (N=5) were orally gavaged with a dose of 100, 200, or
300 mg/kg of Morus ethanol extract 13-1, as described in Example
13, 1 hour after carrageenan inoculation. Ethanol extract of Moms
were effective in both measures as low as 100 mg/kg. As depicted in
Table 29, rats treated with 300 mg/kg showed the highest inhibition
in pain (48.0%-31.6%) and inflammation (53.1%-37.0%) when compared
to vehicle control. Similarly, a range of 45.8%-24.6% reduction in
paw edema and 34.7%-22.1% reduction in pain were observed for rats
treated with a dose of 200 mg/kg of Morus ethanol extract 13-1.
These reductions were statistically significant at each time point
examined.
TABLE-US-00030 TABLE 29 Analgesic and Anti-Inflammatory Activity of
Morus Ethanol Extract 13-1 Percent change of vehicle Dose Paw edema
Pain sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr
Ibuprofen 200 5 53.2* 64.3* 50.6* 57.1* 61.5* 44.3* 300 5 53.1*
46.1* 37.0* 48.0* 46.1* 31.6* M. alba 200 5 45.8* 35.9* 24.6* 34.7*
36.4* 22.1* 13-1 100 5 16.6 18.3** 12.3** 20.3* 31.2* 6.3 Data are
presented as a percent change as compared to vehicle alone. Female
Lewis rats (N = 5) were treated with ibuprofen (200 mg/kg) and
ethanol extract of M. alba 13-1 (300 mg/kg, 200 mg/kg, and 100
mg/kg), or vehicle alone an hour after carrageenan inoculation. *P
.ltoreq. 0.001 vs vehicle. **P .ltoreq. 0.05 vs vehicle.
Example 49
Efficacy of Pure Compounds and Extracts of Morus in
Carrageenan-Induced Rat Paw Edema Model
[0277] Based on activity guided fractionation and compound
isolation; four major actives, oxyresveratrol, mulberroside A,
kuwanon G and morusin isolated from extract of Moms root bark as
described in Examples 3 and 5, were evaluated in
carrageenan-induced rat paw edema model for their in vivo activity.
Animals were orally administered with purified Moms compounds at a
dose of 100 mg/kg, one hour after carrageenan inoculation. In this
study EtOAc fractions and ethanol extracts 11, 13-1 and 13-3 of
Morusat a dose of 200 mg/kg were included. As seen in Table 30, all
marker compounds showed statistically significant inhibition in
pain and inflammation when compared to vehicle control. However, a
sharp drop in percent inhibition was observed when extract with
high active content extract 13-1 was compared to low active
contents extract 13-3 in marker compounds. As a result, these data
indicate that root bark Moms extracts having a high content of both
stilbenes and prenylated flavonoids will likely result in maximum
pain and inflammation inhibition.
TABLE-US-00031 TABLE 30 Analgesic and Anti-Inflammatory Activity of
Morus Extracts and Compounds Percent change of vehicle Dose Paw
edema Pain sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5
hr Ibuprofen 200 5 51.6* 61.9* 50.0* 55.4* 65.9* 49.3*
Oxyresveratrol 100 5 44.7* 54.5* 38.3* 53.3* 54.8* 38.5*
Mulberroside 100 5 48.4* 50.6* 37.3* 54.2* 52.2* 35.5* A Kuwanon G
100 5 36.5* 37.7* 29.3* 33.3* 40.5* 31.2* Morusin 100 5 37.3* 40.0*
38.0* 33.3* 38.5* 30.2* 13-1 200 5 37.1* 36.1* 33.9* 36.0* 41.1*
30.6* 13-3 200 5 21.1* 24.9* 23.1* 24.2* 26.7* 18.4* 11 200 5 27.0*
32.9* 31.7* 31.2* 35.5* 19.7* Data are presented as a percent
change as compared to vehicle alone. Female Lewis rats (N = 5) were
treated with ibuprofen (200 mg/kg), marker compounds (100 mg/kg),
13-1 (Ethanol extract of M. alba at a dose of 200 mg/kg), 13-3 (M.
alba supernatant at a dose of 200 mg/kg), 11 (EtOAc Fraction of
Morus alba at a dose of 200 mg/kg) or vehicle an hour after
carrageenan inoculation. *P .ltoreq. 0.001 vs vehicle.
Example 50
Efficacy of Morus:Curcuma Compositions on Carrageenan-Induced Rat
Paw Edema Model
[0278] Once analgesic and anti-inflammatory activity of Curcuma and
Morus extracts were confirmed in multiple animal models, a study
was designed to evaluate activity of a composition comprising a
mixture of these two extracts. The plant extracts from Morus and
Curcuma were produced according Examples 10 and 19, respectively.
Curcuma and Morus extracts were combined at different ratios,
including 4:1, 2:1, 1:1, 1:2 and 1:4. The compositions 1C:1M,
1C:2M, 2C:1M, 1C:4M and 4C:1M were administered orally at a dose of
300 mg/kg. As seen in Table 31, all compositions showed
statistically significant inhibition of pain and inflammation at
all-time points examined. Among them, rats gavaged with the
composition combining Curcuma and Morus extracts at a ratio of 1:1
showed the maximum inhibition both in pain and inflammation, which
is the composition that was selected for subsequent tests.
TABLE-US-00032 TABLE 31 Analgesic and Anti-Inflammatory Activity of
C:M Compositions Percent change vs. Vehicle Dose Paw edema Pain
sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen
200 5 53.9* 59.0* 52.6* 56.4* 62.2* 45.0* 1C:1M 300 5 51.4* 46.6*
41.4* 54.4* 49.4* 41.8* 1C:2M 300 5 57.6* 45.3* 41.1* 56.5* 48.6*
39.5* 2C:1M 300 5 27.7* 35.8* 31.3* 40.8* 46.2* 27.7* 1C:4M 300 5
50.1* 33.7* 27.8* 46.5* 40.7* 25.6* 4C:1M 300 5 27.3* 25.1* 26.4*
23.7* 29.9* 20.4** Data are presented as a percent change as
compared to vehicle alone. Female Lewis rats (N = 5) were treated
with ibuprofen (200 mg/kg) and composition C:M (300 mg/kg), or
vehicle an hour after carrageenan inoculation. *P .ltoreq. 0.001 Vs
vehicle. **P .ltoreq. 0.05 Vs vehicle.
Example 51
Dose Response of Curcuma:Morus Composition in Carrageenan-Induced
Rat Paw Edema Model
[0279] The Curcuma:Morus: composition with a blending ratio of
1C:1M was further subjected to a dose-response study to determine
the dose that would result in the most significant inhibition in
pain and inflammation. For this purpose, female Lewis rats (N=5)
were gavaged orally a dose of 100, 200, 300 or 400 mg/kg of 1C:1M
composition as described in Example 50, one hour after intraplantar
carrageenan injection. Statistically significant, dose correlated,
inhibition in pain and inflammation were observed for all doses
administered, with the highest inhibition observed for the 400
mg/kg dose and the lowest inhibition for the 100 mg/kg dose of the
1C:1M composition.
TABLE-US-00033 TABLE 32 Analgesic and Anti-Inflammatory Activity of
1C:1M Composition Percent change of vehicle Dose Paw edema Pain
sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen
200 5 53.9* 59.0* 52.6* 56.4* 62.2* 45.0* 1C:1M 400 5 55.1* 51.5*
45.5* 55.9* 54.2* 44.4* 1C:1M 300 5 51.4* 46.6* 41.4* 54.4* 49.4*
41.8* 1C:1M 200 5 50.1* 40.7* 30.8* 42.5* 39.7* 32.0* 1C:1M 100 5
35.6* 28.0* 22.6* 21.7* 30.2* 10.4** Data are presented as a
percent change as compared to vehicle alone. Female Lewis rats (n =
5) were treated with ibuprofen (200 mg/kg), composition 1C:1M (400
mg/kg, 300 mg/kg, 200 mg/kg or 100 mg/kg), or vehicle an hour after
carrageenan inoculation. *P .ltoreq. 0.001 as compared to
vehicle.
Example 52
Evaluation of Morus:Curcuma Composition Synergy in a
Carrageenan-Induced Rat Paw Edema Model
[0280] Carrageenan-induced paw edema model was used to evaluate a
possible synergy or unexpected effect of the extracts from Curcuma
and Morus when formulated together in a specific ratio of 1C:1M as
described in Example 50, using Colby's method (Colby, 1967). Rats
treated with the 1C:1M (12.5 wt % curcuminoids, 1.5 wt % prenylated
flavonoids, 1.5 wt % stilbenes) composition at a dose of 300 mg/kg
showed greater (synergistic) activity than the theoretically
calculated (additive effect) for both inflammation and pain
sensitivity at each time point analyzed (1, 3 or 5 hours after
treatment). Similarly, the composition also showed a greater
inhibition in pain sensitivity and inflammation than either Curcuma
or Morus extract administered alone at the same dose of 300 mg/kg
(see Tables 33 and 34).
TABLE-US-00034 TABLE 33 Analgesic and Anti-Inflammatory Activity of
1C:1M Mixture Percent change of vehicle Dose Paw edema Pain
sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen
200 5 53.9* 59.0* 52.6* 56.4* 62.2* 45.0* 1C:1M (50) 300 5 51.4*
46.6* 41.4* 54.4* 49.4* 41.8* M. alba (10) 300 5 45.1* 38.3* 31.3*
44.6* 39.2* 32.5* M. alba (10) 150 5 31.4* 26.2* 18.3* 31.3* 27.0*
24.0* C. longa (19) 300 5 41.8* 35.3* 29.2* 39.0* 44.7* 30.9* C.
longa (19) 150 5 27.7* 24.3* 21.5* 25.0* 30.5* 21.4* Data are
presented as a percent change as compared to vehicle alone. Female
Lewis rats (N = 5) were treated with ibuprofen (200 mg/kg),
composition 1C:1M (300 mg/kg), Morus alba extract (150 mg/kg or 300
mg/kg), Curcuma longa extract (150 mg/kg or 300 mg/kg) or vehicle
an hour after carrageenan inoculation. *P .ltoreq. 0.001 vs
vehicle.
TABLE-US-00035 TABLE 34 Analgesic and Anti-Inflammatory Activity of
1C:1M Mixture Percent change vs Vehicle Composition/ Dose Paw Edema
Pain Sensitivity Compound* Synergy mg/kg N 1 hr 3 hr 5 hr 1 hr 3 hr
5 hr 1C -- 150 5 27.7 24.3 21.5 25.0 30.5 21.4 1M -- 150 5 31.4
26.2 18.3 31.3 27.0 24.0 1C:1M Expected** -- -- 50.4 44.1 35.9 48.5
49.2 40.3 Observed.sup. 300 5 51.4 46.6 41.4 54.4 49.4 41.8 Data
are presented as a percent change as compared to vehicle alone.
Rats (n = 5) were gavaged with composition 1C:1M (300 mg/kg),
Curcuma and Morus extracts (150 mg/kg), and vehicle alone 1 hour
after carrageenan induced paw edema induction. *C--Curcuma;
M--Morus. **Expected--Calculated value according to Colby's method
= A - B i.e A = (C + M), B = (CM)/100. .sup. Observed--data
observed when a composition was orally administered at 300
mg/kg.
Example 53
Efficacy of Morus:Curcuma:Peppermint Compositions in
Carrageenan-Induced Rat Paw Edema Model
[0281] The efficacy of composition 1C:1M with a peppermint
extractadded was examined for increased efficacy. The effective
dose of 1C1M was set at 200 mg/kg and Peppermint extract 24 was
added at a dose of 50, 100, 150 or 200 mg/kg to result in ratios of
1C:1M:0.5P, 1C:1M:1P, 1C:1M:1.5P and 1C:1M:2P, respectively. A
direct correlation in response was observed for analgesic and
anti-inflammatory activity of the composition when the proportion
of added Peppermint extract 24 increased from 50 mg/kg to 200
mg/kg. The highest inhibition was observed for 1C:1M:2P, while the
lowest was recorded for 1C:1M:0.5P. Nonetheless, all of
compositions 1C:1M:0.5P, 1C:1M:1P, 1C:1M:1.5P and 1C:1M:2P showed a
higher efficacy than 1C:1M (Table 35).
TABLE-US-00036 TABLE 35 Analgesic and Anti-Inflammatory Activity of
C:M:P and C:M Compositions Percent change of vehicle Dose Paw edema
Pain sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr
Ibuprofen 200 5 57.2* 67.6* 53.5* 56.1* 65.9* 47.9* 1C:1M:2P 400 5
50.6* 47.5* 43.5* 52.5* 51.2* 40.3* 1C:1M:1.5P 350 5 47.3* 42.6*
38.4* 48.3* 45.9* 35.9* 1C:1M:1P 300 5 45.3* 40.8* 31.2* 43.9*
44.4* 31.7* 1C:1M:0.5P 250 5 42.4* 37.8* 24.2* 43.3* 40.2* 30.9*
1C:1M 200 5 37.9* 35.4* 23.1* 42.1* 38.0* 30.2* Data are presented
as a percent change as compared to vehicle alone. Female Lewis rats
(N = 5) were treated with ibuprofen (200 mg/kg), composition
1C1M0.5P (250 mg/kg), 1C1M1P (300 mg/kg), 1C1M1.5P (350 mg/kg),
1C:1M:2P (400 mg/kg), 1C:1M (200 mg/kg) or vehicle an hour after
carrageenan inoculation. *P .ltoreq. 0.001 vs vehicle
Example 54
Efficacy of Morus:Curcuma:N-Acetylglucosamine (Nag) Composition in
Carrageenan-Induced Rat Paw Edema Model
[0282] N-acetylglucosamine (NAG) is the building block of collagen
in the joint. By adding NAG into Morus and Curcuma composition
1C:1M, it may be possible to enhance the joint care benefit without
changing the anti-inflammatory and anti-pain activity of the C:M
composition. To examine this hypothesis, a study was performed
using carrageenan-induced rat paw edema as the disease model. In
this study, rats were orally treated with 1C:1M at a dose of 200
mg/kg or an equivalent dose of 3C:3M:5NAG at a dose of 366 mg/kg
one hour after disease induction. NAG alone at 166 mg/kg was
included in this study. As shown in Table 36, NAG neither enhances
nor inhibits analgesic and anti-inflammatory activity of the CM
composition in this model. At least in this animal model, it could
be concluded that NAG has minimal to no activity in inhibiting pain
or inflammation at a dose of 166 mg/kg.
TABLE-US-00037 TABLE 36 Analgesic and Anti-Inflammatory Activity of
a C:M:NAG Composition Percent change of vehicle Dose Paw edema Pain
sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen
200 5 57.2* 67.6* 53.5* 56.1* 65.9* 47.9* 1C:1M 200 5 37.9* 35.4*
23.1* 42.1* 38.0* 30.2* 3C:3M:5NAG 366 5 40.3* 34.6* 27.7* 42.1*
37.4* 30.6* NAG 166 5 8.2 15.8 6.2 8.8 3.6 2.6 Data are presented
as a percent change as compared to vehicle alone. Female Lewis rats
(n = 5) were treated with ibuprofen (200 mg/kg), composition 1C1M
(200 mg/kg), 3C:3M:5NAG (366 mg/kg), NAG (166 mg/kg) or vehicle
alone an hour after carrageenan inoculation. *P .ltoreq. 0.001 vs
vehicle
Examples 55
Dose Response of Morus:Curcuma:Nag Composition in
Carrageenan-Induced Rat Paw Edema Model
[0283] To further examine whether N-acetylglucosamine (NAG) had a
neutral effect on composition CM efficacy, a dose-response study
was designed for 1C:1M:2NAG at oral doses of 600, 500, 400 and 300
mg/kg in carrageenan-induced rat paw edema model. Rats were gavaged
the composition one hour after intraplantar carrageenan
inoculation. These dosages correlate with doses of 300, 250, 200
and 150 mg/kg of 1C1M, respectively. As seen in Table 37, all
compositions showed statistically significant inhibition in pain
and inflammation, the highest being in the 600 mg/kg and the lowest
in 300 mg/kg. These data again show that NAG neither enhances nor
inhibits the analgesic and anti-inflammatory activity of the mixed
Curcuma:Morus composition.
TABLE-US-00038 TABLE 37 Analgesic and Anti-Inflammatory Efficacy of
1C:1M:2NAG Composition Percent change of vehicle Dose Paw edema
Pain sensitivity Group (mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr
Ibuprofen 200 5 54.2* 57.7* 48.6* 53.7* 61.5* 47.5* 1C1M2NAG 600 5
55.7* 48.1* 43.4* 56.1* 52.2* 43.6* 1C1M2NAG 500 5 53.4* 47.5*
41.3* 54.3* 50.3* 41.6* 1C1M2NAG 400 5 42.2* 43.6* 36.6* 46.9*
42.8* 35.3* 1C1M2NAG 300 5 33.7* 31.0* 28.1* 33.6* 37.2* 27.3* Data
are presented as a percent change as compared to vehicle alone.
Female Lewis rats (N = 5) were treated with ibuprofen (200 mg/kg),
composition 1C:1M:2NAG (600, 500, 400 or 300 mg/kg), or vehicle an
hour after carrageenan inoculation. *P .ltoreq. 0.001 vs
vehicle
Example 56
Efficacy of Morus:Curcuma:Nag Composition in Writhing Test
[0284] Composition 1C:1M:2NAG was further tested at doses of 600
mg/kg, 500 mg/kg and 400 mg/kg for capability to alleviate visceral
pain inflicted by intraperitoneal administration of acetic acid in
CD-1 mice. In this study, 1C:1M (without NAG) and NAG
(N-acetylglucosamine) alone at a dose of 300 mg/kg were used as
controls. Immediately after injection of the irritant, animals
showed abdominal constrictions consisting of contractions of the
abdominal muscle which progressed posteriorly and ended with
simultaneous flexor extension of both hind limbs with arching of
the back.
TABLE-US-00039 TABLE 38 Effect of 1C:1M:2NAG Composition on
Visceral Pain Sensitivity Groups Dose (mg/kg) Mean + SD % change
P-values Vehicle 0 96.2 .+-. 16.3 -- -- Ibuprofen 200 34.5 .+-.
12.7 64.1 0.0000 1C:1M 300 51.5 .+-. 7.9 46.4 0.0001 NAG 300 91.0
.+-. 18.7 5.4 0.6210 1C:1M:2NAG 600 50.8 .+-. 7.8 47.1 0.0001
1C:1M:2NAG 500 64.5 .+-. 10.8 32.9 0.0027 1C:1M:2NAG 400 76.8 .+-.
12.4 20.1 0.0432 CD-1 mice (N = 6) were gavaged with ibuprofcn (200
mg/kg), 1C:1M:2NAG (600, 500 or 400 mg/kg), 1C:1M (300 mg/kg),
N-acetylglucosamine (NAG, 300 mg/kg) or vehicle alone half an hour
before acetic acid injection.
[0285] The number of behavioral responses observed for 30 minutes
were reduced to 50.8.+-.7.9, 64.5.+-.7.8 and 76.8.+-.12.4 for
1C:1M:2NAG after oral administration at doses of 600, 500 and 400
mg/kg, respectively, as compared to the vehicle control, i.e.,
96.2.+-.16.3 (Table 53). A similar response of 51.5.+-.7.9 was
observed for mice treated with 300 mg/kg of 1C:1M (Table 53).
However, mice receiving NAG alone showed 91.0+18.7 behavioral
reaction. This finding indicates that 1C:1M:2NAG provides an
analgesic effect in a dose dependent manner, and that 1C:1M is the
active component in C:M:NAG composition, while NAG has minimal to
neutral effect on analgesic activity of 1C:1M in this model.
Example 57
Efficacy of Morus:Uncaria Compositions in Carrageenan-Induced Rat
Paw Edema Model
[0286] Morus alba ethanol extract 10 (M), as described in Example
10, was formulated with Uncaria gambir extract 21 (G), as described
in Example 21, at ratios of 1G:1M, 1G:2M, 1G:4M, 2G:1M (13.3 wt %
flavans, 1 wt % prenylated flavonoids, 1 wt % stilbenes) and 4G:1M
(16 wt % flavans, 0.6 wt % prenylated flavonoids, 0.6 wt %
stilbenes) and tested in carrageenan-induced rat paw edema model at
a dose of 300 mg/kg. For comparison, each constituent extract,
Uncaria and Morus, were each administered orally at dose of 300
mg/kg. As seen in Table 39, all treatment groups (ratios and
individual components) showed statistically significant inhibition
in pain and inflammation when compared to vehicle control. But,
unexpected enhanced (synergistic) activity was observed for ratios
of 1G:1M (10 wt % flavans, 1.5 wt % prenylated flavonoids, 1.5 wt %
stilbenes), 1G:2M (about 6.7 wt % flavans, 2 wt % prenylated
flavonoids, 2 wt % stilbenes) and 1G:4M (4 wt % flavans, 2.4 wt %
prenylated flavonoids, 2.4 wt % stilbenes) as compared to either
Uncaria or Morus given alone at the same dose of 300 mg/kg.
TABLE-US-00040 TABLE 39 Analgesic and Anti-Inflammatory Activity of
GM Compositions Compared to "G" Extract 21 and "M" Extract 10
Percent change vs Vehicle Dose Paw edema Pain sensitivity Group
(mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen 200 5 53.0* 60.1*
51.3* 52.4* 59.7* 43.3* 1G:1M 300 5 50.2* 53.3* 48.7* 51.8* 52.5*
40.0* 1G:2M 300 5 48.6* 51.4* 48.4* 47.0* 49.1* 38.7* 1G:4M 300 5
43.4* 50.8* 39.4* 42.9* 44.7* 33.2* 2G:1M 300 5 31.1* 42.7* 27.1*
36.6* 42.8* 28.8* 4G:1M 300 5 32.3* 41.7* 20.9* 33.7* 36.7* 21.1* G
(Gambir) 300 5 28.7* 34.3* 17.4* 33.9* 30.9* 17.5* M (Morus) 300 5
38.2* 43.9* 31.4* 38.9* 37.1* 30.7* Data are presented as a percent
change as compared to vehicle. Female Lewis rats (N = 5) were
treated with ibuprofen (200 mg/kg), composition G:M (300 mg/kg),
Morus alba (300 mg/kg), Uncaria gambir (300 mg/kg) or vehicle an
hour after carrageenan inoculation. *P .ltoreq. 0.001 vs
vehicle
Example 58
Efficacy of Morus:Acacia Compositions in Carrageenan-Induced Rat
Paw Edema Model
[0287] Compositions comprising extract 22 from Acacia catechu, as
described in Example 22, and Morus alba ethanol extract 10, as
described in Example 10, were tested at ratios of 1A:1M, 1A:2M,
1A:4M (4 wt % flavans, 2.4 wt % prenylated flavonoids, 2.4 wt %
stilbenes), 2A:1M (13.3 wt % flavans, 1 wt % prenylated flavonoids,
1 wt % stilbenes) and 4A:1M (16 wt % flavans, 0.5 wt % prenylated
flavonoids, 0.5 wt % stilbenes) in carrageenan-induced rat paw
edema model at a dose of 300 mg/kg. For comparison, extract from
each constituent, A. catechu extract 22 and M alba extract 10 were
each individually administered orally at dose of 300 mg/kg. As seen
in Table 40, all treatment groups (ratios and individual
components) showed statistically significant inhibition in pain and
inflammation when compared to vehicle control. However, unexpected
enhanced activities were observed for ratios 1A:1M (10 wt %
flavans, 1.5 wt % prenylated flavonoids, 1.5 wt % stilbenes) and
1A:2M (6.7 wt % flavans, 2 wt % prenylated flavonoids, 2 wt %
stilbenes) as compared to either A. catechu extract 22 or M. alba
extract 10 given alone at the same dose of 300 mg/kg.
TABLE-US-00041 TABLE 40 Analgesic and Anti-Inflammatory Activity of
A:M Compositions Compared to "A" Extract 22 and "M" Extract 10
Percent change vs Vehicle Dose Paw edema Pain sensitivity Group
(mg/kg) N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen 200 5 53.0* 60.1*
51.3* 52.4* 59.7* 43.3* 1A:1M 300 5 41.8* 44.5* 38.6* 46.3* 47.3*
33.2* 1A:2M 300 5 55.4* 49.2* 43.0* 51.4* 48.4* 36.6* 1A:4M 300 5
32.7* 46.4* 37.9* 40.9* 46.4* 32.3* 2A:1M 300 5 41.4* 36.8* 22.7*
46.5* 44.2* 27.6* 4A:1M 300 5 32.7* 34.6* 20.6* 36.6* 41.0* 21.5* A
(Acacia) 300 5 35.5* 29.3* 17.3* 35.0* 31.1* 17.7* M (Morus) 300 5
38.2* 43.9* 31.4* 38.9* 37.1* 30.7* Data are presented as a percent
change as compared to vehicle alone. Female Lewis rats (N = 5) were
treated with ibuprofen (200 mg/kg), composition A:M (300 mg/kg),
Morus alba (300 mg/kg), Acacia catechu (300 mg/kg) or vehicle an
hour after carrageenan inoculation. *P .ltoreq. 0.001 vs
vehicle.
Example 59
Dose Correlated Analgesic and Anti-Inflammatory Activity of
Morus-Based Compositions
[0288] As described in Examples 57 and 58, mixed compositions of
1G:1M, 1A:2M and 1A:1M showed superior anti-inflammatory and
analgesic activity over individual components G, A or M at a dose
of 300 mg/kg. To determine the dose of compositions that would
result in the most significant inhibition in pain and inflammation,
each composition was tested at a dose of 300, 200 and 100 mg/kg in
a carrageenan-induced rat paw edema model administered orally an
hour post model induction. As seen in Table 41, a clear dose
correlated, statistically significant, inhibition in
hypersensitivity and inflammation was observed for all the
compositions tested.
TABLE-US-00042 TABLE 41 Dose correlated Analgesic and
Anti-Inflammatory Activity of 1G:1M, 1A:2M and 1A:1M Compositions
Percent change vs Vehicle Dose Paw Edema Pain sensitivity Group
mg/kg N 1 hr 3 hr 5 hr 1 hr 3 hr 5 hr Ibuprofen 200 5 52.5* 62.9*
51.6* 58.6* 64.0* 50.7* 1G:1M 300 5 53.7* 55.3* 48.8* 56.1* 53.3*
44.8* 200 5 41.7* 40.9* 38.9* 39.6* 42.0* 37.1* 100 5 31.4* 33.0*
26.6* 33.6* 30.3* 28.3* 1A:2M 300 5 53.3* 54.3* 46.3* 54.8* 53.8*
43.6* 200 5 39.3* 40.5* 36.5* 42.9* 41.3* 36.3* 100 5 25.2* 26.8*
24.2* 31.8* 31.3* 28.8* 1A:1M 300 5 45.9* 44.3* 42.6* 49.3* 50.3*
38.0* 200 5 36.8* 39.5* 36.1* 37.3* 39.4* 30.8* 100 5 24.4* 22.0*
20.5* 28.9* 31.5* 27.3* Data are presented as a percent change as
compared to vehicle alone. Female Lewis rats (N = 5) were treated
with ibuprofen (200 mg/kg), composition 1G1M, 1A2M or 1A1M (300
mg/kg, 200 mg/kg or 100 mg/kg), or vehicle alone an hour after
carrageenan inoculation. *P .ltoreq. 0.001 vs vehicle.
Example 60
Evaluation of Specific Morus:Acacia Composition in
Carrageenan-Induced Rat Paw Edema Model
[0289] Despite the fact that compositions 1G:1M, and 1A:2M of
Examples 57 and 58 excelled in efficacy as analgesic and
anti-inflammatory agents as compared to individual components G, A
or M, a study using a carrageenan-induced rat paw edema model was
conducted to evaluate the potential synergistic activity of
components when formulated together at a specific ratios of 1G:1M
and 1A:2M using Colby's method (Colby, 1967). When rats were given
1G:1M (10 wt % flavans, 1.5 wt % prenylated flavonoids, 1.5 wt %
stilbenes) or 1A:2M (6.7 wt % flavans, 2 wt % prenylated
flavonoids, 2 wt % stilbenes) compositions at a dose of 300 mg/kg,
the observed results were greater than the theoretically calculated
values both in inflammation and pain sensitivity at each time point
analyzed (1, 3 or 5 hours after treatment) (Table 42).
TABLE-US-00043 TABLE 42 Analgesic and Anti-Inflammatory Activity of
1G:1M and 1A:2M Compositions Percent change vs Vehicle Dose Paw
Edema Pain Sensitivity Composition Compound mg/kg N 1 hr 3 hr 5 hr
1 hr 3 hr 5 hr 1G:1M 1G* 150 5 25.6 26.1 23.8 27.4 30.0 22.4 1M 150
5 30.6 29.6 24.2 30.1 31.5 23.0 Expected** -- -- 48.4 48.0 42.2
49.2 52.0 40.2 Observed.sup. 300 5 53.7 55.3 48.8 56.1 53.3 44.8
1A:2M 1A 100 5 21.9 23.0 17.6 23.9 27.5 22.6 2M 200 5 32.2 33.0
27.9 33.8 34.3 25.7 Expected** -- -- 47.1 48.4 40.6 49.6 52.4 42.4
Observed.sup. 300 5 53.3 54.3 46.3 54.8 53.8 43.6 Data are
presented as a percent change as compared to vehicle alone. Rats (n
= 5) were gavaged with composition 1G:1M or 1A:2M (300 mg/kg), G
(150 mg/kg), A (100 and 150 mg/kg), M extract (150 and 200 mg/kg),
or vehicle alone 1 hour after carrageenan-induced paw edema.
*G--Uncaria gambir, M--Morus alba, A--Acacia catechu. **Expected:
calculated value according to Colby's method = A - B, i.e., A = (C
+ M), B = (CM)/100. .sup. Observed: data observed when a
composition was orally administered at 300 mg/kg.
[0290] Clearly, the combination of a Morus ethanol extract with
either an Acacia or Gambir extract yielded compositions with
unexpected synergy and superior analgesic and anti-inflammatory
efficacy.
Example 61
Effect of Acacia Extract on Ex Vivo GAG Release
[0291] Rabbit cartilage explants were cultured with rhIL-1.alpha.
(5 ng/ml) in the absence or presence of Acacia extract 23, as
prepared in Example 23, to examine the protective effects on
proteoglycan (PG) degradation. Acacia extract was tested at four
doses--25, 50, 100 and 200 .mu.g/ml. Acacia extract interfered with
the rhIL-1.alpha.-mediated degradation of PG in a dose dependent
manner.
TABLE-US-00044 TABLE 43 Effect of Acacia Extract on Ex Vivo GAG
Release Sample Dose % GAG release (-) -- 44.8 IL-1.alpha. 5 ng/ml
100.0 Diclofenac 300 .mu.g/ml 26.5 Acacia 25 .mu.g/ml 90.6 50
.mu.g/ml 82.4 100 .mu.g/ml 73.8 200 .mu.g/ml 68.2
Example 62
Effect of Gambir (G):Morus (M) Compositions on Ex Vivo GAG
Release
[0292] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in absence or presence of composition of
Gambir and Morus extract to examine the protective effects on PG
degradation. The compositions were tested at two doses--100 and 200
.mu.g/ml. As shown in the Table 44, all compositions of plant
extracts prevented rhIL-1.alpha. mediated degradation of articular
cartilage in a concentration dependent manner. The order of
efficacy observed was
1G:2M>1G:1M>1G:4M>2G:1M>4G:1M.
TABLE-US-00045 TABLE 44 Effect of G:M Compositions on Ex Vivo GAG
Release Sample Dose % GAG release (-) -- 44.8
TABLE-US-00046 Sample Dose % GAG release IL-1.alpha. 5 ng/ml 100.0
Diclofenac 300 .mu.g/ml 26.5 1G:1M 100 .mu.g/ml 60.6 200 .mu.g/ml
51.1 1G:2M 100 .mu.g/ml 56.0 200 .mu.g/ml 40.2 1G:4M 100 .mu.g/ml
66.5 200 .mu.g/ml 51.2 2G:1M 100 .mu.g/ml 72.7 200 .mu.g/ml 59.9
4G:1M 100 .mu.g/ml 71.6 200 .mu.g/ml 65.9
Example 63
Evaluation of of Gambir (G):Morus (M) Composition Synergy on Ex
Vivo Gag Release
[0293] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in the absence or presence of a Gambir
extract: Moms extract mixed composition to examine the potential
protective effect on PG degradation. The plant extracts from Gambir
and Moms were produced according the above examples. The
compositions were tested at two doses--100 and 200 .mu.g/ml--to
examine whether the combination showed synergistic effects. A
composition of Gambir and Moms extract interfered with the
rhIL-1.alpha.-mediated degradation of PG in a concentration
dependent manner. Whether a synergistic effect was present was
calculated by using the Colby formular (Colby, 1967). All five GM
combinations 1G:1M (10 wt % flavans, 1.5 wt % prenylated
flavonoids, 1.5 wt % stilbenes), 1G:2M (6.7 wt % flavans, 2 wt %
prenylated flavonoids, 2 wt % stilbenes), 1G:4M (4 wt % flavans,
2.4 wt % prenylated flavonoids, 2.4 wt % stilbenes), 2G:1M (13.3 wt
% flavans, 1 wt % prenylated flavonoids, 1 wt % stilbenes) and
4G:1M (16 wt % flavans, 0.6 wt % prenylated flavonoids, 0.6 wt %
stilbenes) showed unexpected synergy at two doses.
TABLE-US-00047 TABLE 45 Synergistic Effect of G:M Compositions on
Ex Vivo GAG Release Sample Dose (.mu.g/ml) % Inhibition Remark
1G:1M 100 62.8 Theoretical value 71.4 Experimental result G 50 3.0
M 50 61.7 1G:1M 200 71.8 Theoretical value 88.5 Experimental result
G 100 32.6 M 100 58.2 1G:2M 100 41.3 Theoretical value 79.7
Experimental result G 33.3 3.0 M 66.7 39.5 1G:2M 200 55.7
Theoretical value 100 Experimental result G 66.7 3.0 M 133.3 54.3
1G:4M 100 54.8 Theoretical value 60.6 Experimental result G 20 3.0
M 80 53.4 1G:4M 200 71.6 Theoretical value 88.5 Experimental result
G 40 3.0 M 160 70.7 2G:1M 100 32.7 Theoretical value 49.5
Experimental result G 66.7 3.0 M 33.3 30.6 2G1M 200 53.8
Theoretical value 72.7 Experimental result G 133.3 23.6 M 66.7 39.5
4G:1M 100 48.3 Theoretical value 51.4 Experimental result G 80 25.5
M 20 30.6 4G:1M 200 50.5 Theoretical value 61.8 Experimental result
G 160 14.7 M 40 42.0
[0294] A confirmatory study of 1G:1M and 1G:2M at 50, 100 and 200
.mu.g/ml was carried out to validate the unexpected synergistic
effect of two individual extracts being combined. The individual
extracts used in the mixed compositions were tested at
concentrations that were in proportion to the weight content of
those extracts in the mixed compositions. Gambir and Morus extracts
interfered with the rhIL-1.alpha.-mediated degradation of PG in a
concentration dependent manner. Synergistic effect was calculated
by using Colby formular (Colby, 1967). Both 1G:1M and 1G:2M
compositions demonstrated unexpected synergy at all three
dosages.
TABLE-US-00048 TABLE 46 Synergy of G:M Combinations on Ex Vivo GAG
Release Sample Dose (ug/ml) % Inhibition Remark 1G:1M 50 27.6
Theoretical value 41.5 Experimental result G 25 18.7 M 25 11 1G:1M
100 72.5 Theoretical value 67.2 Experimental result G 50 50.8 M 50
44.2 1G:1M 200 45 Theoretical value 88.7 Experimental result G 100
0 M 100 45 1G:2M 50 54.4 Theoretical value 49.4 Experimental result
G 16.7 28 M 33.3 36.7 1G:2M 100 60 Theoretical value 60.4
Experimental result G 33.3 37.4 M 66.7 36.1 1G:2M 200 79
Theoretical value 96.4 Experimental result G 66.7 12.6 M 133.3
76
Example 64
Effect of Curcuma (C):Gambir (G):Morus (M) Composition on Ex Vivo
GAG Release
[0295] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in absence or presence of composition of
Curcuma, Uncaria, and Morus extracts to examine the protective
effects on PG degradation. The compositions were tested at two
doses--50 and 100 .mu.g/ml. The individual extracts in the
compositions were tested at concentrations that were in proportions
of the weight contents of those extracts in the compositions. As
shown in the Table 47, the composition of plant extracts prevented
with the rhIL-1.alpha. mediated degradation of articular cartilage
in a concentration dependent manner.
TABLE-US-00049 TABLE 47 Effect of C:G:M Compositions on Ex Vivo GAG
Release Sample Dose % GAG release (-) -- 44.8 IL-1.alpha. 5 ng/ml
100.0 Diclofenac 300 .mu.g/ml 26.5 1C:2G:1M 50 .mu.g/ml 82.1 100
.mu.g/ml 73.0
Example 65
Effect of Acacia (a):Morus (M) Compositions on Ex Vivo Gag
Release
[0296] Rabbit cartilage explants were cultured with rhIL-1.alpha.
(5 ng/ml) in absence or presence of composition of acacia and moms
extract to examine the protective effects on PG degradation. The
compositions were tested at two doses--100 and 200 ug/ml. As shown
in the Table 48, all compositions of plant extracts prevented the
rhIL-1.alpha. mediated degradation of articular cartilage.
TABLE-US-00050 TABLE 48 Effect of A:M Compositions on Ex Vivo GAG
Release Sample Dose % GAG release (-) 52.2 IL-1.alpha. 5 ng/ml
100.0 Diclofenac 300 .mu.g/ml 42.2 1A:1M 100 .mu.g/ml 66.8 200
.mu.g/ml 54.8 1A:2M 100 .mu.g/ml 66.4 200 .mu.g/ml 65.4 1A:4M 100
.mu.g/ml 70.5 200 .mu.g/ml 62.5 2A:1M 100 .mu.g/ml 65.5 200
.mu.g/ml 66.2 4A:1M 100 .mu.g/ml 71.6 200 .mu.g/ml 68.6
Example 66
Evaluation of Acacia (A):Morus (M) Composition Synergy on Ex Vivo
GAG Release
[0297] Rabbit cartilage explants were cultured for 24 hr with
rhIL-1.alpha. (5 ng/ml) in the absence or presence of composition
of acacia and moms extract to examine the protective effects on PG
degradation. The plant extracts from Acacia and Moms were produced
according to the above examples. The compositions were tested at
two doses--50 and 100 .mu.g/ml--to examine whether the combined
extracts together produce a unexpected synergistic effect on
cartilage protection. The individual extracts in the compositions
were tested at concentrations that were in proportion to the weight
content of those extracts in the mixed compositions. Acacia and
Morus extracts interfered with the rhIL-1.alpha.-mediated
degradation of PG in a concentration dependent manner. Synergy was
calculated by using the Colby formular (Colby, 1967). Both 1A:1M
(10 wt % flavans, 1.5 wt % prenylated flavonoids, 1.5 wt %
stilbenes) and 1A:2M (6.7 wt % flavans, 2 wt % prenylated
flavonoids, 2 wt % stilbenes) demonstrated unexpected synergy in
two doses.
TABLE-US-00051 TABLE 49 Synergistic Effect of A:M Compositions on
Ex Vivo GAG Release Sample Dose (ug/ml) % Inhibition Remark 1A:1M
50 28.4 Theoretical value 29.9 Experimental result A 25 19.6 M 25
11 1A:1M 100 64.7 Theoretical value 69.6 Experimental result A 50
36.8 M 50 44.2 1A:2M 50 65.6 Theoretical value 63.0 Experimental
result A 16.7 45.7 M 33.3 36.7 1A:2M 100 53.4 Theoretical value
70.5 Experimental result A 33.3 27.0 M 66.7 36.1
Example 67
Joint Protection Function of Compositions on In Vivo Mia
(Monosodium Iodoacetate) Induced Osteoarthritis (OA) Rat Model
[0298] The animals were randomized and assigned to treatment groups
before the study began. After anesthetization with isoflurane, rats
were injected with 50 .mu.l containing 1 mg Monosodium iodoacetate
(Sigma, St. Louis, Mo.; lot # SLBB6147V) using a 26 gauge needle
inserted through the patellar ligament into the intra-articular
space of the right knee. Normal rats were injected with an
equivalent volume of saline instead of MIA. Animals were treated
orally with Celecoxib 100 mg/kg, Diclofenac 5 mg/kg, Univestin.RTM.
(Scutellaria:Acacia extract mixture) 400 mg/kg, 1C:1M 600 mg/kg and
1C:1M:2NAG 600 mg/kg once a day for 4 weeks. The first sample
treatment was administered 1 hr before MIA injection. Normal and
control rats were given orally an equal volume of vehicle (0.5% CMC
in saline). Body weight and allodynia were measured once a week for
4 weeks. Allodynia was evaluated by measuring responsiveness to a
tip of Randall-Selitto test (2390 series, IITC, Woodland Hills,
Calif.) applied perpendicular to the central plantar surface of the
right hind paw. Three animals in each group were evaluated for
structural alterations of articular cartilage surface and
subchondral bone architecture by Micro CT scan (SkyScan1173,
Belgium). Histological changes were assessed to confirm the
protection effect on cartilage degeneration in the knee joints of
OA rats. After decalcification, joint tissues were stained with
hematoxylin and eosin (HE), and also Safranin O-fast green to
enable evaluation of proteoglycan content.
Example 68
Organic Extracts of Prenylated Flavonoids
[0299] Prenylchalcone, prenylflavones, prenylflavonols and
prenylflavanones all belong to prenylflavonoids. Prenylated
flavonoids have limited distribution in the plant kingdom. Many
prenylated flavonoids have been found in the Moraceae family, but
they are also disseminated in other families, such as Canabaceae,
Fabaceae, Meliaceae, Rutaceae, Platanaceae, Cecropiaceae,
Mimosaceae, Asclepiadaceae, Scrophulariaceae, Gesneriaceae,
Asteraceae, and Zingiberaceae. The prenyl isoflavonoids are more
restricted to subfamilies of the Leguminosae family.
[0300] Five different genera of plants reported to contain
prenylated flavonoids were selected for extraction, as shown in
Table 50. A total of 20 grams ground powder of each plant was
loaded into a 100 ml stainless steel tube and extracted twice with
an organic solvent mixture (methylene chloride/methanol in a ratio
of 1:1) using an ASE 350 automatic extractor at 80.degree. C. and
under 1,500 psi of pressure. The extract solution was automatically
filtered and collected. The combined organic extract solution was
evaporated with a rotary evaporator to give a crude organic extract
(OE). The organic extracts of the eight plants were tested in the
GAG release assay described herein.
TABLE-US-00052 TABLE 50 Prenylated flavonoid Yield from Selected
Plants Extraction SAMPLE_ID FAMILY GENUS SPECIES PARTS NB_ID YIELD
P00288 Fabaceae Sophora Flavescens root P00288-OE 22.6% P00309
Fabaceae Psoralea Corylifolia fruit P00309-OE 11.5% P00572 Fabaceae
Glycyrrhiza Glabra rhizome-root P00572-OE 29.2% P00635 Cannabaceae
Humulus Lupulus flower P00635-OE 48.5% P01302 Cannabaceae Humulus
Americanus flower-leaf-vin P01302-OE 18.2% P01962 Fabaceae
Millettia Usaramensis root P01962-OE 6.3% P01963 Fabaceae Millettia
Usaramensis bark P01963-OE 8.4% P01964 Fabaceae Millettia Oblata
leaf P01964-OE 8.2%
[0301] Xanthohumol and isoxanthohumol, which are prenylated
chalcones and flavanones from hops (cones of Humulus lupulus), were
reported as major and active compounds of the plants. Glabridin is
one of the major prenylated flavonoids specifically reported from
Glycyrrhiza glabra. Cathayanon A is a Diels-Alder adduct isolated
from Milicia excelsa.These four prenylated flavonoids were obtained
from commercial sources and tested in the GAG release assay.
##STR00139##
Example 69
Effect of Various Organic Extracts on Ex Vivo GAG Release
[0302] Organic extracts generated from five different plant genera
as described in previous Example 68 were tested at three doses--50
.mu.g/ml, 100 .mu.g/ml, and 200 .mu.g/ml--in the GAG release model
as described in Example 27. As shown in Table 51, every extract
tested inhibited ex vivo GAG release. In particular, organic
extracts from Sophora, Psoralea, Glycyrrhiza and Humulus showed a
strong cartilage protective effect as reflected by a reduction in
GAG release, whereas the Millettia extract, while inhibiting GAG
release, showed a weaker efficacy by comparison.
TABLE-US-00053 TABLE 51 Effect of Various Organic Extracts on Ex
Vivo GAG Release Sample Dose (.mu.g/ml) % GAG release Negative
control -- 53.0 IL-1.alpha. 0.005 100.0 Diclofenac 300 19.6 P00288
(Sophora) 50 68.6 100 48.9 200 50.7 P00309 (Psoralea) 50 66.4 100
57.3 200 45.4 P00572 (Glycyrrhiza) 50 56.7 100 38.1 200 43.6 P00635
(Humulus) 50 46.7 100 39.5 200 34.9 P01302 (Humulus) 50 84.9 100
69.8 200 54.1 P01962 (Millettia) 50 87.7 100 86.1 200 84.8 P01963
(Millettia) 50 108.8 100 105.7 200 94.8 P01964 50 113.2
Example 70
Effect of Purified Prenylated Flavonoids on Ex Vivo GAG Release
[0303] Four different prenylated flavonoids (glabridin, Compound
14; xanthohumol, Compound 13; isoxanthohumol, Compound 14; and
cathayanon A, Compound 15), purified as described in Example 68,
were tested in the ex vivo GAG release model as described in
Example 27. Rabbit cartilage explants were cultured with
rhIL-1.alpha. (5 ng/ml) in the absence or presence of each purified
prenylated flavonoid compound to examine the protective effects on
cartilage degradation. Each purified prenylated flavonoid was
tested at four concentrations--6.25 .mu.g/ml, 12.5 .mu.g/ml, 25
.mu.g/ml and 50 .mu.g/ml.
TABLE-US-00054 TABLE 52 Effect of Prenylated Flavonoids on Ex Vivo
GAG Release Sample Dose (.mu.g/ml) % GAG release (-) 48.9
IL-1.alpha. 0.005 100.0 Diclofenac 300 38.0 Glabridin 6.25 66.1
12.5 47.9 25 47.5 50 46.3 Xanthohumol 6.25 77.4 12.5 55.3 25 59.2
50 51.2 Isoxanthohumol 6.25 97.8 12.5 73.5 25 41.7 50 37.3
[0304] As shown in Table 52, all four prenylated flavonoids
inhibited rhIL-1.alpha.-mediated degradation of cartilage in a dose
dependent manner.
Example 71
In Vivo Anti-Nociceptive Efficacy of a Gambir:Morus Composition in
a Mouse Writhing Model
[0305] Composition containing the extracts of Gambir:Morus at a
ratio of 1:1 by weight (1G:1M) was tested at doses of 400 mg/kg,
300 mg/kg and 200 mg/kg to alleviate a visceral pain inflicted by
the intraperitoneal administration of 0.7% of freshly prepared
acetic acid in CD-1mice. CD-1 mice (N=6) were orally gavaged with
ibuprofen (200 mg/kg), 1G:1M (400, 300 or 200 mg/kg), or vehicle 30
minutes before intraperitoneal administration of freshly made
acetic acid solution (0.7% in 0.9% NaCl) at 10 ml/kg. Immediately
after injection of the irritant, animals showed abdominal
constrictions consisting of contractions of the abdominal muscle
which progressed posteriorly and ended with simultaneous flexor
extension of both hind limbs with arching of the back. These
behavioral responses observed for the duration of 30 minutes.
TABLE-US-00055 TABLE 53 Effect of 1G:1M Composition on Visceral
Pain Sensitivity Group Dose (mg/kg) Mean .+-. SD. % Inhibition P
Value Vehicle 0 77.4 .+-. 18.7 -- -- Ibuprofcn 200 25.3 .+-. 14.3
67.4 0.0003 1G:1M 400 42.2 .+-. 24.0 45.5 0.0176 300 50.5 .+-. 17.6
34.8 0.0279 200 65.7 .+-. 17.2 15.2 0.2836
[0306] The behavioral responses were found to be reduced to
42.2.+-.24.0, 50.5.+-.17.6 and 65.7.+-.17.2 by oral administration
of 1G:1M at doses of 400, 300 and 200 mg/kg, respectively, as
compared to that of the vehicle control, i.e., 77.4.+-.18.7 (Table
54). The positive control ibuprofen showed 25.3.+-.14.3 or 67.4%
reduction of the pain behavior. The reduction in pain sensitivity
was statistically significant for both ibuprofen and 1G:1M (at
doses of 400 mg/kg and 300 mg/kg) when compared to vehicle
control.
Example 72
In Vivo Anti-Nociceptive Efficacy of an Acacia:Morus Composition in
a Mouse Writhing Model
[0307] A composition containing extracts of Acacia:Morus blended at
a ratio of 1:2 by weight (1A:2M) was tested at doses of 300 mg/kg,
200 mg/kg and 100 mg/kg for the ability to alleviate visceral pain
inflicted by intraperitoneal administration of acetic acid. CD-1
mice (n=6) were orally gavaged with ibuprofen (200 mg/kg), 1A:2M
(300, 200 or 100 mg/kg), or vehicle alone 30 minutes before
intraperitoneal administration of freshly prepared acetic acid
solution (0.7% in 0.9% NaCl) at 10 mL/kg. Immediately after
injection of the irritant, animals showed abdominal constrictions
consisting of contractions of the abdominal muscle, which
progressed posteriorly and ended with simultaneous flexor extension
of both hind limbs with arching of the back. These behavioral
responses were observed for 30 minutes.
TABLE-US-00056 TABLE 54 Effect of 1A:2M Composition on Visceral
Pain Sensitivity Dose % Group (mg/kg) Mean .+-. SD. Inhibition P
Value Vehicle 0 77.5 .+-. 16.3 -- -- Ibuprofen 200 41.8 .+-. 12.6
46.0 0.0016 300 50.8 .+-. 17.2 34.4 0.0197 1A:2M 200 54.3 .+-. 15.5
29.9 0.0294 100 64.0 .+-. 11.5 17.4 0.1256
[0308] The behavioral responses were found to be reduced to
50.8.+-.17.2, 54.3.+-.15.5 and 64.0.+-.11.5 after oral
administration of 1A:2M at doses of 300, 200 and 100 mg/kg,
respectively, as compared to the vehicle control, i.e.,
77.5.+-.16.1 (Table 54). The positive control ibuprofen showed
41.8.+-.12.6 or 46.0% reduction of pain behavior. The reduction in
pain sensitivity was statistically significant for both ibuprofen
and 1A:2M (at doses of 300 mg/kg and 200 mg/kg) when compared to
the control of vehicle alone.
Example 73
Effect of Curcuma:Morus Compostions on Pain and Inflammation in an
Adjuvant-Induced Arthritis (AIA) Rat Model
[0309] Adjuvant-induced arthritis (AIA) in rats is one of the most
widely used experimental animal models of inflammatory joint
conditions with clinical and pathological features similar to
rheumatoid arthritis shared by many higher animals. It is
characterized by chronic inflammation of multiple joints associated
with subsequent progressive, erosive destruction of articular bone
and cartilage, mononuclear cell infiltration, pannus formation and
functional impairment (Wooley, Curr. Rheumatol. Rev. 4:277, 2008;
Bolon et al., J. Biomed. Biotechnol. 2011:569068, 2011).
[0310] Use of a complete adjuvant as an antigen to induce a disease
model of arthritis in rats was found to elicit two intertwined
phases of the immune response that lead to inflammation. The
primary reaction is an acute inflammation mediated partially
through the COX/LOX pathways (on day 0 through day 8) at the site
of inoculation, which was followed by a more delayed and complex
secondary systemic reaction as a result of a generalized
immunologic burst (on days 9 through 14) against antigen that
triggers both cellular and humoral responses in association with
TNF-.alpha., IL1-.beta. and NF-.kappa.B (Newbould, Br. J.
Pharmacol. Chemother. 21:127, 1963). Therefore, anti-inflammatory
agents that inhibit either immune response or pro-inflammatory
pathways will show efficacy in this AIA model measured by edema or
ankle diameter and pain sensitivity.
[0311] This adjuvant-induced rat arthritis model was used to
evaluate the anti-pain and anti-inflammatory activity of a
Curcuma:Morus (C:M) composition. Purpose bred female Wistar rats
weighing 150-175 g (Charles River Laboratories, Inc., Wilmington,
Mass.) were acclimated upon arrival for a week before being
assigned randomly to their respective group. The rats were provided
with fresh water and rodent chow diet ad libitum while being housed
in a temperature controlled room (22.2.degree. C.) on a 12 hour
light-dark cycle. Treatment was started a day before antigen
inoculation, wherein animals (n=9) were orally gavaged with a
positive control ibuprofen, a 1C:1M test article, or a vehicle only
control (propylene glycol). On the next day, arthritis was induced
by sensitizing rats with an injection of complete Freund's adjuvant
containing 5 mg/ml (w/v) suspension of heat killed Mycobacterium
tuberculosis in liquid paraffin into the subplantar region of right
hind paw of sedated rats (Currey, Ann. Rheum. Dis. 29:314, 1970;
Whitehouse et al., Can. Med. Assoc. J. 129:249, 1983) an hour after
a second treatment dose.
Anti-Inflammatory Activity--Paw Edema Measurement
[0312] Treatment with the controls or test articles was started a
day before intraplantar injection of complete adjuvant into the
right hind paw. The anti-inflammatory effect of a C:M composition
was reflected in the measured change in paw edema. Rats (n=9) were
treated orally with 1C:1M composition (200 mg/kg, 100 mg/kg or 50
mg/kg), ibuprofen (100 mg/kg) or vehicle for 14 days. Data are
expressed as mean.+-.SD and p-values were calculated against
vehicle. Paw edema was measured with the use of a plethysmometer
(IITC, Woodland Hills, Calif.; Model 520) on day 1 (before
antigen), day 3, 5, 7, 9 and 13 after antigen injection.
[0313] The AIA model showed cardinal signs of inflammation
(including hyperalgesia, swelling and hyperemia) were evident in
all animals 24 hours post-priming with antigen. Rats treated with
the positive control (ibuprofen) showed a statistically significant
reduction in paw edema of 28.8%, 21.1%, 19.4%, 24.3% and 32.7% on
days 3, 5, 7, 9 and 13, respectively, as compared to vehicle
control. Animals treated with an oral dose of C:M compositions
showed a reduction in paw edema as compared to the vehicle control
animals on days 3, 5, 7, 9 and 13, respectively, of (a) 24.0%,
32.1%, 30.6%, 38.5% and 48.4% at a dose of 200 mg/kg, (b) 21.8%,
29.3%, 25.0%, 33.7% and 38.8% at a dose of 100 mg/kg, and (c)
15.6%, 17.1%, 18.8%, 27.1% and 38.2% at a dose of 50 mg/kg (Table
55). These percentage reductions were statistically significant at
each time point analyzed.
TABLE-US-00057 TABLE 55 Effect of C:M Compostion on Paw Edema in
AIA Model Day 3 Day 5 Day 7 Day 9 Day 13 Mean .+-. P- Mean .+-. P-
Mean .+-. P- Mean .+-. P- Mean .+-. P- Groups SD Value SD Value SD
Value SD Value SD Value Vehicle .sup. 5 .+-. 0.6 -- 3.9 .+-. 0.4 --
3.8 .+-. 0.7 -- 3.6 .+-. 0.6 -- 3.1 .+-. 0.6 -- Ibuprofen 3.5 .+-.
0.7 0.0003 3.1 .+-. 0.8 0.0007 3.1 .+-. 0.7 0.0067 2.7 .+-. 0.6
0.0041 2.1 .+-. 0.58 0.0016 100 mg/kg C:M 3.8 .+-. 0.3 0.0001 2.7
.+-. 0.4 0 2.7 .+-. 0.5 0.0005 2.2 .+-. 0.4 0 1.6 .+-. 0.4 0 200
mg/kg C:M 3.9 .+-. 0.3 0.0002 2.8 .+-. 0.2 0 2.9 .+-. 0.4 0.0013
2.4 .+-. 0.3 0 1.9 .+-. 0.3 0.0001 100 mg/kg C:M 4.2 .+-. 0.3
0.0003 3.3 .+-. 0.4 0.0020 3.1 .+-. 0.3 0.0079 2.6 .+-. 0.5 0.0007
1.9 .+-. 0.5 0.0002 50 mg/kg
[0314] The positive control showed greater inhibition of
inflammation after 3 days of daily oral treatment as compared to
any of the test compositions, but the degree of inhibition observed
for the test compositions increase beyond the positive control as
treatment days extended to day 13. These results indicate the C:M
composition compounds may persist during this treatment regimen,
which means a lower dose of C:M compositions may be used for
chronic inflammation management and treatment.
Anti-Pain Activity--Allodynia Measurement
[0315] Treatment with the controls or test articles was started a
day before intraplantar injection of complete adjuvant into the
right hind paw. The anti-pain effect of a C:M composition was
reflected by allodynia (induced pain). Rats (n=9) were treated
orally with 1C:1M composition (200 mg/kg, 100 mg/kg or 50 mg/kg),
ibuprofen (100 mg/kg) or vehicle for 14 days. Data are expressed as
mean.+-.SD and p-values were calculated against vehicle. Allodynia
was evaluated by responsiveness to pressure applied perpendicular
to the central plantar surface of the right hind paw using the
Randall-Selitto test (Randall and Selitto, Arch. Intl Pharmacodyn
Therap. 133:233, 1957). A positive response to the applied
mechanical pressure, noted by sharp withdrawal of the paw, was
recorded automatically by an electronic Von Frey Anesthesiometer
(2390 series Electrovonfrey, IITC, Woodland Hills, Calif.)
(Vivancos et al., 2004). Mechanically induced allodynia was
evaluated before antigen treatment, and then on days 3, 5, 7, 9 and
13 after antigen injection.
[0316] Oral administration of a C:M composition and ibuprofen
showed a marked reduction in pain sensitivity. As shown in Table
56, a statistically significant reduction in pain sensitivity was
observed when rats were treated with 100 mg/kg of ibuprofen (31.3%,
39.5%, 48.8%, 52.5% and 52.5% reductions on day 3, 5, 7, 9 and 13,
respectively). The pain sensitivity inhibitions of orally gavaged
C:M composition at a dose of 200 mg/kg were 27.1%, 38.2%, 51.6%,
52.8% and 54.2%, at a dose of 100 mg/kg were 25.6%, 34.9%, 39.0%,
47.6% and 46.2%, and at a dose of 50 mg/kg were 21.8%, 24.3%,
29.0%, 37.6% and 40.8% (Table 56).
TABLE-US-00058 TABLE 56 Effect of C:M Compostion on Allodynia in
AIA Model Day 3 Day 5 Day 7 Day 9 Day 13 Mean .+-. P- Mean .+-. P-
Mean .+-. P- Mean .+-. P- Mean .+-. P- Groups SD Value SD Value SD
Value SD Value SD Value Vehicle 98.2 .+-. 6.3 -- 90.7 .+-. 5.4 --
84.0 .+-. 2.9 -- 81.6 .+-. 3.6 -- 69.3 .+-. 3.5 -- Ibuprofen 67.4
.+-. 5.6 0 54.8 .+-. 2.6 0 43.0 .+-. 4.6 0 38.8 .+-. 2.3 0 32.9
.+-. 2.6 0 100 mg/kg C:M 71.6 .+-. 3.6 0 56.0 .+-. 2.0 0 40.7 .+-.
4.9 0 38.5 .+-. 1.7 0 31.7 .+-. 2.7 0 200 mg/kg C:M 73.1 .+-. 3.7 0
59.1 .+-. 2.6 0 51.2 .+-. 3.6 0 42.8 .+-. 3.2 0 37.3 .+-. 1.0 0 100
mg/kg C:M 76.8 .+-. 5.4 0 68.7 .+-. 2.7 0 59.6 .+-. 1.8 0 50.9 .+-.
4.1 0 41.1 .+-. 2.1 0 50 mg/kg
[0317] These data make clear that ibuprofen (positive control)
showed the strongest analgesic activity by day 3, but C:M
compositions at 100 mg/kg or 50 mg/kg were stronger thereafter.
Nevertheless, coinciding with the paw edema data, activity of the
composition at any of the doses administered were augmented as the
treatment days were extended to day 13.
Anti-Inflammatory Activity--Ankle Width Measurement
[0318] Treatment with the controls or test articles was started a
day before intraplantar injection of complete adjuvant into the
right hind paw. The anti-inflammatory effect of a C:M composition
was reflected in the measured change in ankle diameter. Rats (n=9)
were treated orally with 1C:1M composition (200 mg/kg, 100 mg/kg or
50 mg/kg), ibuprofen (100 mg/kg) or vehicle for 14 days. Data are
expressed as mean.+-.SD and p-values were calculated against
vehicle Ankle diameter was measured using a Pocket Thickness Gage
(7309, Mitutoyo corp. Japan) on day 1 (before antigen), day 3, 5,
7, 9 and 13 after antigen injection.
[0319] As shown in Table 57, a greater reduction in ankle diameter
reduction support the harmonized effect of C:M composition in
reducing inflammation in a joint. Animals treated with an oral dose
of 200 mg/kg C:M showed 43.1%, 47.3%, 45.5%, 52.4 and 60.9%
reduction, with an oral dose of 100 mg/kg showing a 35.9%, 39.0%,
39.2%, 42.0% and 51.9% reduction, and with an oral dose of 50 mg/kg
showing a 30.9%, 32.2%, 34.1%, 36.5% and 48.7% reductions in ankle
diameter on days 3, 5, 7, 9 and 13, respectively, as compared to
vehicle control treated animals. These percentage reductions were
statistically significant at each time point analyzed. The positive
control ibuprofen showed statistically significant 37.2%, 34.8%,
36.8%, 33.5% and 44.2% reduction in ankle diameter on days 3, 5, 7,
9 and 13, respectively, compared to vehicle control (Table 57).
TABLE-US-00059 TABLE 57 Effect of C:M Compostion on Ankle Width in
AIA Model Day 3 Day 5 Day 7 Day 9 Day 13 Mean .+-. P- Mean .+-. P-
Mean .+-. P- Mean .+-. P- Mean .+-. P- Groups SD Value SD Value SD
Value SD Value SD Value Vehicle 1.7 .+-. 0.2 -- 1.5 .+-. 0.2 -- 1.8
.+-. 0.2 -- 1.5 .+-. 0.2 -- 1.4 .+-. 0.1 -- Ibuprofen 1.1 .+-. 0.1
0.0028 1.0 .+-. 0.1 0.0076 1.2 .+-. 0.1 0.0009 1.0 .+-. 0.2 0.0116
0.8 .+-. 0.1 0.0016 100 mg/kg C:M 1.0 .+-. 0.1 0.0009 0.8 .+-. 0.1
0.0002 1.0 .+-. 0.1 0 0.7 .+-. 0.1 0 0.5 .+-. 0.1 0 200 mg/kg C:M
1.1 .+-. 0.1 0.0057 0.9 .+-. 0.1 0.0028 1.1 .+-. 0.2 0.0020 0.9
.+-. 0.1 0.0003 0.7 .+-. 0.1 0 100 mg/kg C:M 1.2 .+-. 0.1 0.0053
1.0 .+-. 0.1 0.0143 1.2 .+-. 0.2 0.0103 1.0 .+-. 0.2 0.0260 0.7
.+-. 0.2 0.0004 50 mg/kg
[0320] In this particular case, the C:M composition (at 200 mg/kg)
showed the greatest inhibition of ankle swelling as compared to any
other treatment group, including positive control ibuprofen, and at
all time points monitored. In fact, rats treated with an oral dose
of ibuprofen at 100 mg/kg was comparable to treatment with a C:M
composition at 50 mg/kg in anti-inflammatory effect.
Example 74
Curcuma:Morus, Acacia:Morus and Gambir:Morus Compositions Inhibit
Cox-1 and Cox-2 Enzyme Activity
[0321] COX inhibition was tested using a colorimetric COX (ovine)
inhibition assay kit (Cayman Chem., Co.). Briefly, 150 .mu.l of
assay buffer, 10 .mu.l of heme, 10 .mu.l of COX-1 or COX-2 enzyme
and 20 .mu.l of test material were added into 96-well plates. The
plate was shaken carefully for a few seconds, incubated at
25.degree. C. for 5 minutes, and then 20 .mu.l colorimetric
substrate solution and arachidonic acid were added to initiate the
reaction. After shaking, the reaction was allowed to proceed for 10
minutes at 25.degree. C. and then the absorbance of each well was
measured at 590 nm using a plate reader.
TABLE-US-00060 TABLE 58 Effect of C:M, G:M, and A:M Compositions on
COX-1/COX-2 Activity Dose % Inhibition of COX-1 % Inhibition of
COX-2 (.mu.g/ml) C:M G:M A:M C:M G:M A:M 10 17.3 .+-. 0.23 36.3
.+-. 0.55 38.1 .+-. 0.67 14.3 .+-. 1.11 23.2 .+-. 1.35 23.7 .+-.
1.51 25 39.8 .+-. 0.35 64.9 .+-. 0.35 54.1 .+-. 0.74 19.7 .+-. 1.21
46.6 .+-. 0.44 46.0 .+-. 1.15 50 57.6 .+-. 0.06 78.8 .+-. 0.25 72.3
.+-. 0.64 35.8 .+-. 1.29 63.8 .+-. 0.26 51.9 .+-. 0.47 100 107.8
.+-. 0.61 90.5 .+-. 0.21 81.0 .+-. 0.35 63.6 .+-. 0.49 82.0 .+-.
0.15 72.7 .+-. 0.70 IC.sub.50 40.5 .mu.g/ml 12.4 .mu.g/ml 20.9
.mu.g/ml 74.1 .mu.g/ml 39.8 .mu.g/ml 49.2 .mu.g/ml
[0322] As shown in Table 58, IC.sub.50 values of C:M, G:M and A:M
compositions were 40.5, 12.4 and 20.9 .mu.g/ml, respectively, in
the COX-1 enzyme activity assay, and 74.1, 39.8 and 49.2 .mu.g/ml,
respectively, in COX-2 enzyme activity assay. All samples showed
more potent effects in inhibition of COX-1 enzyme than inhibition
of COX-2 enzyme, each in a dose-dependent manner.
Example 75
Curcuma:Morus, Acacia:Morus and Gambir:Morus Compositions Inhibit
5-Lipdxygenase Activity
[0323] The effect on 5-lipoxygenase (5-LOX) was tested us a
Lipoxygenase inhibitor screening assay kit (5-LOXs: potato; Cayman
Chem., Co.). Briefly, 90 .mu.l of 5-LOX enzyme and 10 .mu.l of test
materials were added into 96-well plates, carefully shaken for a
few seconds, and then 10 .mu.l linoleic acid was added to initiate
the reaction. The plates were placed on a shaker for 5 minutes, and
then 100 .mu.l chromogen was added to each well to stop the enzyme
reaction. To develop the reaction, the plates were placed on a
shaker for 5 minutes and the absorbance of each well was then
measured at 490 nm using a plate reader.
TABLE-US-00061 TABLE 59 Effect of C:M, G:M, and A:M Compositions on
5-LOX Activity Dose % Inhibition of 5-LOX Enzyme (.mu.g/ml) C:M G:M
A:M 10 25.7 .+-. 2.59 37.3 .+-. 1.93 41.4 .+-. 1.25 25 56.3 .+-.
1.04 77.7 .+-. 0.00 78.6 .+-. 0.40 50 75.3 .+-. 0.40 92.8 .+-. 0.36
93.4 .+-. 0.20 IC.sub.50 26.3 .mu.g/ml 13.6 .mu.g/ml 11.1
.mu.g/ml
[0324] As shown in Table 59, all samples showed more potent effect
than that of 5-LOXIN and all three compositions showed a
dose-dependent effect. The IC.sub.50 values of C:M, G:M and A:M
were 26.3, 13.6 and 11.1 .mu.g/ml, respectively, in this 5-LOX
enzyme activity assay.
Example 76
Anti-Nociceptive Effect of a Gambir:Morus Composition in a
Mono-Iodoacetate (MIA)-Induced Osteoarthritis Rat Model
[0325] Osteoarthritis (OA) is a degenerative joint disease
characterized by joint pain and a progressive loss of articular
cartilage and, to date, with no cure. As the disease advances, the
biochemical alterations that occur within the articular cartilage
will result in imbalances between anabolic and catabolic processes
that ultimately alter the overall joint structure and function, and
lead to chronic pain. Multiple animal models have been developed
and utilized to study the pathogenesis of OA and to evaluate the
effectiveness of novel therapeutic agents with limited success. An
animal model with a robust induction and reproducibility of joint
pathology, along with pain associated with the disease, was
desired, so the minimally invasive mono-iodoacetate (MIA) induced
OA model was employed. Mono-iodoacetate (MIA) is an inhibitor of
glyceraldehyde-3-phosphate dehydrogenase activity shown to induce
chondrocyte death and hence reproduces cartilage lesions with loss
of proteoglycan matrix and functional joint impairment similar to
human OA (Marker and Pomonis, Methods Mol. Biol. 851:239,
2012).
[0326] Male Sprague--Dawley (SD) rats weighing about 170 to about
230 g (6 weeks of age) were purchased and acclimated for one week.
One day before disease induction, animals were randomized into four
group as follows: G1 (Normal), G2 (Vehicle), G3 (Diclofenac; 10
mg/kg) and G4 (G:M; 500 mg/kg). Each group was orally gavaged with
their respective treatment. Anesthetized rats were injected with
0.8 mg of MIA in a 50 .mu.l saline solution into the
intra-articular pocket one hour after the second dose of
treatments. Pain sensitivity was measured once a week using a
Randall-Salitto meter and treatment lasted for 6 weeks. Body
weights were measured once a week to calculate the respective
weekly dosage of each group. Once the in-life study was concluded,
structural and cellular alterations of joint tissues as a result of
disease progression and/or treatment efficacy was assessed by using
histopathology with a modified Mankin scoring system.
TABLE-US-00062 TABLE 60 Inhibition of Pain Sensitivity by G:M
Composition in an OA Model Week Group/Dose 0 1 2 3 4 5 6 G1
(Normal) Mean 174.53 172.53 174.67 175.40 171.40 166.07 163.60 SD
29.51 6.53 13.90 23.95 39.09 19.86 9.32 % 100.00 98.85 100.08
100.50 98.20 95.15 93.74 G2 (Vehicle) Mean 173.23 158.07 151.90
160.07 143.10 121.03 122.07 SD 18.04 15.08 42.97 16.12 23.00 12.77
15.17 % 100.00 91.24 87.69 92.40 82.61 69.87 70.46 G3 (Diclofenac;
Mean 173.20 146.37 155.67 162.90 150.90 146.23 144.23 10 mg/kg) SD
15.61 27.86 23.85 28.90 19.62 22.73 27.57 % 100.00 84.51 89.88
94.05 87.12 84.43 83.28 G4 (G:M; Mean 173.33 168.13 178.87 174.37
166.90 170.00 148.93 500 mg/kg) SD 17.44 22.68 57.83 26.48 27.17
21.13 26.12 % 100.00 97.00 103.19 100.60 96.29 98.08 85.92 P-values
vs Vehicle G1 0.9311 0.0226 0.1535 0.2446 0.1907 0.0041 0.0000 G3
0.9965 0.2626 0.8120 0.7905 0.4255 0.0085 0.0428 G4 0.9901 0.2600
0.2532 0.1655 0.0491 0.0000 0.0135
[0327] One of the cardinal symptoms of OA (i.e., pain) was apparent
a week following model induction. As shown in Table 60, rats with
an intra-articular injection of MIA showed a progressive increase
in pain sensitivity as exhibited by the mean pain sensitivity
values of untreated vehicle control with MIA. In contrast, rats
treated with a dose of 500 mg/kg of G:M orally per day for 6 weeks
showed statistically significant reductions in pain sensitivity
after 4 weeks of oral treatment. A 16.6%, 40.5% and 22.0%
reductions in pain sensitivity were observed for rats treated with
1G:1M (500 mg/kg) at week 4, week 5 and week 6, respectively.
Diclofenac (positive control) showed significant reduction of pain
sensitivity beginning week 5 and percentage reductions of 20.8% and
18.2% were observed in week 5 and week 6, respectively.
Example 77
Protection of Articular Cartilage by Gambir:Morus Composition
[0328] In the rat model of Example 76, articular cartilage matrix
integrity was also measured. In agreement with the pain sensitivity
reduction data in Example 76, statistically significant improvement
in articular cartilage matrix integrity was found as reflected by
the total Mankin score for animals treated with G:M at a dose of
500 mg/kg (Table 61). In contrast, the positive control,
Diclofenac, while showing a positive trend, showed a change that
was not statistically significant in the structure, cellular
abnormality and matrix integrity, as compared to vehicle control
(Table 61).
TABLE-US-00063 TABLE 61 Effect of G:M Composition on
Histopatholical Scoring in OA Model Cellular Safranin-O Total Group
Structure Abnormality Staining Mankin (Dose) (0-6)* (0-3).dagger.
(0-4).dagger-dbl. Score Normal 0 0 0 0 Vehicle 2.78 .+-. 1.79 1.78
.+-. 0.44 2.67 .+-. 1.32 7.22 .+-. 3.19 Diclofenac 1.9 .+-. 1.45
1.3 .+-. 0.67 1.7 .+-. 0.82 4.9 .+-. 2.69 (10 mg/kg) GM 1.0 .+-. 0*
1.4 .+-. 0.52 1.3 .+-. 0.95* 3.7 .+-. 1.33* (500 mg/kg) *Structure
Score (0-6): 0 = Normal; 1 = Irregular surface, including fissures
in to the radial layer; 2 = pannus; 3 = Absence of superficial
cartilage layers; 4 = Slight disorganization (an absent cellular
row and some small superficial clusters); 5 = Fissures into the
calcified cartilage layer; 6 = Disorganization (chaotic structure,
clusters and oesteoclastic activity) .dagger.Cellular abnormality
Score (0-3): 0 = Normal; 1 = Hyper cellularity, including small
superficial clusters; 2 = Clusters, 3 = Hypocellularity
.dagger-dbl.Matrix (Safranin-O) Staining Score (0-4): 0 =
Normal/slight reduction of staining; 1 = Staining reduced in the
radial layer; 2 = Staining reduced in the intcrtcrritorial matrix;
3 = Staining reduce in pericellular matrix; 4 = Staining
absent.
Example 78
Human Clinical Study of Combination Extracts from Curcuma, Uncaria,
Acacia and Morus on Supporting Joint Functions
[0329] In a human clinical trial, a double blind randomized placebo
and positive comparator controlled trial will be carried out to
examine the efficacy and safety of a mixture of C-Curcuma, G-Gambir
or A-Acacia, and M-Morus in osteoarthritis (OA) patients. The study
will evaluate change in pain severity on a 0-10 Numeric Rating
Scale (visual analog scale, VAS), change in pain severity on the
WOMAC scale, and change in physical functional and stiffness as
measured by the WOMAC scale. Objective measures of improvement will
be evaluated at baseline and end of study, range of motion by
BIODEX and distance walked in six minutes plus safety evaluations
are also included.
[0330] Before screening, subjects must read and sign the IRB
approved Informed Consent Form. The study population will consist
of male and female subjects older than 18 and less than 75 years
and in generally good health as determined by a medical history.
Female subjects of childbearing potential must have a negative
urine pregnancy test at baseline. The goal of the study is to
enroll sufficient subjects to treat 40 subjects per study arm.
[0331] A clear definition of OA as listed in Inclusion criteria:
Male/Female healthy adult 18 to 75 years of age, inclusive, meet
pain entry criteria, a history of knee joint pain for greater than
6 months, medial or lateral tibiofemoral joint line tenderness,
unilateral knee pain 6/10 or greater, on average, on the visual
analog scale (VAS), that interferes with function most days per
week, and Kellgren grade II or III radiographic changes of
osteoarthritis. Willingness to discontinue use of all analgesic
medications (including over-the-counter [OTC] analgesics) except
those provided as the study treatment and rescue medication
specifically for study purposes
Primary Objective
[0332] Change in pain severity on a 0-10 Numeric Rating Scale,
Change in Pain Severity on 0-10 cm VAS [0333] Change in Pain
Severity on WOMAC Pain Subscale (0-100), Change in WOMAC Total
Score all subscales.
Secondary Objectives Safety Assessments
[0333] [0334] Patient global assessment of response to treatment,
Physician global assessment of response to treatment Improvement in
Physical Function and Stiffness subscale of the WOMAC and WOMAC
[0335] Change in joint function as measured by active and passive
range of motion, distance walked in the 6 minute walk test. QOL:
generic health status measure, the SF-36 and specific health status
measures, the WOMAC
Safety Evaluations:
[0335] [0336] Complete Blood Count, Chemistry Panel with liver
function tests, PT/INR, HCG and AE assessments will be
performed.
Data Analysis
[0337] In this study 120 subjects, randomized equally to receive
Product 1, Product 2, or Placebo (40 subjects each). If the
attrition rate is 30% from the per-protocol population over the
course of the 12-week study, there should be approximately 21
analyzable subjects per group. A power analysis was carried out to
determine the effect size (difference between products in mean
12-week changes of efficacy endpoints) that would provide an 80%
chance of obtaining a significant result of p<0.05 with 21
analyzable subjects per group.
[0338] The statistical design parameters for this study are: [0339]
Alpha Level: 0.05 (p<0.05 considered statistically significant);
[0340] Power: 0.8 (an 80% chance of obtaining significant p value);
[0341] Primary Null Hypothesis: Mean 12-week change for any
supplement will equal the 12-week change for Placebo [0342]
Alternate Hypothesis: Changes are not equal between products.
[0343] Statistical Test: Analysis of Covariance (power calculations
based on unpaired Student t test); [0344] Sample Size: 120 enrolled
subjects, 40 in each product group;
TABLE-US-00064 [0344] TABLE 58 Study Procedures Procedure Visit 1
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Subject Visit Day 90
Screening Day 0 Day 14 Day 30 Day 60 Exit Visit Timing Day - 14 Day
0 Day 14 .+-. 1 Day 30 .+-. 1 Day 60 .+-. 2 Day 90 .+-. 2 Informed
Consent X Inclusion/Exclusion X X Continuance X X X X Criteria
Medical History X Physical Exam X X Demography X Height X Weight X
X X X X X Vital signs X X X X X X Identify target joint X Chemistry
panel X X X X with LFT CBC with X X X X differential, PT/INR
Collect blood X X X X samples for Cytokines .beta.-HCG Pregnancy X
X Test WOMAC pain X subscale (5 items) Complete X X X X WOMAC 3
subscales 100 mm VAS Scale X X X X Daily Assessment Maximum
Distance X X X X (feet) walked in 6 minutes Concomitant X X X X X X
Medications Adverse Events/ X X X X Intercurrent Illness Dispense
Rescue X Medication Return Rescue X X X X Medication Dispense Test
X X X Product Return Test Product X X X X
[0345] The various embodiments described above can be combined to
provide further embodiments. All of the U.S. patents, U.S. patent
application publications, U.S. patent applications, foreign
patents, foreign patent applications and non-patent publications
referred to in this specification or listed in the Application Data
Sheet are incorporated herein by reference, in their entirety.
Aspects of the embodiments can be modified, if necessary to employ
concepts of the various patents, applications and publications to
provide yet further embodiments. These and other changes can be
made to the embodiments in light of the above-detailed
description.
[0346] In general, in the following claims, the terms used should
not be construed to limit the claims to the specific embodiments
disclosed in the specification and the claims, but should be
construed to include all possible embodiments along with the full
scope of equivalents to which such claims are entitled.
Accordingly, the claims are not limited by the disclosure.
* * * * *